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Abstract
Signaling pathways are crucial for multicellular organisms: they are necessary for cell
communication and development, they enable cells to specialize and act together. TNF-α
signaling is one such pathway crucial for orchestrating the body’s response to cellular
stress or invasion by pathogens. TNF-α signaling mediates inflammation, a key event for
an efficient innate immune response. As inflammation has to be tightly controlled in order
to avoid damage to the host, deregulation of TNF-α signaling has been implicated in the
pathogenesis of many inflammatory diseases and cancer.
TNF-α exerts inflammatory effects by binding to its receptor, TNFR1. Upon binding,
several proteins including DD (death domain) proteins are recruited to TNFR1 to form the
TNFR complex, resulting in the activation of the IκB kinase complex (IKK). Subsequently,
inhibitor of κB (IκB) proteins are phosphorylated and degraded, releasing transcription
factors of the NF-κB family. NF-κB then controls the expression of hundreds of different
genes required for inflammation and innate immunity.
The aim of my PhD project was to identify new factors required for TNF-α signaling.
In order to monitor NF-κB transcriptional activity upon stimulation with TNF-α, I estab-
lished a cell-based dual luciferase assay. This assay was suited to measure TNF-α signaling
activity in miniaturized format necessary for large-scale experiments. For finding novel reg-
ulators of TNF-α signaling, I used the cell-based dual luciferase assay in two genome-wide
RNAi screens. These screens identified several candidates potentially implicated in NF-κB
activation by TNF-α. I next established secondary assays for confirming the requirement
of these candidates in TNF-α signaling. On the basis of the results of these secondary
assays, I selected three candidates, SPP1, GAB3 and CASP4, for further characterization.
Epistasis experiments revealed that SPP1, GAB3 and CASP4 are required for the acti-
vation of the IκB kinase complex. Further experiments demonstrated that the candidates
are not essential for proper TNFR1 cell surface expression. SPP1, a multifunctional pro-
tein, has been described to interact with the DD protein MyD88 during Toll-like receptor
signaling. It could thus interact with DD proteins present in the TNFR complex. GAB3
belongs to a family of scaffold proteins of which one member, GAB2, has been shown to
interact with RANK, a TNFR family member. Analogously, GAB3 could act as a scaffold
at TNFR1 supporting the recruitment of signaling molecules. CASP4 is an inflammatory
caspase. My results indicate that CASP4 catalytical activity is dispensable for its role
in TNF-α signaling. CASP4 could thus serve as another scaffold protein in the TNFR
complex as described for other caspases. Future experiments will identify the interaction
partners of SPP1, GAB3 and CASP4, clarifying the molecular details of their mode of
action in TNF-α-induced activation of NF-κB.

Zusammenfassung
Signalwege sind zur Kommunikation zwischen den Zellen komplexer Organismen unent-
behrlich. Sie steuern Prozesse wie Zelldifferenzierung und Entwicklung. Inflammatorische
Signalwege spielen bei Immunantworten und der Reaktion auf Zellstress eine Rolle. Ein
zentraler Mediator von Entzündungsreaktionen ist das inflammatorische Cytokin TNF-α.
Aufgrund seiner Schlüsselfunktion sind Missregulierungen des TNF-α Signalwegs an vielen
inflammatorischen Krankheiten und Krebs beteiligt.
TNF-α vermittelt Entzündungsreaktionen durch seine Bindung an den TNF-α-Rezeptor
(TNFR) 1. Die Aktivierung des Rezeptors induziert die Ausbildung des TNFR-Komplexes,
in den z.B. Proteine mit "death domains" (DD) rekrutiert werden. Der TNFR-Komplex
aktiviert den "inhibitor of κB" (IκB) Kinasekomplex (IKK), der IκB phosphoryliert und
zum Abbau markiert. Durch den Abbau von IκB werden Transkriptionsfaktoren der NF-
κB-Familie freigesetzt. Diese aktivieren daraufhin die Expression vieler verschiedener Gene,
die für Entzündungsreaktionen und angeborene Immunantworten benötigt werden.
Ziel dieser Doktorarbeit war es, neue Komponenten des TNF-α Signalweges zu identi-
fizieren. Es wurde ein so genannter "dual luciferase assay" in HEK293T Zellen etabliert,
um die Aktivierung des Transkriptionsfaktors NF-κB nach Stimulation mit TNF-α zu
messen. Dieser Assay ermöglichte es, in genomweiten RNA-Interferenz Screens nach Re-
gulatoren des TNF-α Signalweges zu "fahnden". Mithilfe zweier Screens wurden mehrere
solche mögliche Regulatoren identifiziert. Sekundärassays wurden etabliert, mit deren Hilfe
die Phänotypen der Screening-Kandidaten überprüft und schließlich die drei Kandidaten
SPP1, GAB3 und CASP4 zur weiteren Charakterisierung ausgewählt wurden.
Durch Epistaseexperimente wurde gezeigt, dass alle drei Proteine an der Aktivierung
des IKK beteiligt sind. Ihre Expression wurde nicht für die Lokalisation des TNFR1 an der
Zelloberfläche benötigt. Diese Arbeit stellt Modelle vor, welche Rolle die drei identifierten
Proteine im TNF-α Signalweg einnehmen könnten. SPP1 erfüllt viele diverse Funktionen.
Unter anderem interagiert es am TLR9 mit dem DD-Protein MyD88. Es könnte also mit
DD-Proteinen im TNFR-Komplex interagieren. GAB3 gehört einer Familie von Adaptor-
proteinen an, deren Mitglieder mit der Aktivierung von NF-κB in Verbindung gebracht
wurden. So wurde von GAB2 berichtet, dass es mit dem TNFR Familienmitglied RANK
interagieren kann. Analog dazu wäre es denkbar, dass GAB3 an TNFR1 bindet. CASP4
gehört zu den inflammatorischen Caspasen, einer Familie von Cysteinpeptidasen. Experi-
mente weisen jedoch darauf hin, dass CASP4 unabhängig von seiner Enzymaktivität NF-
κB aktiviert. Auch für andere Caspasen wurde eine nicht-enzymatische Adaptorfunktion
beschrieben. Um die vorgestellten Modelle zu testen, müssen nun die Interaktionspartner
der drei Kandidaten identifiziert werden.
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Chapter 1
Introduction
1.1 Innate Immunity
The body is protected from intrusion of pathogens by its skin and mucosal surfaces. How-
ever, if pathogens penetrate these barriers, the body has to be able to detect and fight the
intruders. The immune system confers these abilities. It can be divided into two branches:
innate immunity acting as a first line of defense; and adaptive immunity, comprising the
activation and proliferation of B and T lymphocytes. In contrast to adaptive immunity,
innate immune responses are fast and target pathogens unspecifically, e.g. by mediating
their lysis or phagocytosis. Additionally, innate immune responses can also activate the
adaptive immune system when innate immunity is not sufficient to fight the pathogen.
1.1.1 Inflammation in innate immunity
Signaling pathways involved in innate immune responses are evolutionarily conserved.
There are two main types of receptors that are important for an efficient innate immune
response: receptors that recognize pathogens and receptors that facilitate to alert the body
to the threat.
(i) Pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), recog-
nize pathogen-associated molecular patterns (PAMPs) on the surface of pathogens, e.g.
bacterial proteoglycans or lipids like lipopolysaccharide (LPS). There are many different
receptors belonging to the PRRs; they can be transmembrane receptors (TLR4, scavenger
receptors), secreted into the plasma (complement system) or intracellular [e.g. nucleotide
oligomerization domain protein-like receptors (NLRs)]. As diverse as the make-up and
function of PRRs is their expression in different tissues. However, they all share the ability
to sense pathogens directly (for more information see [5] and references therein).
(ii) Cytokine and chemokine receptors bind to inflammatory molecules that are secreted
1
2by cells activated by PRRs. Main source of inflammatory cytokines and chemokines are
activated tissue macrophages [167]. These inflammatory molecules help to alert the body
to potential intruders and mediate an inflammatory response that is characterized by heat,
pain, redness and swelling. During inflammation, blood vessels become dilated and perme-
abilized, thus enabling leukocytes to enter the tissue at the site of an infection. Additionally,
inflammatory cytokines induce the expression of adhesion molecules on endothelial cells,
further facilitating extravasation of cells of the immune system. Inflammatory chemokines
serve as chemoattractants to guide leukocytes to the site of infection or damaged tissue. In-
flammation is hence key to mount an efficient immune response or to promote healing after
tissue injury (Figure 1.1). However, if inflammatory processes become chronic or systemic,
tissue damage and diseases entail (e.g. Crohn’s disease, psoriasis) [126, 31].
infection stress
inflammation
defence against
infection
autoimmunity,
tissue damage
tissue repair respones,
elimination of or adaption to stress
fibrosis,
tumor growth chronic inflammation
Figure 1.1: The role of inflammation in health and disease. Inflammatory responses are induced
by different triggers such as infection and cell stress due to disturbances of tissue homeostasis. If the
physiological purpose of inflammation is met, e.g. clearance of infection or restoration of the home-
ostatic state, the transient inflammatory response is terminated. Under pathological circumstances
(marked in red), prolonged inflammation causes diseases.
1.1.2 TNF-α in innate immunity
Cytokines and their receptors can be classified into the following groups: (i) hematopoietins
[e.g. interleukin (IL) 6] whose receptors signal through receptor-associated kinases, (ii)
chemokines (e.g. IL-8) that bind to seven-transmembrane-domain receptors interacting
with intracellular trimeric GTP-binding proteins, and (iii) the tumor necrosis factor (TNF)
3family (e.g. TNF-α) [152].
19 proteins have been classified according to their structure to belong to the TNF-α
family [22]. This family includes mediators of immune responses [such as lymphotoxin-α
(LT-α) and CD40 Ligand (CD40L)] as well as death-inducers [like CD95 Ligand/Fas lig-
and (FasL) and TNF-related apoptosis-inducing ligand (TRAIL)] and factors involved in
organogenesis [such as receptor activator of NF-κB ligand (RANKL)] [12, 152]. All family
members initiate similar pathways (Figure 1.2). These pathways ultimately induce apop-
tosis and activation of nuclear factor κB (NF-κB) [243, 90]. Signaling by the founding
member of the TNF family, TNF-α, is subject of this thesis.
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Figure 1.2: Signaling pathways initiated by members of the TNF-α family share similarities with
each other as well as other immune signaling pathways such as TLR (Toll like receptor) signaling.
They involve scaffold proteins bearing death domains (such TRADD, FADD, RIP) and/or TRAF
proteins as well as MAPKs (mitogen-activated kinases). Pathways ultimately either activate NF-κB
transcriptional activity or initiate the caspase cascade and apoptosis.
TNF-α was first identified as a soluble factor that is able to induce necrosis in tumor
cells [36]. Later it was realized that, depending on the cellular context and the duration
of the signal, TNF-α induces either apoptotic or anti-apoptotic proteins in target cells.
However, TNF-α’s main effect is not its cytotoxicity but its ability to mediate inflamma-
tion [12]. TNF-α can be produced by all cell types, including non-immune cells such as
fibroblasts and endothelial cells as well as immune cells like monocytes, lymphocytes and
macrophages. TNF-α is made as a transmembrane protein in response to activation of
PRRs and has to be cleaved in order to be secreted into the extracellular space [20]. The
secreted cytokine is active as a homotrimer [233]. It induces the expression of cell surface
proteins like integrins that facilitate the extravasation of leukocytes, chemotactic proteins
and cytokines further promoting inflammation. Secreted systemically (e.g. during septic
4shock), TNF-α is toxic for the body, causing for example wasting syndrome and liver fail-
ure. Observed cytotoxicity is probably caused by TNF-α-induced production of mediators
of tissue destruction like nitric oxide (NO) and reactive oxygen species (ROS) [247].
There are two TNF-α receptors, TNFRSF1A (TNFR1) and TNFRSF1B (TNFR2).
While TNFR1 is constitutively expressed in most tissues, TNFR2 expression is typical
for immune cells [247]. TNFR2 fulfills functions in lymhoid organ development. It cannot
be fully activated by secreted TNF-α, having a higher affinity for the membrane-bound
cytokine. Thus, TNFR1 is the main mediator of the effects of soluble TNF-α [88].
1.1.3 TNF-α receptor 1 signaling - an overview
Binding of TNF-α to its receptor mainly causes either activation of NF-κB or apoptosis by
activation of caspases. TNFR1 mediates responses by recruitment of different adaptor and
signaling molecules to the intracellular tail of the receptor, which contains death domains
(DDs). These domains are important for homotypic protein-protein interactions (table 1.1)
[234, 39]. Triggering of TNFR1 induces the interaction of the DDs of the receptor with
the DD protein TNFR1-associated death domain protein (TRADD), initiating formation
of TNFR complex I (TNFR-C). This in turn activates a signaling cascade that leads via
mitogen-activated protein kinases (MAPKs) to the activation of the inhibitors of NF-κB
kinase (IKK) complex. The activated IKK then phosphorylates inhibitors of NF-κB (IκB).
Subsequently, IκB proteins are degraded and release NF-κB transcription factors into the
nucleus (Figure 1.3).
In addition to initiating inflammatory and proliferative responses via the activation
of NF-κB, DD interactions are also important for the induction of the caspase cascade
by TNF-α ultimately resulting in apoptosis. Upon receptor internalization [204], TRADD
recruits Fas-associated death domain protein (FADD) to the TNFR [109] inducing the
formation of the TNFR complex II [171]. FADD associates with caspase (CASP) 8, an
initiator caspase activating a signaling cascade which results in apoptosis (Figure 1.3)
[207, 258].
Even though the DDs of TNFR1 are main mediators of signaling events, TNFR1 can
also interact with non-DD proteins. For example, the intracellular domain of TNFR1 in-
teracts with the scaffold protein growth factor receptor-bound protein (GRB) 2, thereby
initiating Rat sarcoma (Ras) signaling upon receptor ligation [100]. In addition, signaling
through TNFR1 activates the MAPK cascade, including MAP3Ks, Jun N-terminal kinases
(JNKs), p38 and extracellular signal-regulated kinases (ERKs), either promoting cell sur-
vival or cell death by activating the transcription factor AP-1 [212]. TNF-α also induces
5the production of ROS, promoting DNA damage [40]. Stress responses are additionally
induced by the production of the second messenger ceramide via activation of acidic and
neutral sphingomyelinases (SMases) [2, 27]. Furthermore, PI(3)Ks, PKCs and PKB become
activated upon TNFR1 ligation, all having influence on NF-κB as well [247].
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Figure 1.3: Schematic presentation of human TNF-α signaling. Activated TNFR1 recruits death
domain containing proteins. These serve as adaptors for further protein binding resulting in the
activation of MAP kinases that activate the IκB kinase (IKK) complex. IKK in turn phosphorylates
IκB, thus releasing NF-κB. Once released, the transcription factor can translocate into the nucleus
and induce the expression of target genes like cytokines. In parallel, signaling through TNFR1 can
also lead to induction of apoptosis by activation of caspase 8.
1.1.4 NF-κB signaling downstream of TNFR1
The TNFR1 complex When trimeric TNF-α binds to the extracellular domains of its
trimeric receptor, TNFR1 translocates to lipid rafts [146] and TRADD associates with the
DDs in the intracellular part of TNFR1 [117]. TRADD serves as a scaffold for the binding of
TNFR-associated factor (TRAF) 2 [108] and receptor interacting protein (RIP1) [224, 237],
initiating the formation of the TNFR-C.
Regulation of TNF-α signaling is strongly dependent on reversible modifications of sig-
naling components (see box 1). Ubiquitination is such a modification that either targets
a protein for destruction or enhances its interaction with other signaling molecules. It is
mediated by three enzymes, a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating
enzyme (E2) and finally a ubiquitin-ligating enzyme (E3) which confers specificity to the
process as it recognizes the substrate [13]. Ubiquitination at the TNFR-C is mediated by
6a "team" of proteins: the E2 complex Ubc13/Uev1A (Ubiquitin conjugating enzyme/Ubc-
like factor ubiquitin conjugating enzyme variant) and TRAF-2 [78]. Nearly all members of
the TRAF protein family carry Really Interesting New Gene (RING) domains that confer
ubiquitin ligase (E3) activity (table 1.1) [246]. TRAF2 does not only mediate ubiquitina-
tion, it is also ubiquitinated itself. Both processes are needed for TNF-α-induced NF-κB
activation [58].
TRAF2 mediates binding of the inhibitor of apoptosis (IAP) family members cIAP-1
and cIAP-2 [196, 217], two proteins bearing RING domains as well [265, 111]. cIAP-1 can
ubiquitinate TRAF2, causing its degradation and interfering with TNF-α-induced NF-κB
activation [148]. Besides, cIAP-1 and cIAP-2 inhibit the activation of the apoptotic caspase
cascade via CASP8 [248].
The IKK - the link between receptor and NF-κB activation - is recruited by two pro-
cesses to the TNFR-C. Firstly, TRAF2 cooperates with TRAF5 in incorporating the IKK
complex into the TNFR-C [232]. Secondly, TRAF2 ubiquitinates RIP1 with the help of
Ubc13/Uev1A [108, 65]. Subsequently, RIP1 interacts with the ubiquitin-binding domain
(UBD) of IKK-γ [260, 65], the regulatory subunit of the IKK that is crucial for IKK func-
tion [60]. IKK-γ thereby helps to recruit the IKK to the TNFR-C [262].
Table 1.1: Protein domains important in TNF-α signaling. TNFR1: TNF receptor superfamily
member 1A, TNFR2: TNF receptor superfamily member 1B, TRADD: TNFR1-associated death
domain protein, FADD: Fas-associated death domain, RIP: receptor interacting protein, IAP: in-
hibitor of apoptosis
domain examples function
death domain TNFR1, TRADD, protein-protein
(DD) FADD, RIP1 interactions
TNFR-associated factor TNFR2, protein-protein
(TRAF) TRAF proteins interactions
really interesting new gene TRAF proteins E3 ligase activity
(RING) cIAP1, cIAP2
The IκB kinase complex The activation of the IKK is the key event leading to NF-κB
activation. In addition to IKK-γ, the IKK consists of two catalytically active subunits,
IKK-α and IKK-β [90]. IKK activation is achieved by phosphorylation of the catalytical
subunits in their activation loops [57, 150]. Activated IKK phosphorylates proteins of the
7IκB family [227, 13], marking them for degradation by the proteasome [61] and thereby
releasing NF-κB. Subsequently, the transcription factor NF-κB can translocate into the
nucleus to interact with other transcriptional regulators and DNA. Two general pathways
lead to the activation of the IKK: the non-canonical and the canonical pathway. The non-
canonical pathway is mediated by MAP3K14 and IKK-α (for review see [23], also see
Figure 1.4). The canonical pathway, e.g. activated by TNF-α, leads to phosphorylation of
IKK-β [90]. The kinase activating IKK-β still awaits identification. Even though RIP1 is
required for TNF-α-induced activation of the IKK [130], its kinase activity is dispensable
[108, 237]. Hence, RIP1 does not activate the IKK directly. Two possibilities remain how
the IKK is catalytically activated: (i) the IKK complex, brought together in close proximity
with the help of RIP1, autophosphorylates itself or (ii) the IKK complex is phosphorylated
by a kinase that is recruited to the TNFR-C by RIP1 [125]. Several candidate kinases
have been proposed, most of them MAPKs, e.g. MEKK3 [264] or transforming growth
factor-β-activated kinase (TAK) 1 [202].
domain examples function
Rel homology 
domain (RHD) NF-κB
interaction with other NF-κBs or 
proteins of IκB family, DNA 
binding
transactivation 
domain (TAD) NF-κB activation of gene transcription
ubiquitin binding 
domain (UBD) IKK-γ
binding of lysine 63-
    linked ubiquitin
IKK
NF-κBIκB
IKK-α
MAP3K14
canonical
    non-
canonical
e.g. TNF-α, 
 IL-1, LPS
  e.g. LT-αβ, 
CD40L, BAFF
Figure 1.4: Inducers and regulators of NF-κB signaling. NF-κB transcriptional activity can be
stimulated by either canonical signaling, as described in the text, or by non-canonical signaling
via activation of MAP3K14. The table lists domains important in the activation and regulation of
NF-κB transcriptional activity.
Activation of NF-κB Transcription factors of the NF-κB family regulate diverse gene
expression programs mediating inflammatory responses as well as anti-apoptotic and devel-
opmental processes [96]. In mammals, there are five NF-κB family members that all share
8a common Rel homology domain (RHD): (i) NF-κB1/p50, (ii) NF-κB2/p52, (iii) c-Rel,
(iv) RelA/p65 as well as (v) RelB. NF-κB proteins form homo- and heterodimers via in-
teraction through their RHD. Only c-Rel, RelA and RelB can activate gene transcription
due to a C-terminal transcription activation domain (TAD); p50 and p52 do not contain a
TAD and act as repressors unless they form dimers with TAD-containing family members
[96].
A wide range of signaling pathways results in the activation of NF-κB. Among these
are pathways induced by receptors recognizing extracellular danger [166] in innate and
adaptive immunity (such as TLR4 or T cell and B cell receptor, respectively). NF-κB
can also be activated via intracellular signaling pathways responding to intruders (e.g.
the inflammasome) or physical stress such as UV radiation and ROS [188]. Activation of
NF-κB is regulated by proteins of the IκB family. IκB proteins bind to NF-κB and retain
them in the cytoplasm [257]. Different IκB proteins fulfill different functions which are
determined by the kinetics of their degradation upon phosphorylation by the IKK [104]
and their binding affinity for specific NF-κB dimers [84]. IκB-α, the target of TNF-α-
induced NF-κB activation, binds to and regulates the activity of RelA:p50 dimers which
are to date the best studied NF-κB dimers.
Upon TNF-α-induced activation of IKK and degradation of IκB-α, NF-κB is released
to translocate into the nucleus and induce target gene expression. However, NF-κB is only
fully activated after phosphorylation and acetylation [176]. These modifications enhance
DNA binding and mediate the interaction with additional transactivators such as CREB
binding protein (CPB)/p300 and histone acetyl transferases (HATs) [44]. Many proteins
have been shown to modify NF-κB [179, 249, 103], including nuclear IKK-α [218, 44, 263, 7].
However, IKK-α also plays a role in the termination of the NF-κB response (see below).
For a comprehensive review on modifications of NF-κB see [187].
Fully activated NF-κB then drives the expression of target genes. The induced target
gene expression profile is not only dependent on which NF-κB proteins were activated but
also on NF-κB nuclear oscillations [177, 105] (see box 1). Among TNF-α-induced target
genes are cytokines such TNF-α itself [211, 51], chemokines like CCL20/MIP-3α (CC-motif
chemokine ligand 20) [139, 238], and IL-8 [138] as well as TNF-α pathway components such
as IκB-α [95, 230, 56] and c-IAP2 [248].
9BOX 1: Principles of signaling mechanisms
Discoveries in TNF-α signaling often have identified principles of signaling regulation that
have later been shown to be also valid for other signaling pathways. These findings argue
for a more complex view on signaling pathways than just mere induced interaction be-
tween different proteins. One such principle of regulation has been established for a while:
reversible modifications such as ubiquitination and phosphorylation. These modifications
are involved in the regulation of many components of TNF-α signaling, but also play a role
in regulating other immune signaling pathways (e.g. [45, 229, 16]). A recently emerged prin-
ciple of regulation of signaling is compartmentalization. At the plasma membrane, TNFR
complex I consisting of TRADD, TRAF2/5 and RIP1, signals to anti-apoptotic NF-κB.
Upon endocytosis the apoptotic TNFR complex II is formed comprising FADD and caspase
8 which induces apoptosis [205]. CD40-induced MAPK and IKK signaling is regulated in
a similar manner [165, 206]. TLR signaling has recently been reported to be regulated by
compartmentalization as well [70, 11]. Lastly, kinetics is another principle of regulation.
Signaling to NF-κB is a fast reponse, and only if activation of the pathway is sustained,
apoptosis induction can occur (see also Figure 1.5). Moreover, kinetics determine the gene
expression program induced by activated NF-κB [177, 105].
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BOX 1 continued
Figure 1.5: The outcome of TNF-α-induced signaling events is not merely dependent on inter-
acting proteins. (1) Modifications such as phosphorylation and ubiquitination either act as binding
sites for interaction partners and activators of enzymes or signal proteasomal degradation. (2)
Compartmentalization is fundamental in the decision between life and death (e.g. TNFR complex
I at the plasma membrane vs. endocytosed TNFR complex II). (3) Kinetics is another important
factor: fast reponses usually entail NF-κB activation which is shut down again with a time lag (e.g.
the fast ubiquitination of RIP1 enables interaction with signaling molecules, whereas its delayed
poly-ubiquitination causes its degradation). Kinetics also determine the transcriptional outcome
of induced signaling events (e.g. NF-κB nuclear oscillations).
1.1.5 Termination of TNFR1 signaling
The termination of TNF-α-induced NF-κB activation is still poorly understood (Figure 1.6)
[84]. There are several negative feedback loops involved in this process. One is affecting
TNF-α mRNA stability (and interferes thereby with a positive feedback loop consisting in
TNF-α-induced TNF-α production). TNF-α mRNA bears an AU-rich element (ARE) se-
quence in the 3’ untranslated region (UTR) [34]. Tristetraprolin (TTP) is an ARE sequence-
binding protein mediating deadenylation and destabilization of bound mRNAs. TTP is
induced by TNF-α, promoting the decay of TNF-α mRNA [235]. Another TNF-α target
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gene is IκB-α which can bind to RelA:p50 in the nucleus and shuttle it back to the cyto-
plasm [230, 195, 112]. IKK-α can terminate NF-κB activation by promoting RelA nuclear
degradation [142].
TNF-α-induced protein (TNFAIP) 3 is involved in a negative feedback loop further
upstream at the level of RIP1 activation. This protein possesses both de-ubiquitinating
(DUB) enzyme as well as ubiquitin ligase activities [256]. TNFAIP3 removes activating
lysine 63-linked ubiquitin from RIP1 and adds lysine 48-linked poly-ubiquitin, thus mark-
ing RIP1 for destruction [256]. Cylindromatosis (CYLD) is another negative regulator of
TNF-α signaling, detaching lysine 63-linked ubiquitin from IKK-γ and TRAF2 [136, 239].
Even further upstream acts the so-called receptor shedding, consisting in the secretion of
TNFR1 from the plasma membrane [99]. Receptor shedding has two consequences. Firstly,
the cell cannot respond to TNF-α because of lost excitability. Secondly, soluble TNFR1
scavenges extracellular TNF-α so that less cytokine is available for stimulation. Defects in
proteolytic shedding of TNFR1 are thought to be involved in TNFR-associated periodic
syndrome (TRAPS) that is characterized by chronic inflammation and fever [80].
The inducible expression of TNFR2 offers yet another interesting way of regulation.
The intracellular domains of TNFR2 have a higher affinity to TRAF2, thereby depleting
the TRAF2 pool in the cell [77]. Hence, TRAF2 is missing at the TNFR1 complex, NF-κB
activation is impeded and apoptosis is favored.
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Figure 1.6: TNF-α signaling and NF-κB transcriptional activity are negatively regulated by
multiple means. (1) Receptor shedding renders the cell less excitable and releases solube TNFR1
that can scavenge extracellular TNF-α. (2) The de-ubiquitinating enzymes CYLD and TNFAIP3
remove activating ubiquitins from TRAF2 and IKK-γ as well as RIP1, respectively. Additionally,
TNFAIP3 possesses ubiquitin ligase activity for tagging RIP1 for degradation. (3) TRAF2 can be
scavenged to TNFR2 and be degraded, after being ubiquitinated by cIAP-1. (4) Re-synthesized
IκB-α shuttles NF-κB back to the cytosol. (5) Besides, NF-κB gets degraded upon phosphorylation.
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1.2 RNA Interference
The amount of protein being made from a gene can be controlled at the level of transcrip-
tion and translation. The sequences of enhancer and promoter regions of a gene determine
the efficacy of transcription. Transcription factors controlled by inducible signaling path-
ways activate the expression of genes that are not constitutively expressed. But also after
transcription, gene expression can be altered. RNA interference (RNAi) is one mechanism
of posttranscriptional gene regulation.
RNAi evolved as a defense mechanism against molecular parasites such as viruses and
transposons [252, 156]. Discovered in plants and first described as RNAi in Caenorhabditis
elegans [68, 74], this evolutionarily conserved gene silencing mechanism has proven to be
a valuable tool for studying gene function in several species by transiently silencing genes
[94].
RNAi is mediated by small double-stranded RNAs and relies on sequence comple-
mentarity between the small RNA and its mRNA target [168]. These double-stranded
RNAs can either be of endogenous origin or be artificially introduced. Naturally occurring
RNAs are microRNAs (miRNAs), endogenously expressed short interfering RNAs (endo-
siRNAs), Piwi-interacting RNAs (piRNAs), trans-acting siRNAs (tasiRNAs), small-scan
RNAs (scnRNAs) and repeat-associated siRNAs (rasiRNAs) as well as viral non-coding
RNAs [50, 184]. The best studied naturally occurring RNAi-mediating RNAs are miRNAs.
These non-coding RNAs are involved in posttranscriptional gene regulation in both ani-
mals and plants. They are transcribed as pri-miRNAs, possessing a characteristic stem-loop
structure, that are cleaved twice - once in the nucleus by Drosha [144, 59, 87, 92, 141],
once in the cytoplasm by Dicer [266, 153] - yielding the mature miRNAs [10, 63]. miRNAs
mediate either cleavage or translational repression of their complementary mRNAs [242].
Among artificially introduced RNAi reagents are e.g. short interfering (si) RNAs, short
hairpin (sh) and long hairpin RNAs as well as long double-stranded (ds) RNAs. The lat-
ter three are converted inside the cell into siRNAs by Dicer, a cytoplasmic endonuclease
[115, 89, 145]. Dicer cleaves long RNA into short RNA duplexes of about 21 nucleotides hav-
ing 5’ phosphates and 2-nucleotide 3’ overhangs, characteristic for small RNAi-mediating
RNAs [14, 67]. These short RNA duplexes represent the "mature" RNAi-mediating RNA
species.
In order to mediate gene silencing effects, the small RNAs have to be incorporated
into the RNA-induced silencing complex (RISC) [91, 73]. For enabling association with
this multiprotein complex, the small RNA has to be unwound: the strand with the least
thermodynamically stable 5’ end becomes incorporated into the multiprotein complex [86].
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Single-stranded RNAs interact with RISC complex proteins belonging to the family of
Argonaute proteins [222, 154, 155]. Argonaute proteins exist in prokaryotes as well as
eukaryotes and catalyze RNA cleavage reactions [6]. In eukaryotes, Argonaute proteins
are key components of RNAi processes [223]. In complex with these proteins, the small
RNA finds its target by sequence complementarity [160]. As a result, the targeted mRNA
becomes either degraded or translationally repressed (Figure 1.7) [151, 190, 161, 69].
DicerDicer
RISC
RISC
AAAA
Figure 1.7: Mechanism of RNAi. Short hairpin (sh) RNA-encoding plasmids are transcribed in
the nucleus as long RNAs having a characteristic stem-loop structure. Exported into the cytoplasm,
the shRNA is converted into small interfering (si) RNAs through cleavage by the RNase III en-
donuclease Dicer. Similarly, long double stranded (ds) RNAs are cleaved by Dicer into siRNAs. One
strand of the siRNA becomes then incorporated into the RNA-induced silencing complex (RISC)
guiding the RNAi machinery to the mRNA target by sequence complementarity. As a result, the
mRNA becomes degraded.
1.3 Using RNAi to Study Gene Function
Two general approaches are used to infer gene function from loss-of-function phenotypes.
Classical forward genetics employ mutagenesis screens in order to create mutant pheno-
types. Mutations then have to be mapped to the gene whose loss-of-function caused a
phenotype. In contrast, reverse genetics experiments take the gene as starting point assess-
ing whether its loss-of-function yields a phenotype.
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Table 1.2: Artificially introduced small non-coding RNAs.
small non-coding RNA organism function
double-stranded RNAs bathing of fly cells, processed to siRNAs:
(dsRNAs) feeded to worms mRNA cleavage
small interfering RNAs transfection of mRNA cleavage
(siRNAs) mammalian cells
endoribonuclease-prepared short transfection of mRNA cleavage
interfering RNAs (esiRNAs) mammalian cells
short hairpin RNAs transduction/transfection of matured to siRNAs:
(shRNAs) mammalian cells mRNA cleavage
RNAi is a powerful tool for reverse genetics experiments. Common RNA species applied
in these experiments are dsRNAs, siRNAs, endoribonuclease-prepared short interfering
RNA (esiRNAs), shRNAs and long hairpin RNAs (table 1.2). dsRNAs are used to study
gene function e.g. in C. elegans (applied by feeding or injection), Drosophila melanogaster
(applied by bathing ex vivo) and Schmidtea mediterranea (applied by feeding or injection).
shRNA-encoding plasmids can be transfected into mammalian cells using viral or non-viral
transfection methods. shRNAs are transcribed in the nucleus into pri-miRNA-similar stem
loop precursors and mature like miRNAs into "active" siRNAs. siRNAs and esiRNAs are
"mature" RNAi-mediating species and are transfected as such into mammalian cells using
transfection reagent- or electroporation-based methods. For their use in mammalian cells,
siRNAs are chemically modified in order to improve mRNA silencing effects, while avoiding
adverse effects such as an interferon response [48, 3, 116, 241].
In genome-wide RNAi screens, each annotated gene in the genome is targeted by an
RNAi-mediating reagent. This allows for the systematic investigation of gene function in
different biological processes, inferred from their loss-of-function phenotypes. Using the
appropriate reporter system for a biological question, the consequences of silencing a gene
in any process can be determined. This can be done working in cell culture or even in whole
organisms such as worms and flies [132, 62]. Cell-based reporter systems range from assess-
ing cell viability with the help of specific dyes or luciferase reactions and transcriptional
activity in low-content screens to monitoring cell morphology in high-content microscopy
screens (Figure 1.8) [9, 30, 178, 28].
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Figure 1.8: Genome-wide RNAi screening approaches. Different RNAi-mediating RNA species
are used in research for functional genomics, e.g. double stranded RNAs (dsRNAs), that are fed to
worms (via E. coli expressing dsRNA) or taken up by fly cells by a process called bathing. Small in-
terfering (si) RNAs and short hairpin (sh) RNA-encoding plasmids are employed for transfection of
mammalian cells. The application of barcoded shRNAs permits performing screens in genome-wide
pools (multiplexed screens), which are analyzed e.g. by microarray hybridization or DNA sequenc-
ing. In contrast, in arrayed screens only one gene is targeted per spot (well). This screening format
enables different read-outs, e.g. luciferase-based read-outs looking at cell viability or transcription
factor activity. Using clear bottom plates, staining cells with dyes is a possible read-out. Applica-
ble microscopy-based read-outs range from single dye measurements [e.g. studying cell cycle phase
by PI staining, measured with the help of an Acumen plate reader or by fluorescence activated
cell sorting (FACS)], simple measurements using multiple stains such as nuclear translocation to
complex cell morphological studies. As more sophisticated screens generate ever more information,
often interrogating multiple features simultaneously, analysis tools need to retrieve, integrate and
display more and more parameters.
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1.3.1 Cell-based assays employed in RNAi screening
As an example of a screening approach, the dual luciferase assay will be explained. This
assay is based on a system that emits visible light at two different wavelengths. One
luciferase construct reports whether the biological process of interest is active or not.
Another luciferase construct serves as co-reporter to control cell viability and transfection
efficiency. The two different reporters can be used in parallel since they convert different
substrates and emit light at different wavelengths (Figure 1.9).
For usage as a pathway-specific reporter, a luciferase gene, e.g. the firefly luciferase gene,
is under the control of regulatory elements relevant to the biological process being studied.
For example, if the regulation of one specific gene is to be investigated, the luciferase gene
expression is driven by the promoter region of the gene of interest [83]. Likewise, if one
specific transcription factor is of interest, transcription factor binding sites can be employed
[147]. The reporter has to respond to treatment reflecting the biological process of interest.
Accordingly, reporter expression has to be decreased if the studied biological process is
interrupted, e.g. by RNAi-mediated gene silencing.
As co-reporter, another luciferase (e.g. the Renilla luciferase) construct is used, where
the luciferase gene is under the control of a constitutively expressed promoter. Expression of
this second reporter is used to normalize the expression of the pathway-specific reporter to.
Data acquired through low-content screening are of low dimensionality such as lists of lu-
minescence counts of two luciferases. In contrast, high-content screening data are complex,
usually consisting of microscopic images acquired in different channels. As more sophisti-
cated screens generate ever more information, analysis tools need to retrieve, integrate and
display increasing numbers of parameters (e.g. [35]).
1.3.2 RNAi reagents and cell-based screening formats
Different RNAi libraries are available for screening the human genome (or that of model
organisms) systematically for effector genes in any biological process of interest. Arrayed
libraries are ususally transfected in a miniaturized format (96-, 384- or 1536-well), with
either one well per gene, targeted by pooled siRNAs (e.g. [101]), or multiple wells per gene,
each of them containing an individual siRNA (e.g. [134]). In contrast, using barcoded
shRNA libraries, screens can be performed in genome-wide pools (multiplexed). After se-
lection of the cell population presenting the phenotype of interest, the targeted gene has
then to be defined by determining the identity of an shRNA-specific barcode (e.g. [172]).
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Figure 1.9: Concept of the dual luciferase assay. A constitutively expressed luciferase reporter
is used to control cell viability and transfection efficiency. Another luciferase construct reports
whether the biological process of interest is active or inactive. Its expression is controlled by reg-
ulatory elements relevant to the biological process being studied. A: Triggering of the biological
pathway induces pathway-specific reporter expression. B: Pathway-specific reporter expression is
decreased when the studied biological process is inhibited by RNAi-mediated gene silencing. Ex-
pression of the control reporter stays unchanged.
1.3.3 Assay design
Negative and positive controls are essential for RNAi experiments. These controls are
needed to categorize phenotypes observed after siRNA-mediated knockdown of proteins. A
negative control consists of an siRNA without cellular target or targeting a protein unre-
lated to the biological process studied. Negative controls should not influence expression of
the pathway-specific reporter allowing to determine "normal" reporter expression level. A
positive control consists of an siRNA targeting a known component of the biological pro-
cess of interest and allows to determine expression levels of the pathway-specific reporter
upon disruption of this process. Besides controls, the right assay system has to be chosen
for studying the biological process of interest. Measuring cell numbers by ATP levels for
example will report cell death, but will not yield any information on cell cycle arrest (unless
cell cycle arrest resulted in strongly reduced cell numbers) or morphological abnormalities.
Likewise, cloning the promoter region of a gene of interest into a transiently transfected
reporter will identify e.g. transcription factors involved in the transcriptional regulation of
that gene but cannot cover regulatory mechanisms mediated by chromatin modification.
Therefore, the choice of the reporter system will determine the scope of information that
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can be acquired by screening.
Figure 1.8 summarizes the different possibilities available for performing RNAi-based
screens. The biological question and analysis tools available in the laboratory dictate which
library and assay format are best to use. A variety of genome-wide screens has been per-
formed so far, identifying novel players in several different pathways and thus documenting
the power of the technique [173].
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1.4 Aim of This Thesis
TNF-α is the main mediator of inflammation and a key component of many inflammatory
diseases [137]. Even though the TNF-α pathway is relatively well studied, a variety of
open questions remain, such as the regulation of IKK activation, of NF-κB transcriptional
activity and the termination of the response.
My work aims at finding novel regulators of TNF-α signaling, identified by RNAi screen-
ing. As a first step, an assay system was to be established to measure TNF-α-induced
NF-κB transcriptional activity in human cells. The assay then had to be adapted to high
throughput screening. Subsequently, I intended to perform two genome-wide RNAi screens.
This would allow me to identify putative novel regulators of TNF-α signaling by (i) an
individual "high-stringency" screening analysis and (ii) a comparative screening analysis,
determining hits found in both screens. In the next step, I planned to develop secondary
assays to characterize these high confident candidates. The ultimate goal was to define
the level of action of chosen candidates in the signaling cascade. Identifying interaction
partners would then allow to draw conclusions on mechanistic details of the candidate’s
function in TNF-α signaling.
Chapter 2
Results
2.1 Genome-wide RNAi Screens for Identifying Novel Regu-
lators of TNF-α Signaling
TNF-α is a potent inflammatory cytokine implicated in the pathology of inflammatory dis-
eases. In order to find novel regulators of TNF-α signaling by genome-wide RNAi screening,
I first had to establish a cell-based assay to monitor NF-κB transcriptional activity. This
assay had to be suited for the use in miniaturized format that is required for large-scale
experiments. After quality control of the established assay, two genome-wide RNAi screens
were performed, analyzed and compared to each other. I then determined criteria for hit
selection and performed secondary assays to validate candidates.
2.1.1 Design and development of a cell-based assay to study NF-κB
transcriptional activity
To perform a cell-based genome-scale RNAi screen for TNF-α signaling, I first identi-
fied a cell line that was suited for studying the TNF-α pathway and could be efficiently
transfected with siRNAs. Further, siRNA transfection conditions and a cell-based assay to
monitor NF-κB transcriptional activity had to be established.
Choice of cell line Human embryonic kidney (HEK) 293T cells have been used succes-
fully in previous studies monitoring TNF-α-induced NF-κB activation (see e.g. [76, 47]).
In addition, they could be transfected with siRNAs as well as plasmids very efficiently. To
assess their response to TNF-α, HEK293T cells were treated with increasing amounts of
TNF-α for different periods of time before cell viability was assessed by measuring ATP
levels. Results presented in Figure 2.1 indicate that TNF-α did not induce cell death in
HEK293T cells. However, TNF-α induced NF-κB transcriptional activity in these cells
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(Figure 2.2), demonstrating that HEK293T cells are a suitable model cell line for studying
TNF-α-induced activation of NF-κB.
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Figure 2.1: TNF-α treatment does not induce cell death in HEK293T cells. HEK293T cells were
treated with increasing amounts of TNF-α (ng/ml) for different periods of times (12 - 20 hours (h))
before cell viability was assessed by measuring ATP levels. Measured relative light units (RLU)
were normalized to those of untreated cells. RLU describe the strength of ATP-dependent luciferase
luminescence. Error bars represent standard deviations of 4 technical replicates. One representative
result of 3 independent experiments is shown.
The dual luciferase assay: development of a reporter for monitoring NF-κB
transcriptional activity In order to detect NF-κB transcriptional activity a cell-based
dual luciferase assay was developed. It is based on a system that emits visible light in two
different wavelengths. The dual luciferase assay system is well suited for high throughput
screening since it performs reliably also in miniaturized assay format and all necessary
processing steps can be supported by automation.
To obtain an NF-κB-dependent reporter with high fold induction upon TNF-α treat-
ment, the firefly luciferase gene was fused to an artificial promoter containing eight NF-κB
binding sites. Using this "4-4-FL" reporter, I tested whether HEK293T cells responded
to TNF-α with induction of NF-κB transcriptional activity. Different amounts of TNF-α,
ranging from 2 to 40 ng/ml, were used to stimulate cells for different periods of time.
Transfecting different amounts of 4-4-FL (2 - 40 ng/well) showed that induction was high-
est upon transfection of 2 ng of reporter per well (data not shown). NF-κB reporter ex-
pression increased with increasing amounts of TNF-α and increasing stimulation periods
(Figure 2.2). Using 2 ng of the reporter and 20 ng/ml TNF-α for 16 hours, the expression
of the 4-4-FL NF-κB reporter was induced about 16-fold. The experiment demonstrated
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that the 4-4-FL reporter could be used to monitor TNF-α-induced NF-κB activation. In
further experiments HEK293T cells were therefore stimulated with 20 ng/ml TNF-α for
16 hours. Under these conditions NF-κB-dependent firefly luciferase was highly expressed
without further induction of expression after longer incubations.
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Figure 2.2: TNF-α treatment induces NF-κB transcriptional activity in HEK293T cells.
HEK293T cell were transfected with 2 ng 4-4 FL NF-κB reporter per 384-well plate well and
treated with different amounts of TNF-α (ng/ml) for different time periods. Fold induction of
luciferase expression was calculated in relation to basal (unstimulated) expression. Error bars
represent standard deviations of at least 4 technical replicates. One representative result of 3 in-
dependent experiments is shown.
The dual luciferase assay: development of a constitutively expressed co-reporter
In luciferase assays based on transient transfection, transfection efficiency of plasmids and
cell viability have to be monitored to avoid false positives: besides changes in transcriptional
activity, low NF-κB reporter expression could also result from cell death or less effective
plasmid transfection. Therefore, a constitutively expressed Renilla luciferase reporter was
used to control transfection efficiency and cell viability. Renilla luciferase converts a dif-
ferent substrate and emits light at another wavelength than firefly luciferase enabling the
parallel use of these two luciferases.
Two commonly used plasmids encoding Renilla luciferase (RL), CMV-RL and TK-RL,
driven from constitutively active promoters - CMV and TK, respectively - were tested
in HEK293T cells in combination with TNF-α treatment. Neither of them was suitable
since Renilla luciferase expression from both plasmids was influenced by TNF-α under the
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conditions used (Figure 2.3). Whereas CMV-RL expression was strongly induced upon
TNF-α treatment, TK-RL expression was decreased by TNF-α to such low levels that the
expression would not have been robust enough for a high-throughput assay. As both these
promoters are of viral origin and therefore are likely influenced by immune modulatory
molecules such as TNF-α [192], a plasmid was cloned containing a constitutively active,
non-viral promoter, the human β-actin promoter (act-RL).
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Figure 2.3: Influence of TNF-α stimulation on Renilla expression driven by viral promoters. Cells
were stimulated for the indicated time periods with 20 ng/ml TNF-α before Renilla luciferase
expression was determined. A: 2 ng/384-well plate well of CMV-RL were used, yielding a strong
luciferase expression. Expression is further increased by TNF-α, rendering the plasmid unsuited for
monitoring cell viability defects. One representative result of at least 3 independent experiments
is shown. B: 20 ng/384-well plate well of TK-RL were used yielding a much weaker luciferase
expression. TK-RL expression was decreased by TNF-α to such low levels that the expression would
not be robust enough for a high-throughput assay. A+B: RLU: relative light units representing the
strength of luciferase luminescence. Errror bars represent standard deviations of at least 4 technical
replicates.
Constitutive expression of the control act-RL reporter was assessed by transfecting
HEK293T cells with both reporter plasmids and stimulating these cells two days after
transfection with 20 ng/ml TNF-α for 16 hours (Figure 2.4). Even though act-RL ex-
pression was reduced by approximately 50% after TNF-α treatment, act-RL expression
was high enough to yield stable results under stimulated conditions (in contrast to TK-
RL, Figures 2.3 and 2.4). Stimulation by TNF-α was confirmed by induced expression of
the 4-4-FL reporter. Subsequent assays showed that TNF-α-induced reduction of act-RL
expression was also reduced upon silencing of all TNF-α signaling components tested, ex-
cept for silencing of TNFR1 (data not shown). Since all TNF-α treated samples (except
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for TNFR1 knockdown cells) exhibited similar act-RL expression levels, the reporter was
suitable as a reporter for cell viability and transfection efficiency.
By these experiments I determined optimal assay conditions. In further experiments, 2
ng per well 4-4-FL and 20 ng per well act-RL were transfected simultaneously. act-RL ex-
pression was used to normalize 4-4-FL expression by dividing firefly luciferase luminescence
counts by Renilla luciferase luminescence counts.
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Figure 2.4: Expression levels of NF-κB-dependent 4-4-FL and constitutively expressed act-RL
without and with TNF-α treatment (20 ng/ml) for 16 h. RLU: relative light units representing the
strength of luciferase luminescence. One representative result of at least 5 independent experiments
is shown. Error bars indicate standard deviations of at least 4 technical replicates.
Further aspects to be taken into consideration for assay establishment Firstly,
since there are two receptors mediating TNF-α signaling, TNFRSF1A (TNFR1) and
TNFRSF1B (TNFR2), I tested which one of these was the major mediator of TNF-α-
induced signaling in HEK293T cells. Cells were reverse transfected with relevant siRNAs
before being transfected with 4-4-FL and act-RL plasmids on the next day. TNF-α signal-
ing was induced for 16 hours using 20 ng/ml TNF-α. As shown in Figure 2.5A, knockdown
of TNFR1 but not of TNFR2 abolished the induction of the NF-κB-dependent firefly lu-
ciferase. These phenotypes were observed using different individual siRNAs and siRNA
pools. Double-knockdown of both TNF-α receptors did not enhance the TNFR1 knock-
down phenotype. Thus, TNFR1 but not TNFR2 mediated TNF-α signaling in HEK293T
cells. Hence, I used siRNA targeting TNFR1 as a positive control in future assays. Positive
and negative siRNA controls are used in RNAi experiments to be able to categorize pheno-
types observed after siRNA-mediated knockdown of transcripts. In addition to siTNFR1,
siRNA against the TNF-α pathway component RelA was selected as a positive control.
Both siRNAs strongly reduced TNF-α-induced 4-4-FL expression (Figure 2.5B). siLRP5
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and siControl #1 (siCon) were selected as negative controls (Figure 2.5B). LRP5 is a
known component of the Wnt signaling pathway, whereas siCon is a scrambled siRNA
without a predicted target. siLRP5 did not significantly alter 4-4-FL expression and was
thus well suited as a negative control. Even though siCon showed a mild induction of
NF-κB transcriptional activity, it was used as a negative control in a kinase pilot screen
(see below).
Secondly, starving cells before cytokine treatment is often used to reduce background
signaling activity (e.g. [135, 181, 118]). In order to assess the effect of the absence or
presence of serum on the reporter system, the culture medium was exchanged 24 h prior
to stimulation and replaced by either complete serum (10%) or reduced serum (0.5%)
containing medium. As NF-κB transcriptional activity was similar under both conditions
(Figure 2.5C), all luciferase assays were performed in 10% serum containing medium.
Finally, it was technically not feasible to stimulate cells for 16 hours with TNF-α and
successively process all plates of a genome-wide screen on one day. Therefore, I had to find
a means to uncouple the endpoint of stimulation and the readout. To this end, I tested
whether lysed cells could be frozen without loss of the luciferase signal after thawing. Cell
lysates were frozen at -80◦C and thawed on the next day to perform the luciferase readout.
As shown in Figure 2.5D, freezing and thawing did not influence luciferase luminescence,
rendering the assay setup feasible for genome-scale experiments.
Validation of the assay: small-scale pilot screen
Before performing a genome-wide RNAi screen I conducted a small-scale pilot screen to as-
sess the quality of the established assay. The pilot screen consisted in three 384-well plates
containing 779 known and predicted kinases and 80 cell cycle regulators (Dharmacon Hu-
man Protein Kinase Set). The screen was performed in duplicate under the same conditions
as a genome-wide screen, including freezing plates after addition of the lysis buffer at -80◦C
and thawing them on the next day for the luciferase readout. Data was analyzed using the
Bioconductor/R package "cellHTS" [29]. First, data consisting in luciferase luminescence
reads were log2 transformed and shorth normalized (for details see Material and Methods).
After dividing firefly by Renilla luciferase values, replicates are averaged. The following
critical points, reflecting the assay quality, were assessed after analysis:
(i) Plate effects. Spacial effects can affect luminescence reads. As shown in the overview
of all plates of the pilot screen in Figure 2.6A, there were no severe plate position effects
affecting luciferase counts.
(ii) Reproducibility of replicates. Results of the pilot screen were highly reproducible
with an average Spearman rank correlation of replicates of 0.9 (best replicates 0.93, worst
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Figure 2.5: Optimizing the NF-κB luciferase assay. A: TNF-α signaling in HEK293T cells was
mediated by TNFRSF1A (TNFR1). Knockdown of TNFRSF1B (TNFR2) did not decrease relative
signaling pathway activity (compared to mock control). Cells were transfected with four individual
siRNAs (1-4) or with pools of four siRNAs (pool, siLRP5). R1+R2: double-knockdown of both
receptors (siRNA pools), siLRP5: negative control; siRNA concentration used: 50 nM. One repre-
sentative result of two independent experiments is shown. B: Phenotypes of the siRNA controls
that were used in the RNAi screens. siTNFR1 and siRelA strongly reduced NF-κB reporter activity
and served as positive controls. siLRP5 and siCon did not target a known component of the TNF-α
pathway and were used as negative controls. Pools of four siRNAs were used. One representative
result of at least 3 independent experiments is shown. C: Serum in the culture medium does not
affect firefly luciferase expression. Cells in either complete serum (10%) or reduced serum (0.5%)
containing medium express comparable amounts of firefly luciferase. RLU (relative light units)
representing strength of firefly luciferase luminescence are shown. One representative result of two
independent experiments is shown. D: Freezing cell lysates at -80◦C and thawing does not affect
luciferase luminescence. One representative result of two independent experiments is shown. B+D:
Relative signaling pathway activity compared to mock control is shown. mock: medium transfected
cells. siRNA concentration used: 50 nM. All error bars represent standard deviations of at least 4
technical replicates.
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Figure 2.6: Performance of the established luciferase assay in a small scale pilot screen. A:
Overview of all plates of the pilot screen. Normalized firefly luciferase signals are visualized in
heat maps to uncover plate position effects. Blue depicts reduction, red color induction of signaling
activity. Wells 2A-H: siTNFR1 (strong positive control), 2I-P: siRelA (intermediate phenotype),
3I-L: siCon, 3M-P: siLRP5 (negative controls). B: Evaluation of positive and negative controls used
in the screen. The plot shows the range of log2 transformed values of positive (strong: siTNFR1,
weaker phenotype: siRelA) and negative (siLRP5) controls; distributions of negative and positive
controls seperated clearly (also reflected in the high Z’-factor of 0.62).
replicates 0.87).
(iii) Performance of the controls. Two different positive controls were used: RelA (NF-κB),
whose knockdown resulted in an intermediate phenotype, and TNFR1, whose knockdown
decreased firefly luciferase expression after TNF-α stimulation to levels comparable to the
unstimulated state. siTNFR1 treatment was termed "positive control" in further analysis.
Likewise, two different negative controls were used. siCon could not serve as a negative
control, since it strongly increased 4-4-FL reporter expression (data not shown). siCon
was therefore excluded from further luciferase assays. siLRP5 was termed "negative con-
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trol" in further analysis. Positive and negative controls showed clearly distinct phenotypes
(Figure 2.6B). The Z’-factor which is a statistical way to express how well the distribution
of values for positive and negative controls seperate was calculated to be 0.62. This means
that the assay had a very good quality (for details see Material and Methods).
By these means of quality assessment, the established assay was shown to perform well
in small-scale pilot screen and could thus be used in genome-wide screens for monitoring
TNF-α signaling activity without further modification. Besides, the pilot screen identi-
fied several factors implicated in NF-κB signaling such as the MAPKs (mitogen-activated
protein kinases) MAP2K3 and MAP2K2 as well as RIPK1 (receptor-interacting protein
kinase) as positive regulators.
2.1.2 Genome-wide RNAi screening
I performed two genome-wide RNAi screens to both use their individual data sets to identify
novel regulators of TNF-α signaling as well as to compare the results of the two screens to
each other. For the first genome-wide RNAi screen I used siRNA library A (as indicated in
Materials and Methods). The library targeted almost 22 000 genes and consisted of 68 384-
well plates. For the second screen I used the genome-wide siRNA library B (as indicated in
Materials and Methods), targeting about 21 000 genes. This library consisted of 56 384-well
plates. Both screen were done in duplicate and were analyzed using the Bioconductor/R
package cellHTS. The first step of analysis consisted in a logarithmic transformation of
the data, followed by normalization. Then firefly luciferase counts were divided by Renilla
luciferase values and replicates were averaged (for details see Materials and Methods). In
a second step, the quality of the screens was assessed.
Genome-wide screen using library A
The quality of screen A was assessed by means of plate position effects, reproducibility of
replicates and separation of the controls.
(i) Plate effects (Figure 2.7A). The "plate view" representation, an overview of all
screening plates, indicated only minor edge effects for most plates, consisting in decreased
firefly luciferase expression in the first row of the plates. (These rows were excluded from
further analysis.) However analysis of the raw data, exemplified in Figure 2.7B, revealed
severe plate position effects on many plates of the first batch that was processed. These
effects consisted in lower luciferase values in the center of the plate than compared to
the edges. These "thawing effects" illustrate that thawing plates for 20 minutes at room
temperature was not long enough since the center of the plates was still cold. Less lumines-
cence was detected in the cold center positions probably because catalytic reactions such
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as luciferase substrate conversion are temperature-dependent. Plates were thawed longer
(30 minutes at 37◦C) as soon as this effect was discovered. Plates affected were excluded
from analysis.
(ii) Reproducibility of replicates. Results of the screen A showed a lower avarage repro-
ducibility than the pilot screen with an average Spearman rank correlation of replicates of
0.68 (best plates 0.92, worst plates 0.2). However, screening data was reproducible between
most replicates, as depicted in Figure 2.8A.
(iii) Performance of the controls (Figure 2.8B and C). As for the pilot screen, siRNAs
against TNFR1, giving a strong reduction in TNF-α-dependent 4-4-FL reporter activ-
ity, and against RelA, having an intermediate phenotype, were used as positive controls.
siLRP5 was used as negative control. The Z’-factor calculated for screen A was 0.5. This
Z’-factor indicates that the assay was of good quality [19].
Screen A identified 230 genes whose knockdown strongly reduced TNF-α-induced NF-κB
activation (according to criteria specified in 2.1.3).
Genome-wide screen using library B
Likewise, the quality of screen B was assessed.
(i) Plate effects. Figure 2.9B gives an overview of the raw data of all screening plates.
There were no thawing effects detectable since plates were thawed 30 minutes at 37◦C.
However, there were strong edge effects that were also apparent in the overview of all
screening plates after normalization (Figure 2.9A): on most plates, either the first or the
last (two) row(s) showed an increased luciferase activity. These rows were excluded from
further analysis.
(ii) Reproducibility of replicates. The Spearman rank correlation of replicates averaged
0.6 (best plates 0.8, worst plates 0.31) demonstrating a similar reproducibility of screening
results as screen A. The reproducibility of replicates is also visualized in Figure 2.10A.
(iii) Performance of the controls. Even though the same controls were used, the Z’-factor
was with maximal 0.38 lower than the one in screen A (Figure 2.10B and C). This indicated
that the quality of the assay (in terms of separation of the controls) was acceptable, but
not good.
Screen B, being of similar quality as screen A, identified 219 genes whose knockdown
strongly reduced TNF-α-induced NF-κB activation (according to criteria specified in 2.1.3).
2.1.3 Hit definition and screen comparison
After screening, I was interested in defining so-called hits, namely genes whose knockdown
strongly influenced NF-κB reporter activity. To this end, I used a statistical means to
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Figure 2.7: Overview of all plates of screen A. A: Color-coded normalized luciferase signal inten-
sities of all plates in screen A (blue equals reduction of the intensity compared to the mean, red
means increase of the intensity). This visualization can display plate effects - differences in mea-
sured luciferase values resulting from different cell growing conditions according to the position
of the well on the plate (edges versus middle). Many plates show mild edge effects consisting in
decreased firefly luciferase expression in the first row of the plate. The "plate view" also visualizes
pipetting errors as depicted in the alternating pattern of luciferase expression in column 2 of plate
33. Besides, an accumulation of wells with low luciferase expression on plate 26 is striking: this
plate contained siRNAs targeting genes encoding ribosomal proteins whose silencing strongly de-
creased viability. Plate 40 is not depicted since both replicates were excluded because of "freezing
effects" (see B). B: Unnormalized firefly luciferase intensity of one individual plate of the screen.
This plate is affected by "freezing effects" (see text), illustrated by lower luciferase values in the
center of the plate than compared to the edges. P = positive controls (A-H: siTNFR1, I-P: siRelA),
N = negative controls (siLRP5).
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Figure 2.8: Reproducibility of screening results and separation of controls in screen A. A: Scatter-
plot plotting measurements of the two replicates against each other for channel 1 (Renilla luciferase)
and channel 2 (firefly luciferase). Results of screen A are reproducible, indicated by the distribution
of plotted measurements along the diagonal. Red dots depict measurements for positive controls,
blue dots for negative controls. B+C: Distribution of normalized luciferase intensities of controls in
replicate one and two, respectively. The Z’-factor is a statistical means for expressing the separation
of the distribution of luciferase expression values measured for positive (siTNFR1, yellow; siRelA,
red) or negative controls (siLRP5, blue). Z’-factors from 0-0.5 depict acceptable, from 0.5-1 very
good assays [19].
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Figure 2.9: Overview of all plates of screen B. A: Color-coded normalized luciferase signal in-
tensities of all plates in screen B (blue equals reduction of the intensity compared to the mean,
red means increase of the intensity). This visualization can display plate effects - differences in
measured luciferase values resulting from different culture conditions according to the position of
the well on the plate (edges versus middle). On most plates of screen B, either the first or the last
(two) row(s) showed an increased luciferase activity. B: Unnormalized firefly luciferase intensity of
one individual plate of the screen. In contrast to screen A, no "freezing effects" were detectable
on plates of screen B. P = positive controls (2E-H, 23I-L: siTNFR1; 2M-P, 23A-D: siRelA), N =
negative controls (2A-D, 23M-P: siCon; 2I-L, 23E-H: siLRP5).
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Figure 2.10: Reproducibility of screening results and separation of controls in screen B. A: Scat-
terplot plotting measurements of the two replicates against each other for channel 1 (Renilla
luciferase) and channel 2 (firefly luciferase). Results of screen B are reproducible, indicated by the
distribution of plotted measurements along the diagonal. Red dots depict measurements for posi-
tive controls, blue dots for negative controls. B+C: Distribution of normalized luciferase intensities
of controls in replicate one and two, respectively. The Z’-factor is a statistical means for expressing
the separation of the distribution of luciferase expression values measured for positive (siTNFR1,
yellow; siRelA, red) or negative controls (siLRP5, blue). Z’-factors from 0-0.5 depict acceptable,
from 0.5-1 very good assays [19].
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classify the strength and robustness of a phenotype, the z-score. The z-score expresses how
many standard deviation an observation is above or below the mean of all measurements
(definition see Materials and Methods). It is used by the software cellHTS to rank all genes
covered by the library in its final output. In the analysis of the TNF-α screens, a negative
z-score represented a reduction of TNF-α signaling activity, a positive z-score an induction.
Figure 2.11: Quantile-quantile plots for screening results. Normally distributed quantiles were
plotted against actual pathway screening result quantiles. A fit to a normal distribution is repre-
sented by the black line. siRNAs in the tail at the negative extreme represent RNAi experiments
with significant phenotype. The red line depicts where the z-score cut-off for further analysis was
set (z-score ≤ -2.5). A: Screen A, B: Screen B.
In a first step, siRNAs were excluded from the hit list of screen A whose phenotypes
were most likely not mediated by specific effects on TNF-α signaling but by cytotoxic
effects. In order to identify such cytotoxic siRNAs a viability screen using library A had
previously been performed in HEK293T cells (Dierk Ingelfinger, unpublished data). These
cytotoxic siRNAs of library A were excluded from the hit list of the TNF-α screen A. For
library B, similar data were not available. In quantile-quantile (QQ)-plots, normally dis-
tributed quantiles are plotted against actual pathway screening result quantiles. A cut-off
was determined where z-scores deviated from a normal distribution. For both screen A and
B the cut-off was set to a z-score of ≤ -2.5, represented by the red lines in Figure 2.11.
Two additional filters were applied to further decrease the number of hits, selecting only
candidates fulfilling stringent cut-off criteria. In a first filtering step (FL filter), only hits
reducing firefly luciferase expression at least by 50% (as compared to the mean of all mea-
surements of the experiment) were selected. In a second filtering step (RL filter), siRNAs
causing viability defects were excluded by selecting only hits that showed a Renilla lu-
ciferase expression level of at least 70% as compared to the mean of all measurements of
the experiment. Applying these criteria, tables with hits were generated (supplementary
36
A.1 and A.2). 74 out of 230 initial hits (defined by z-score cut-off) of screen A and 49
out of 219 intial hits of screen B were selected. In addition, candidates were determined
that were hits in both screens. For this combined data set, the z-score cut-off was set to
≤ -1.25. The loss of stringency (and thereby the increased likeliness of false positives) by
this lower threshold is expected to be compensated by a hit selection based on the overlap
of two hit lists instead of one. The combined data set did non include data points that were
excluded in previous analysis steps in either of the two screens. 177 hits were identified in
the overlap of the two screens.
To analyze the overall overlap of the two TNF-α screens, the z-scores of all genes of both
screens were plotted against each other. Figure 2.12A shows that most siRNAs in both
screens did not show a phenotype (as expected): their z-scores cluster around 0. Strong hits
identified in both screens with a negative z-score would appear in the lower left quadrant
of the plot. However, there is no accumulation of data points in this quadrant. Only seven
genes passed the cut-off that was applied in the individual screening analysis (z-score of
≤ -2.5; among them one of the chosen candidates, LILRA2, Figure 2.12B), indicating that
screen A and B exhibit only a low overlap.
2.1.4 First candidate selection
From the three different hit lists, candidates with strong phenotypes were selected for
further experiments. The most promising candidates were selected by data mining using
public online databases, like PubMed, and the Harvester tool [149]. The following criteria
were applied in this selection process. Firstly, gene ontology (GO) terms were annotated
[81], if available. Candidates were preferred that could be linked to immunity or that were
of unknown function. Further, functional domains of the respective proteins were assessed
(e.g. using UniProt). Proteins of undefined structure or with domains known to be involved
in TNF-α signaling were preferred over those possessing unrelated domains. Additionally,
the functions of orthologues in other species were assessed to identify putative evolution-
arily conserved proteins. Proteins with potentially conserved function were selected. To
summarize, proteins of unknown function or proteins being linked to immune function or
NF-κB signaling were particularly interesting. 77 candidates were selected based on this
data mining.
2.1.5 Secondary validation of candidate genes
In a process termed "secondary validation" screening phenotypes have to be reconfirmed in
order to exclude genes with phenotypes caused by screening artifacts such as plate position
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Symbol z-score   screen A
z-score 
screen B GeneID RefSeq description
WDR1 -3 -3,35 9948 NM_005112
WD repeat protein; might 
be involved in disassembly 
of actin filaments
EML1 -2,76 -2,66 2009 NM_004434
echinoderm microtubule 
associated protein like; 
strong candidate for the 
Usher syndrome
LILRA2 -2,88 -2,5 11027 NM_006866 leukocyte immunoglobulin-
like receptor; integrin
HSMPP8 -2,76 -3,32 54737 NM_017520
M-phase phosphoprotein 8; 
chromatin binding, cell 
cycle
ATF7IP -3,32 -2,85 55729 NM_018179 activating transcription 
factor 7 interacting protein
ZFPM1 -2,57 -2,52 161882 NM_153813
ZFPM1 zinc finger protein, 
multitype 1; zinc and DNA 
binding
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Figure 2.12: Comparison of results of screens A and B. A: In this smoothscatter plot the z-scores
of each gene in both screens were plotted against each other. The density of measurements (the
number of plotted genes) is depicted as a color gradient, with light color depicting low densitiy
(little number of genes) and dark color high density (high number of genes) with a distinct z-score.
Scattered individual measurements are plotted as dark dots. The two screens showed little overlap
in the strongest hits, as indicated by the absent accumulation of points in the left lower quadrant.
B: Table listing the seven genes that fulfilled the cut-off criteria applied in the individual screening
analysis for both screens.
effects. In secondary validation, the original screening assay was repeated to reproduce
screening results. In addition, a different assay - a secondary assay - was employed to
confirm the phenotypes using a different readout. Since the dual luciferase assay is based
on artificially introduced reporters, a secondary assay was established using an endogenous
readout. I used an enzyme-linked immunosorbent assay (ELISA) to detect protein levels
of the TNF-α target gene interleukin (IL) 8. Additionally, siRNA-specific but candidate-
unspecific artifacts (phenotypes due to effects unrelated to the gene that was supposed
to be targeted, such as cytotoxic or off-target effects) were excluded by targeting the
same gene with several individual siRNAs. Only if the same phenotype was observed with
several siRNAs in both luciferase assay and ELISA, a screening hit was considered to be a
confirmed candidate.
Establishing ELISA for IL-8 secretion in HEK293T cells
Since IL-8 is a known target gene of TNF-α [138] and its secretion can easily be measured
by ELISA, I assessed whether HEK293T cells secreted IL-8 in a TNF-α- and NF-κB-
dependent manner. Cells reverse transfected with siRNAs were stimulated with 20 ng/ml
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TNF-α before supernatants were harvested and IL-8 secretion was assessed by ELISA.
As illustrated in Figure 2.13, the amount of secreted IL-8 increased with the duration of
the TNF-α stimulus. Whereas TNFR1 knockdown abolished IL-8 induction almost com-
pletely, there was residual IL-8 secretion upon RelA knockdown. However, IL-8 secretion
was strongly dependent on TNF-α signaling. IL-8 secretion measured by ELISA could thus
serve as a secondary assay for measuring TNF-α signaling activity.
Supernatants were harvested after 16 hours of stimulation in further assays, as it allowed
performing the luciferase assay and the ELISA in parallel and directly comparing the
phenotypes in the two different assays.
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Figure 2.13: HEK293T cells secrete IL-8 upon stimulation with TNF-α. Cells were reverse trans-
fected with negative (medium (mock), siCon) and positive controls (siTNFR1, siRelA). Super-
natants were harvested three days after transfection, and at indicated time points prior to that
cells were treated with 20 ng/ml TNF-α. IL-8 secretion is shown in pg/ml as assessed by ELISA.
siRNA concentration used: 50 nM. One result of two independent experiments is shown. Error bars
represent standard deviations of two technical replicates.
Secondary validation in HEK293T and HepG2 cells
In order to validate screening results, phenotypes of the candidates were first confirmed
with four individual siRNAs per gene from Dharmacon and a pool of these four siRNAs as
well as siRNA pools from Qiagen in HEK293T cells. Silencing effects were assessed both by
luciferase assay and by ELISA for IL-8 secretion (supplementary tables A.6 and A.7). After
this first round of validation, hits were selected according to the strength and the robustness
of their phenotypes. At least two out four individual siRNAs per candidate showed an at
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least 20% reduction in TNF-α signaling activity. Subsequently, luciferase assay and ELISA
were also established in HepG2 cells (Marie Metzig, MD thesis). These secondary assays
were performed in HepG2 cells to test cell type-specific action of candidates (supplementary
tables A.8 and A.9). In the end, seven candidates with the most robust phenotypes in both
cell lines were chosen for further analysis. The process of secondary validation and candidate
selection is summarized in Figure 2.14.
screen A screen B
230 177219
screening
validation I
characterizing
data mining
16 34 27
validation II
6 64
3 22
overlap 
separate analysis of individual screens
z-score ≤ -2.5
combined analysis of both screens
z-score ≤ -1.25
filtering viability
FL, RL
FL
RL
74 49
Figure 2.14: Schematic representation of the decision making from the first hit lists to the final
candidate list. Genome-wide RNAi screens using two different siRNA libraries yielded three lists
of potentially novel regulators of TNF-α signaling. 230 and 219 hits were identified by screens A
and B, respectively (based on a z-score cut-off of ≤ -2.5), 177 hits were determined by the overlap
of the two screens (based on a z-score cut-off of ≤ -1.25). By applying stringent filters to the two
individual screening hit lists, the number of candidates was minimized to 74 (screen A) and 49
(screen B). These filters consisted in: (i) a viability filter (screen A only), excluding siRNAs (and
thus genes) which were shown to be cytotoxic, (ii) FL filter: firefly luciferase expression had to
average at most 50% of the experiment mean, (iii) RL filter: Renilla luciferase expression had
to average at least 70% of the experiment mean. Subsequently, 77 candidates were selected by
data mining, either showing some relation to immune signaling (e.g. by shared protein domains
or interaction partners) or being uncharacterized proteins. The first round of validation consisted
in performing the dual-luciferase assay and an IL-8 ELISA in parallel in HEK293T cells, using
several individual siRNAs per gene. Thereby, candidates were determined that decreased TNF-α
signaling activity in both assays by at least 20 % with at least two different siRNAs. 16 candidates
entered the second round of validation in which the same assays and siRNAs were tested in HepG2
cells to exclude cell type-specific phenotypes. Validation resulted in the identification of candidates
showing robust phenotypes in two assays with at least two individual siRNAs in two different cell
lines.
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Phenotypes of the seven selected candidates
Seven candidates were selected in the validation process described above. For more infor-
mation on these candidates see table 2.1 and the discussion. Figures 2.15 and 2.16 show
the phenotypes of siRNAs targeting the candidates with regards to TNF-α signaling in
HEK293T and HepG2 cells, respectively. Knockdown of candidates reduced TNF-α sig-
naling activity in luciferase assay and ELISA in both cell lines by at least 20% (except
for MEN1 in HepG2 ELISA). In contrast to LILRA2 whose silencing only affected TNF-
α signaling activity with statistical significance in the dual luciferase assay in HEK293T
cells, the effect of CASP4 silencing exhibited statistical significance under all conditions
tested. siGAB3 showed only statistically significant effects in HepG2 cells, whereas the op-
posite was true for siITGA5. Knockdown of SPP1 and GAB3 decreased TNF-α signaling
activity with statistical significance in all assays except for the luciferase assay in HepG2
and HEK293T cells, respectively. Treatment with siMEN1 showed statistically significant
effects in the luciferase assay in HepG2 cells as well as the ELISA in HEK293T cells. In
addition to effects on TNF-α signaling activity, it was confirmed that knockdown of none of
these candidates caused viability defects (Figure 2.17) nor showed pleiotropic phenotypes
as assessed by their phenotypes in other genome-wide screens ([106]; Anan Ragab, Dierk
Ingelfinger, unpublished observations).
Depletion of candidate mRNAs was ascertained by quantitative (q) real time (RT)
PCR (Figure 2.18). Both CASP4 and LILRA2 mRNA levels were strongly reduced to 16
and 15%, respectively, after treatment with specific siRNAs (compared to mRNA levels
of siRL treated cells). siITGA5, siGAB3, siUSP2, siSPP1 and siMEN1 reduced levels of
corresponding mRNAs by more then 55 %.
In conclusion, I selected 77 hits from the different hit lists generated by genome-wide
RNAi screening. Of 77 hits, 7 candidates were determined with the help of two validation
rounds. These consisted in performing secondary assays in two different cell lines using sev-
eral individual siRNAs. Knockdown of the candidates did not affect viability of HEK293T
cells. In addition, neither of the candidates was identified by two other genome-wide screens
performed in the Boutros laboratory. mRNAs of all candidates were depleted in HEK293T
cells upon treatment with corresponding siRNAs.
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Table 2.1: Table of seven potential novel regulators of TNF-α signaling. TLR: Toll-like recep-
tor, GRB: growth factor receptor-bound protein, MAPK: mitogen-activated protein kinase, HIV:
human immunodeficiency virus.
gene symbol name gene function gene ontology
USP2 ubiquitin specific deubiquinating enzyme ubiquitin thiolesterase activity,
peptidase 2 ubiquitin-dependent
protein catabolic process
SPP1 secreted extracellular matrix protein cytokine activity, protein binding,
phosphoprotein 1 that can also act intracellularly; cell adhesion, ossification,
involved in may different processes TLR signaling
such as immunity and
metastasis promotion
GAB3 GRB2-associated scaffold protein involved in protein binding
binding protein 3 macrophage differentiation
MEN1 multiple endocrine nuclear protein, DNA binding, MAPKKK cascade,
neoplasia I interacts with NFkB histone methylation,
negative regulation of
cell proliferation,
osteoblast development,
regulation of transcription
CASP4 caspase 4, inflammatory caspase cysteine-type endopeptidase activity,
apoptosis-related protein binding,
cysteine peptidase induction/regulation of apoptosis
LILRA2 leukocyte immunoglobulin-like integrin found on antigen binding,
receptor, subfamily A, cells of the immune system receptor activity,
member 2 immune response,
signal transduction
ITGA5 integrin, alpha 5 binds SPP1, integrin binding, receptor activity,
(fibronectin receptor, interacts with HIV proteins calcium ion binding,
alpha polypeptide) cell/leukocyte adhesion,
integrin-mediated signaling pathway
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Figure 2.15: Phenoptypes of the seven selected candidates in HEK293T cells using Dharmacon
siRNA pools. A: luciferase assay, B: ELISA. Relative signaling activity (i.e. FL/RL compared to
mock (medium) transfected cells) and relative IL-8 secretion (percent IL-8 compared to siLRP5
transfected cells) is shown, respectively. siRNA concentration used: 50 nM. Mean values of two
independent experiments are shown. Error bars depict standard deviations of the two biological
replicates. p-values were calculated using Student’s T-test. *: p-value < 0.05, **: p-value < 0.01,
***: p-value < 0.001.
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Figure 2.16: Phenoptypes of the seven selected candidates in HepG2 cells using Dharmacon
siRNA pools. A: luciferase assay, B: ELISA. Relative signaling activity (i.e. FL/RL compared
to mock (medium) transfected cells) and relative IL-8 secretion (percent IL-8 compared to mock
transfected cells) is shown, respectively. siRNA concentration used: 50 nM. Mean values of two
independent experiments are shown. Error bars depict standard deviations of the two biological
replicates. p-values were calculated using Student’s T-test. *: p-value < 0.05, **: p-value < 0.01,
***: p-value < 0.001.
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Figure 2.17: Knockdown of the seven selected candidates does not affect cell viability. Measured
relative light units (RLU) were normalized to those of mock (medium) transfected cells. RLU
describe the strength of ATP-dependent luciferase luminescence. siRNA concentration used: 50
nM. One representative result of two independent experiments is shown. Error bars represent
standard deviations of at least 4 technical replicates.
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Figure 2.18: Candidate mRNA levels after treatment of HEK293T cells with siRNAs. Relative
expression compared to the negative control (RL) is shown. RL: siRNA against Renilla luciferase,
pool: siRNA pool specific for respective candidate. siRNA concentration used: 50 nM. One rep-
resentative result of at least 3 independent experiments is shown. Error bars represent standard
deviations of two technical replicates.
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2.2 SPP1, CASP4, GAB3
I selected three of the seven high-confidence candidates, SPP1, GAB3 and CASP4, for
further characterization.
CASP4 CASP4 is a caspase with a caspase recruitment domain (CARD) protein belong-
ing to the family of inflammatory caspases. Overlapping with the CARD domain, CASP4
also possesses a death domain (DD). Both DD and CARD proteins have been described to
be components of the TNFR1 complex [24]. There are only few publications on CASP4,
one of them showing an involvement in TLR4 signaling [140].
GAB3 GAB3 belongs to a family of adaptor proteins which bind growth factor receptor-
bound (GRB) protein 2, a protein that has been shown to interact with TNFR1 [100].
Almost no functional data were available on GAB3.
SPP1 SPP1 is involved in many processes, most of which are dependent on secreted,
extracellular SPP1 (e.g. its role in promoting metastasis [97]). However, SPP1 has also
been found to act intracellularly [275]. A role in Toll-like receptor (TLR) signaling, which
shares homologies with TNF-α signaling, has been described [216].
2.2.1 Knockdown of SPP1, GAB3 and CASP4 interferes with NF-κB
transcriptional activity
Knockdown of SPP1, GAB3 and CASP4 interferes with activation of NF-κB
as assessed by luciferase assay and ELISA
SPP1, GAB3 and CASP4 were selected for further characterization since their knock-
down decreased robustly TNF-α signaling activity as assessed by dual luciferase assay and
ELISA. Figure 2.19A summarizes silencing phenotypes of the three candidates in these
two assays. In addition to the effect of the siRNA pools, phenotypes of treatment with
individual siRNAs are given. In order to compare the strength of the phenotype with
knockdown efficiency, mRNA levels of SPP1, GAB3 and CASP4 were determined for each
siRNA treatment (Figure 2.19B). A correlation between knockdown efficiency and the
phenotypic consequence of siRNA treatment is a strong indicator for the reliability of the
observed phenotype.
For CASP4, knockdown efficiencies of siRNAs 3, 4 and the pool corresponded to the
strength of the phenotype in both luciferase assay and ELISA. Measuring basal level of
CASP4 mRNA in HEK293T cells always yielded variable results (high standard deviations)
due to its low expression. For GAB3, knockdown efficiencies of all siRNAs corresponded
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Figure 2.19: Phenotypes of SPP1, GAB3 and CASP4 knockdown in HEK293T cells using indi-
vidual siRNAs and siRNA pools. HEK293T cells were reverse transfected with siRNAs and the
dual luciferase assay and IL-8 ELISA (A) as well as a qRT-PCR assay measuring candidate mRNA
levels (B) were performed. A: siRNA-mediated decrease in TNF-α-induced NF-κB activity in the
luciferase assay (black bars) and IL-8 ELISA (grey bars). Depicted is relative signaling activity, i.e.
FL/RL compared to mock (medium) transfected cells (luciferase assay) or relative IL-8 secretion
compared to siLRP5 transfected cells (ELISA). TNFR1, RelA: siRNA pools against TNFRSF1A
and RelA, respectively (positive controls), siLRP5: siRNA pool targeting LRP5 (negative control).
Mean values of two independent experiments are shown. Error bars depict standard deviations of
the two biological replicates. B: siRNA-mediated mRNA depletion. Relative mRNA levels com-
pared to cells transfected with the negative control [Renilla luciferase (RL)] are shown. Error bars
depict standard deviations of the two technical replicates. Data representative of 3 independent
experiments is shown. A + B: 1-4: the four different individual siRNAs targeting the same gene,
pool: pool of the four individual siRNAs. siRNA concentration used: 50 nM.
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to the strength of the phenotype in validation assays. For SPP1, all siRNAs except for
siRNA 2 exhibited similar knockdown efficiencies. The failure of siRNA 2 to deplete SPP1
mRNA is reflected by the corresponding phenotype in the ELISA. Knockdown of all three
candidates by one individual siRNA and the siRNA pool reduced TNF-α signaling activity
by more than 40%. Except for GAB3, the knockdown of the candidates decreased TNF-α
signaling activity with statistical significance with at least 2 individual siRNAs and the
pool in both assays (data not shown). Knockdown effects correlated with siRNA-mediated
mRNA depletion. Hence, phenotypes observed after treating cells with siRNAs against
the three candidates were most probably due to candidate knockdown (and not due to
off-target effects).
Knockdown of SPP1, GAB3 and CASP4 interferes with TNF-α target gene
expression
To further confirm the influence of candidate knockdown on endogenous TNF-α signaling
events, I established an assay to measure endogenous TNF-α target genes. TNF-α induces
a wide variety of target genes such as genes encoding cytokines and chemokines, proteins
involved in antigen presentation and cell adhesion, anti-apoptotic proteins and others [247].
I assessed the expression of known TNF-α target genes upon stimulation by qRT-PCR and
determined the following target genes to be induced in HEK293T cells: TNF-α [211, 51],
CCL20/MIP-3α (CC-motif chemokine ligand 20) [139, 238], NFKBIA/IκB-α (nuclear fac-
tor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) [95, 230, 56],
BIRC3/CIAP2 (baculoviral IAP repeat-containing 3) [248] and IL-8. mRNA levels of
TNF-α targets were measured to test whether knockdown of the candidates also affected
the transcription of endogenous target genes.
To assess the influence of knockdown of SPP1, GAB3 and CASP4 on TNF-α target gene
expression, HEK293T cells were reverse transfected with siRNAs against the candidates as
well as siRNAs against Renilla luciferase as negative, against TNFR1 and RelA as positive
controls. After three days of incubation to allow for protein depletion, cells were treated
with 20 ng/ml TNF-α for either 0, 2 or 8 hours before RNA was isolated for qRT-PCR
analysis. Target gene mRNA levels were normalized to hypoxanthine phosphoribosyltrans-
ferase (HPRT) 1 mRNA levels. As depicted in Figure 2.20, SPP1 knockdown decreased
TNF-α-dependent expression of IL-8, BIRC3 and TNF-α significantly, but not expression
of CCL20 and NFKBIA. BIRC3 expression was only affected after 2 hours of stimulation,
whereas IL-8 and TNF-α expression were influenced at both time points. GAB3 knockdown
only affected significantly the expression of IL-8 and BIRC3 after 8 and 2 hours of TNF-α
treatment, respectively (Figure 2.21). Figure 2.22 shows the effect of CASP4 knockdown
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Figure 2.20: Effect of SPP1 knockdown on TNF-α-induced IL-8 (A), BIRC3 (B), TNF-α (C),
CCL20 (D) and NFKBIA (E) expression. HEK293T cells were reverse transfected with siRNAs
and, three days later, target gene mRNA levels were measured by qRT-PCR after 0, 2 and 8 h of
induction using 20 ng/ml TNF-α. Expression levels were normalized to expression in the negative
control sample (siRNA against Renilla luciferase): for each time point, mRNA expression levels were
set to 100% in the control sample and mRNA levels in candidate samples were calculated in relation
to the control. TNFR1 and RelA: siRNAs against TNFRSF1A and RelA, respectively (positive
controls). siRNA concentration used: 50 nM. Data derived from five independent experiments are
shown, error bars indicating the standard deviations of the biological replicates. p-values were
calculated using Student’s T-test. *: p-value < 0.05, ***: p-value < 0.001.
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Figure 2.21: Effect of GAB3 knockdown on TNF-α-induced IL-8 (A), BIRC3 (B), TNF-α (C),
CCL20 (D) and NFKBIA (E) expression. HEK293T cells were reverse transfected with siRNAs
and, three days later, target gene mRNA levels were measured by qRT-PCR after 0, 2 and 8 h of
induction using 20 ng/ml TNF-α. Expression levels were normalized to expression in the negative
control sample (siRNA against Renilla luciferase): for each time point, mRNA expression levels were
set to 100% in the control sample and mRNA levels in candidate samples were calculated in relation
to the control. TNFR1 and RelA: siRNAs against TNFRSF1A and RelA, respectively (positive
controls). siRNA concentration used: 50 nM. Data derived from five independent experiments are
shown, error bars indicating the standard deviations of the biological replicates. p-values were
calculated using Student’s T-test. *: p-value < 0.05.
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Figure 2.22: Effect of CASP4 knockdown on TNF-α-induced IL-8 (A), BIRC3 (B), TNF-α (C),
CCL20 (D) and NFKBIA (E) expression. HEK293T cells were reverse transfected with siRNAs
and, three days later, target gene mRNA levels were measured by qRT-PCR after 0, 2 and 8 h of
induction using 20 ng/ml TNF-α. Expression levels were normalized to expression in the negative
control sample (siRNA against Renilla luciferase): for each time point, mRNA expression levels were
set to 100% in the control sample and mRNA levels in candidate samples were calculated in relation
to the control. TNFR1 and RelA: siRNAs against TNFRSF1A and RelA, respectively (positive
controls). siRNA concentration used: 50 nM. Data derived from five independent experiments are
shown, error bars indicating the standard deviations of the biological replicates. p-values were
calculated using Student’s T-test. **: p-value < 0.01, ***: p-value < 0.001.
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on TNF-α target gene expression. Except for IL-8, the expression of all measured target
genes was statistically significantly reduced upon CASP4 silencing. Whereas BIRC3 and
CCL20 expression was affected at both time points, the induction of TNF-α and NFKBIA
was influenced only after 2 hours of TNF-α treatment. In summary, knockdown of all
candidates showed effects dependent on the target gene and the duration of the stimulus.
Altered target gene expression signature upon knockdown of SPP1, GAB3 and
CASP4
I next asked whether the influence of SPP1, GAB3 and CASP4 silencing on TNF-α sig-
naling would also be reflected in an altered target gene expression signature as assessed
by expression profiling. To address this question expression profiling was carried out using
Illumina microarrays. RNA samples were prepared in the same way as for the qRT-PCR
experiments (see 2.2.1). siRNAs against Renilla luciferase (RL) served as negative con-
trol, siRNAs against TNFR1 and RelA as positive controls. HEK293T cells were either
left unstimulated or were treated with 20 ng/ml TNF-α for 2 or 8 hours, before RNA
was isolated. Prior to hybridization onto chips by the DKFZ core facility, knockdown of
controls (TNFR1, RelA) and of candidates (SPP1, GAB3, CASP4) as well as induction
of target genes by TNF-α were validated by qRT-PCR (data not shown). Each condition
was represented by biological duplicates. Scanned images of hybridized microarrays were
analyzed using the Bioconductor/R packages "beadarray" and "limma" (for details see
Materials and Methods).
Two different TNF-α-induced target gene expression signatures were defined: (i) genes
altered after 2 hours of TNF-α treatment and (ii) genes altered after 8 hours of TNF-α
treatment as compared to unstimulated cells. In order to define a TNF-α-induced gene
expression signature, first differentially expressed genes in TNF-α stimulated cells were de-
termined that were treated with the negative contol siRNA. Subsequently, only those genes
out of these differentially expressed genes were selected that were previously published to
be TNF-α target genes (downloaded from "bioinfo.lifl.fr :: Bioinformatics Software Server"
[18]). The expression signature of these genes was then assessed in all samples.
Similarity of gene expression signatures of the differently treated samples is visualized
using a Trellis dot plot (Figure 2.23). After 2 hours of stimulation, data points or siSPP1
and siRL treated cells lie closely together, indicating that silencing of SPP1 did not affect
TNF-α target gene expression compared to negative control treated cells (Figure 2.23A).
GAB3 and CASP4 knockdown cells show a very similar TNF-α target gene expression
profile after both 2 and 8 hours of TNF-α treatment which is different from siRL treated
cells (Figure 2.23). The expression of many target genes is only slightly influenced by the
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Figure 2.23: Expression of TNF-α target genes in HEK293T cells after 2 hours (A) and 8 hours
(B) of TNF-α treatment as compared to unstimulated cells. Data was transformed logarithmically
before target genes were plotted versus their relative expression. siRL: siRNA against Renilla
luciferase (negative control; blue triangle), siTNFR1 and siRelA: siRNA against TNFRSF1A (pink
plus sign) and RelA (dark green plus sign), respectively (positive controls). Filled circles represent
measurements in cells treated with siSPP1 (red), siGAB3 (yellow) and siCASP4 (green). siRNA
concentration used: 50 nM. Summarized data of two biological replicates is shown. Multiple symbols
of the same type for one target gene indicates that there was more than one probe for that target
gene on the array.
transfection of different siRNAs [TNFRSF9 (8 h), PIM1 (2 and 8 h), NFKB2 (2 and 8 h),
MyB (2 h, except for siGAB3 and siCASP4), Myc (8 h, except for siSPP1), BMP2 (2 and
8 h)]. However, clear effects can be seen for the expression of TNFAIP3, NFKB1, IRF1
and CD83 after 2 hours of TNF-α treatment. Whereas siRL and siSPP1 treated cells show
a clear induction of expression of these target genes, levels are not or only slightly affected
by TNF-α stimulation in the other samples. The remaining, not as strongly induced target
genes show the same trend in their expression profiles. Interestingly, expression of RelB is
only slightly increased after TNF-α stimulation in siRL and siSPP1 treated cells while it is
decreased upon GAB and CASP4 silencing. This expression profile was observed for more
genes after 8 hours of stimulation (TNFAIP3, NFKB1, JunB, IL-8, GADD48B, CD83). In
general, target gene expression profiles of cells that were transfected with siRNAs target-
ing the candidates resemble those of positive control treated cells than to negative control
treated cells. An exception was the gene expression profile of siSPP1 treated cells after 2
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hours of TNF-α treatment. This observation is also visualized in Figure 2.24. Here, simi-
larity of the different microarray samples according to their TNF-α target gene expression
signature was assessed using the heatmap.2 function of the R package "gplots", which
assessed the euclidian distance between data points. siSPP1 treated cells stimulated for
2 hours cluster with siRL treated cells as their TNF-α target gene expression profile is
very similar. TNF-α target gene expression remains largely unaffected by TNF-α treat-
ment in TNFR1 and RelA knockdown cells. In contrast, siGAB3 and siCASP4 treated
cells show the opposite phenotype after 8 hours of stimulation with expression of TNF-α
target genes being decreased. Strikingly, the observed expression of the target genes does
not reflect their published categorization into early response genes, late response genes and
genes whose expression peaks in the middle between the first two [104, 236]. In conclusion,
knockdown of all candidates affected the TNF-α target gene expression signature as com-
pared to the negative control. siCASP4 and siGAB3 treated cells show similar target gene
expression signatures. These signatures are similar to the positive control after 2 hours of
stimulation and show decreased target gene expression after 8 hours of TNF-α treatment.
Whereas knockdown of SPP1 resulted in a TNF-α target gene expression signature similar
to the negative control after 2 hours of stimulation, it caused a phenotype similar to the
positive controls after 8 hours.
2.2.2 Epistasis assays map novel regulators in the pathway
Epistasis assays are means to place potential novel regulators into a known pathway. Epis-
tasis experiments can be performed in different ways. For example, overexpression of dif-
ferent known components of TNF-α signaling induces the pathway at different levels of
the signaling cascade. If a candidate shows a phenotype, the candidate acts downstream of
the overexpressed protein; if silencing does not affect signaling activity, the candidate acts
upstream of the overexpressed pathway component. Another means for epistasis analysis
is detecting phosphorylation status of IκB-α (inhibitor of κB-α) to determine whether a
candidate acts upstream or downstream of the IKK (IκB kinase) that is responsible for
IκB-α phosphorylation [270, 218]. If - after knockdown of a potential regulator - IκB-α
is still phosphorylated, the novel regulator acts downstream of the activation of the IKK.
However, if phosphorylation is lost, IKK activity was not induced upon stimulation with
TNF-α. Thus, the regulator plays a role in activating the IKK.
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Figure 2.24: TNF-α target gene expression signature of HEK293T cells after 2 hours and 8 hours
of TNF-α treatment as compared to unstimulated cells. Data were transformed logarithmically
before similarity was assessed by euclidean distance between data points. Rows of the heatmap are
different genes; their published categorization into early response genes, late response genes and
genes whose expression peaks in the middle between the first two is given in the table. Columns of
the heatmap are different samples. Lower expression compared to unstimulated cells is depicted in
red, higher expression depicted in blue. siRL: siRNA against Renilla luciferase (negative control),
siTNFR1 and siRelA: siRNA against TNFRSF1A and RelA, respectively (positive controls). siRNA
concentration used: 50 nM. Summarized data of two biological replicates is shown.
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Epistasis assays by assessing phospho-IκB-α levels demonstrated candidate ac-
tion at the level or upstream of the IKK.
Phospho-IκB-α levels were assessed in HeLa cells, since these cells express high levels
of IκB-α (Novartis gene expression atlas [182]). HeLa cells were reverse transfected with
siRNAs against Renilla luciferase (siRL) as negative, against TNFR1 as positive con-
trol, or siRNAs against the candidates. After two days of protein depletion, cells were
stimulated for either 0, 5, 10 or 20 minutes with 50 ng/ml TNF-α and then were lysed.
After protein transfer, immunoblotting for phospho-IκB-α revealed that IκB-α phospho-
rylation peaked after 5 minutes of TNF-α stimulation in siRL treated cells (Figure 2.25).
Phosphorylation represents a signal for IκB-α degradation [227, 13], which could be de-
tected as fast as in 20 minutes after induction of TNF-α signaling. In siTNFR1 treated
cells, induction of IκB-α phosphorylation was decreased (Figure 2.25A) or entirely missing
(Figure 2.25B). Likewise, knockdown of SPP1 (Figure 2.25A), GAB3 (Figure 2.25B) and
CASP4 (Figure 2.25C) abolished induction of IκB-α phosphorylation. In conclusion, all
three candidates act at the level or upstream of the activation of the IKK.
siRL siTNFR1siSPP1
0’ 5’ 10’ 20’ 0’ 5’ 10’ 20’ 0’ 5’ 10’ 20’
p-IkB-alpha
alpha-tubulin
siRL siTNFR1siGAB3
0’ 5’ 10’ 20’ 0’ 5’ 10’ 20’ 0’ 5’ 10’ 20’
p-IkB-alpha
alpha-tubulin
siRL siTNFR1siCASP4
0’ 5’ 10’ 20’
p-IkB-alpha
alpha-tubulin
0’ 5’ 10’ 20’ 0’ 5’ 10’ 20’
A
B
C
Figure 2.25: Knockdown of (A) SPP1, (B) GAB3 and (C) CASP4 abolishes IκB-α phosphoryla-
tion upon TNF-α stimulation in HeLa cells. HeLa cells were transfected with siRNA pools before
IκB-α phosphorylation upon TNF-α treatment (50 ng/ml) was assessed by immunoblotting. siRL:
siRNA against Renilla luciferase (negative control), siTNFR1: siRNA against TNFRSF1A (posi-
tive control). siRNA concentration used: 50 nM. As loading control served α-tubulin. Data shown
is representative of four independent experiments. p-IκB-α: phospho-IκB-α.
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Feedback loops interfere with epistasis assays.
I also intended to place the candidates into the TNF-α pathway by overpressing known
pathway components. TNF-α signaling was activated at four different levels: (a) at the
receptor by treating cells with TNF-α, (b) directly downstream of the receptor by over-
expressing TRADD (TNFR-associated death domain), (c) by overexpressing RIP1 (recep-
tor interacting protein 1) and (d) by overexpressing IKK-β. To avoid a positive feedback
loop via NF-κB-induced TNF-α secretion which would impede the epistasis assay design,
cells were additionally treated with Enbrel (soluble TNFR1) to scavenge secreted TNF-α.
HEK293T cells were reverse transfected with siRNAs before luciferase expression and over-
expression plasmids were transfected on the next day. After an incubation for two days
to allow for siRNA-mediated protein depletion and plasmid-encoded protein expression,
the luciferase assay was performed. Control cells were stimulated with 20 ng/ml TNF-α
16 hours prior to the read out, while cells transfected with overexpression plasmids were
treated with 12.5 µg/ml Enbrel.
Figure 2.26 shows the result of the dual luciferase assay. Even when treating cells with
Enbrel, transfection of siRNAs targeting TNFR1 decreased relative signaling activity in-
dependent of the activating stimulus. However, induction via overexpression of pathway
components downstream of the receptor should be independent of the presence or absence
of TNFR1. The phenotype of siTNFR1 can be either explained by the presence of a posi-
tive feedback loop via activation of TNF-α that was not scavenged potently by Enbrel or
alternatively by the necessity of the intracellular part of the TNFR1 for the assembly of
the signaling inducing TNFR complex. Therefore, no conclusive results could be obtained
from this overexpression experiment.
2.2.3 Knockdown of SPP1, GAB3 and CASP4 does not affect TNFR1
cell surface expression
Besides playing a role in the activation of the IKK, silencing of SPP1, GAB3 and CASP4
could also have an effect on the shuttling of TNFR1 to the plasma membrane. Interruption
of this transport could also explain the phenotypes observed after knockdown of SPP1,
GAB3 and CASP4.
HeLa cells were used to determine TNFR1 surface expression because they express
higher levels of TNFR1 than HEK293T cells [182]. HeLa cells were reverse transfected with
siRNAs - against Renilla luciferase as negative, against TNFR1 as positive controls, and
against the candidates. After two days of protein depletion, cells were detached by scraping.
TNFR1 expression on the plasma membrane was detected using a specific antibody labelled
with phycoerythrin (PE). As control served an unspecific antibody of the same isotype.
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Figure 2.26: Epistasis experiments in HEK293T cells by overexpressing known pathway compo-
nents. HEK293T cells were reverse transfected with different siRNA pools (day 1) before TNF-α
signaling was either induced by overexpression of the known pathway components TRADD (20
ng/384-well plates well), RIP1 (RIP, 2 ng/well) and IKK-β (IKK, 2 ng/well; day 2) or treatment
with 20 ng/ml TNF-α (TNF, day 3). The dual luciferase assay was performed, shown is relative
signaling activity (i.e. FL/RL compared to mock (H2O) transfected cells) in control IgG (black
bars) or Enbrel (grey bars) treated cells. TNF-α induced reporter activity 14-fold, whereas TRADD
overexpression induced 5.5-fold, RIP1 overexpression 6.5-fold and IKK-β overexpression 8.5-fold.
siRNA concentration used: 50 nM. Mean values of two independent experiments are shown. Error
bars depict standard deviations of the two biological replicates. Effect of CASP4 (A), GAB3 (B)
and SPP1 (C) knockdown as compared to the positive controls siTNFR1 and siRelA.
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PE staining was assessed by fluorescence activated cell sorting (FACS).
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Figure 2.27: Knockdown of SPP1, GAB3 and CASP4 does not affect TNFR1 cell surface ex-
pression. HeLa cells were transfected with control and candidate siRNAs and were stained for cell
surface TNFR1 after 2 days of incubation. TNFR1 was detected using a specific antibody labelled
with phycoerythrin (PE). PE staining was assessed by FACS (fluorescence activated cell sorting).
A: Histogram representing the intensity of the TNFR1-PE stain (x-axis) in dependency of cell num-
ber (y-axis). An overlay of all samples is shown, with the green curve depicting siCASP4-treated
cells, grey being siGAB3-treated cells, violet siSPP1-treated, blue siTNFR1-treated and red siRL-
treated cells. Whereas TNFR1 depleted cells exhibited less TNFR1-PE staining, the staining of the
other samples was similar. B: Quantification of PE-positive (dark grey) and -negative (light grey)
cells as percentage of all analyzed cells. For quantification, two populations, PE-positive and PE-
negative, were defined based on siRL-treated cells being stained with the isotype-matched control
antibody (isotype control). For each sample the percentage of cells was calculated being in either
of the two populations. Control antibody stained cells showed background staining. anti-TNFR1
staining in siTNFR1 cells was decreased to background, while cells treated with siRNAs against
the candidates or the negative control exhibited similar staining. A + B: siRL: siRNA pool against
Renilla luciferase (negative control), siTNFR1: siRNA pool against TNFRSF1A (positive control),
siCASP4, siGAB3, siSPP1: siRNA pools against the candidates. siRNA concentration used: 50
nM. Data shown is representative of two independent experiments.
Figure 2.27A shows histograms representing the PE-staining intensity and thus the
amount of TNFR1 at the cell surface. The histograms for cells treated with the nega-
tive control (siRL, red curve) and siRNAs against the candidates (siCASP4: green curve,
siGAB3: grey curve, siSPP1: violet curve) overlap. This indicates that cells in these samples
displayed similar amounts of TNFR1 on their cell surface. In contrast, cells treated with
siTNFR1 (positive control, blue curve) exhibited diminished TNFR1 cell surface expres-
sion. The quantification of PE-positive versus PE-negative cells shown in Figure 2.27B
yielded the same result. The staining pattern by the isotype-matched control antibody
(isotype control), defined to be background, was unaffected by all siRNAs, including siT-
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NFR1. Only depletion of TNFR1 diminished the number of cells being stained for TNFR1
(PE-positive). Thus, knockdown of the candidates SPP1, GAB3 and CASP4 had no in-
fluence on TNFR1 cell surface expression. In conclusion, the phenotypes observed upon
SPP1, GAB3 and CASP4 silencing were not caused by interrupted shuttling of the TNFR1
to the cell surface but by interruption of the intracellular TNF-α signaling cascade.
2.3 Caspase 4 As a Novel Regulator of TNF-α Signaling
The role of CASP4 in TNF-α signaling was studied in more detail since siRNA-mediated
silencing of this candidate was the most efficient and showed the strongest phenotype in
the dual luciferase assay, ELISA and the qRT-PCR assay measuring TNF-α target gene
expression. In addition knockdown could be validated at the protein level (Figure 2.28).
RL CASP4 siRNA
CASP4
alpha-
tubulin
~ 55 kDa -
~ 20 kDa -
Figure 2.28: CASP4 protein depletion upon siCASP4 treatment. HeLa cells were treated with
siRNAs against Renilla luciferase (siRL, negative control) and against CASP4 (siCASP4) for two
days before CASP4 protein levels were determined by immunoblotting. siRNA concentration used:
50 nM. As loading control served α-tubulin. Data shown is representative of five independent
experiments.
2.3.1 CASP4 primarily localizes to the cytoplasm
Epistasis experiments showed that CASP4 acts at the level or upstream of IKK. Since the
cytoplasmic TNFR complex I acts upstream of the IKK, it was tested if cellular localization
of CASP4 would permit interaction with the TNFR complex. Since HeLa cells express
CASP4 more strongly than HEK293T cells [182], endogenous CASP4 protein was visualized
in HeLa cells using a specific antibody by confocal microscopy.
CASP4 has been detected at the endoplasmic reticulum (ER) membrane [102, 186], but
is annotated in the Human Protein Reference database as primary cytoplasmatic [122]. To
determine whether CASP4 localizes to the ER, HeLa cells, seeded onto coverslips, were co-
stained with an anti-CASP4 antibody and an antibody detecting the ER marker calnexin
[244]. CASP4 partly co-localized with calnexin in HeLa cells, however the major part of the
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staining appeared to be cytoplasmatic (Figure 2.29). CASP4 could therefore theoretically
interact with the cytoplasmic machinery of TNF-α signal transduction.
In a next step, it was tested whether CASP4 localization changed upon stimulation
of HeLa cells with TNF-α. HeLa cells were seeded onto coverslips and starved for 3-4
hours prior to treatment with 50 ng/ml TNF-α. Cells were then stained for CASP4 using a
CASP4-specific antibody. No obvious change of CASP4 localization could be detected upon
TNF-α stimulation (Figure 2.29). However, the strong ubiquitous cytoplasmic staining
could have masked any changes in localization.
Figure 2.29: Cytoplasmatic localization of CASP4 does not change upon TNF-α treatment as
determined by immunofluorescence microscopy. HeLa cells were seeded onto coverslips. Before
staining for CASP4 with a CASP4-specific antibody (green) and with an antibody against ER-
resident calnexin (red), cells were starved and then treated with 50 ng/ml TNF-α for 0, 5 or 30
minutes. CASP4 staining appeared to be mainly cytoplasmatic (spotty staining) and only partially
overlapped with the ER stain. CASP4 cellular localization did not obviously change upon treatment
with TNF-α. Almost no CASP4 staining was detectable in siCASP4 treated cells, illustrating the
specificity of the CASP4 antibody. Hoechst: DNA stain (blue).
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2.3.2 CASP4 is not cleaved after TNF-α stimulation
Caspases are cysteine-aspartate specific proteases that - when enzymatically activated -
act by cleavage of target proteins. Caspases are enzymatically activated upon induced
aggregation which entails the cleavage of the pre-caspase into two smaller subunits. These
subunits then form the catalytically active caspase [200]. Cleavage of CASP4 could thus
serve as an indirect indicator of whether CASP4 becomes enzymatically activated upon
TNF-α treatment.
To determine CASP4 cleavage by western blotting, HeLa cells were transfected with
siRNA - either siRNAs against CASP4 or Renilla luciferase as a negative control. After
two days of protein depletion, cells were stimulated for either 0, 0.5 or 1 hours with 50
ng/ml TNF-α. After protein transfer, immunoblotting for CASP4 revealed that CASP4
was not cleaved after TNF-α stimulation (Figure 2.30).
CASP4
*
~ 70 kDa -
~ 20 kDa -
~ 55 kDa -
TNF [h]0 0.5 1 0 0.5 1
siRL siCASP4
alpha-tubulin
Figure 2.30: CASP4 is not cleaved upon TNF-α treatment in HeLa cells. HeLa cells were re-
verse transfected with siRNAs against Renilla luciferase (RL, negative control) and CASP4 and
incubated for 2 days to allow for protein depletion. Cells were starved and then stimulated with
50 ng/ml TNF-α for different time periods before CASP4 protein cleavage was determined by
immunoblotting. As loading control served α-tubulin. The asterix indicates a putatively unspecific
band, as it is not diminished upon CASP4 depletion.
In summary, I have shown that siRNA-mediated CASP4 depletion specifically inter-
fered with TNF-α signaling, reducing NF-κB transcriptional activity. Epistasis experiments
demonstrated that CASP4 acted at the level or upstream of the activiation of the IKK.
CASP4 could thus be a component of the TNFR complex. CASP4’s cytoplasmic localiza-
tion would enable interaction with the TNFR complex. However, interaction with a known
62
TNFR complex component has not been shown so far. Results indicate that CASP4 is
not cleaved upon TNF-α treatment (Figure 2.30) and is probably also not enzymatically
activated (data not shown). CASP4’s function might therefore be different from TNF-
α-induced cleavage of a TNF-α pathway component. In conclusion, the presented data
strongly implies CASP4 to be a novel regulator of TNF-α-induced signaling at the TNFR1
complex.
Chapter 3
Discussion
Inflammation is essential for an efficient innate immune response and has to be well con-
trolled in order to avoid damage to the host. The severe consequences of exaggerated
inflammation is most prominently demonstrated by the effects of septic shock upon chal-
lenge with endotoxins, such as LPS [15]. Along these lines, chronic inflammation has been
shown to be a key component of many diseases such as autoimmune disorders and cancer
[79, 159]. Recently, Mantovani proposed to add inflammation to the hallmarks of cancer
that were coined by Hanahan and Weinberg [93, 158].
TNF-α is the major mediator of inflammation. In order to identify novel regulators of
TNF-α signaling, I set out to perform genome-wide RNAi screens. I established a cell-
based assay that was suited to study TNF-α-induced activation of NF-κB transcriptional
activity in miniaturized format. Using this assay, two screens were performed in HEK293T
cells. These screens identified several known components as well as putative novel regu-
lators of TNF-α signaling whose phenotypes were validated in secondary assays. Three
candidates, SPP1, GAB3 and CASP4, were further characterized.
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3.1 RNAi Screening Design and Analysis
I aimed at identifying novel regulators of TNF-α signaling by genome-wide RNAi screens.
The nature of the assay is of paramount importance for any RNAi screen and determines
how much information can be gained from such a screen. Therefore, I critically evaluated
different aspects of the screening setup during assay establishment.
3.1.1 Selection of a suitable cell line for RNAi screening
Since TNF-α signaling is involved in innate immunity, immune cells would have been
the most obvious cells to use for my studies. However, using RNAi reagents in immune
cells can be problematic since the immune system is equipped to recognize introduced
double- and single-stranded (ds/ss) RNAs. Recognition is mediated by different RNA-
binding molecules, like Toll-like receptor (TLR) family members, that induce an interferon
response [107, 219] and the activation of NF-κB [3]. Whereas reports are contradicting
with regards to whether siRNAs trigger these immune mechanisms in non-immune cells
[107, 119, 124], it is agreed on the superior sensitivity of immune cells expressing higher
levels of the dsRNA and ssRNA detection machinery [124]. Hence, I chose to study immune
signaling by RNAi in non-immune cells. TNFR1-mediated signaling can be investigated
in non-immune cells, since this receptor is abundantly expressed [247]. I decided to work
with HEK293T cells as this cell line is responsive to TNF-α and is widely used to explore
proteins’ functions in TNF-α signaling [197, 199, 198, 75]. In contrast to immune cells,
HEK293T cells are less likely to get immune-activated by transfection with RNAi reagents.
Nevertheless, the possibility that RNAi per se could interfere with the assay employed in
the screens that I performed cannot be excluded.
3.1.2 Designing a dual luciferase assay for monitoring NF-κB activity
Activity of TNF-α signaling can be assessed by multiple means e.g. by measuring the pres-
ence of signaling intermediates like phospho-proteins, nuclear translocation of NF-κB or
TNF-α target gene expression. My goal was to identify genes affecting NF-κB transcrip-
tional activity upon TNF-α treatment. Therefore the dual luciferase assay represented a
simple and straight forward assay to monitor the activity of the whole pathway. Other
strategies would have consisted in microscopic assays suited for genome-wide screening.
These assays would have the disadvantage of either not covering the whole pathway (such
as staining a signaling intermediate or monitoring NF-κB nuclear translocation) or giving
the same information as the dual luciferase assay while demanding a more sophisticated
analysis. However, one disadvantage of the dual luciferase assay is its dependance on arti-
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ficially introduced reporters.
To report NF-κB transcriptional activity a highly inducible NF-κB-dependent reporter
is essential. Many commercially available or published reporters make use of different num-
bers of NF-κB binding sites (e.g. [203, 75, 250]). Li et al. tested different numbers of NF-κB
binding sites for their NF-κB-dependent reporter (1, 2, 6, 12, 24) to obtain a reporter with
good signal to noise ratio for their screen [147]. The authors report that 6 NF-κB binding
sites in the artificial promoter exhibited the best signal to noise ratio [147]. My strategy
to determine assay conditions with an optimal signal to noise ratio was to select a re-
porter with high expression levels and subsequently optimize fold induction of expression
upon TNF-α stimulation by varying the amount of transfected reporter (data not shown).
Therefore, I fused an artificial promoter containing 8 NF-κB binding sites to the firefly
luciferase gene. This reporter yielded high expression levels upon TNF-α treatment, be-
ing required for stable results during large-scale experiments such as genome-wide RNAi
screens (Figure 2.4).
In addition to the pathway specific reporter, a constitutively expressed luciferase con-
struct is needed to report differences in plasmid transfection efficiency and cell numbers
between wells and plates. Commonly used reporters controlled by viral promoters have
been shown to be influenced by TNF-α treatment [192]. I decided to use a co-reporter
without viral promoter and fused the β-actin promoter upstream of the Renilla luciferase
coding sequence. The expression of this construct (act-RL) was to some extent negatively
influenced by TNF-α. However in contrast to co-reporters under the control of viral pro-
moters, act-RL reporter expression levels were very stable under stimulated conditions,
prerequisite to monitor viability effects, while being high enough to give rise to stable
results in large-scale experiments (Figure 2.4).
A luciferase-based assay depends on protein synthesis and is therefore not suited to
detect fast changes in signaling activity. To obtain stable firefly expression levels, TNF-α
stimulation for 16 hours was used. Under these conditions I was able to detect phenotypes
of varying strength of silenced positive regulators with high sensitivity. However the long
stimulation with TNF-α yields such a high expression level of the NF-κB-dependent re-
porter that expression cannot be further increased by silencing of negative regulators of
TNF-α signaling. The established assay is thus not suited for detecting negative regulators
(e.g. CYLD (cylindromas) [239]). Besides, as TNF-α signaling is influenced by positive and
negative feedback loops, it is to be expected that the NF-κB-dependent firefly luciferase ex-
pression construct does not only report changes in direct signaling from TNFR1 to NF-κB,
but also changes in induced feedback loops. Therefore, secondary assays allowing shorter
stimulation periods are needed to distinguish direct and feedback loop effects (see below).
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3.1.3 Defining criteria for screening hit selection
Two genome-wide screens using two independent libraries were preformed to identify novel
regulators of TNF-α signaling. Performing two screens for the same signaling pathway in
the same cell line with different libraries allowed me to evaluate hits from single screens as
well as from the overlap of the two screens. RNAi phenotypes identified in both experiments
were independent of the RNAi reagent used and thus less likely to be false positives.
For the individual analysis of either screen, a "high stringency strategy" was pursued.
First, strongest hits were selected by applying a z-score filter of ≤ -2.5. These hits were
further filtered by applying viability (screen A hit list only) as well as firefly and Renilla
luciferase expression filters. In addition, in the combined analysis of both screens the strin-
gency of the z-score cut-off was lowered as reliability of hit selection should be provided
by the overlap of two independent experiments. I assessed different z-score filters for the
number of genes passing the cut-off in the overlap data set. As shown in Figure 3.1A,
only very few genes (seven) are identified in the overlap of the two screens when a z-score
cut-off of ≤ -2.5 is applied. When lowering the cut-off the number of genes in the overlap
data set increases (Figure 3.1A). Determining the p-value by Exact Fisher Test to assess
whether the observed number of overlapping hits is random or not reveals that for most
z-score cut-offs the overlap is statistically significant (Figure 3.1B, dashed line). However,
the odds ratio for the observed number of overlapping hits is only higher than 1 (and thus
higher than expected) for the z-score cut-offs -2.5 and -1.75 (Figure 3.1B, full line). An
obvious z-score cut-off to choose is indicated by the blue line in Figure 3.1B, marking a
negative peak for the p-value and at the same time a positive peak for the odds ratio. But
when setting the cut-off at -1.75 only 46 genes would be selected, among them no known
TNF-α pathway component. I therefore decided to set the z-score cut-off to determine the
screening overlap at -1.25, selecting 177 genes (indicated by the red line in Figure 3.1B).
These genes include the known TNF-α pathway components IKK-α and IKK-β as well as
MAP4K5 (supplementary table A.3).
A comparison of both screens gene by gene revealed only a low overlap (2.12). This low
overlap could be due to three general reasons: (i) technical variation, (ii) high false negative
rates and (iii) high false positive rates. Technical variation could have been introduced
by the use of different siRNA libraries. These libraries contain siRNAs with non-identical
sequences which target the same gene. This might yield different silencing efficiencies or off-
target effects, resulting in different phenotypes for the same targeted gene. Off-target effects
are mediated by siRNAs that silence not only the targeted gene but also gene(s) exhibiting
some sequence complementarity to the used siRNA (e.g. [240]). Another cause of technical
variation might be plate position effects possibly disguising or mimicking phenotypes of a
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Figure 3.1: Overlap of the two screens at different z-score cut-offs. A: Number of genes identified
in the overlap of the two genome-wide screens when setting the cut-off at the indicated z-scores.
#: number. B: p-value and odds ratio for the observed number of overlapping hits at the indicated
z-score cut-offs as calculated by Exact Fisher Test. Dashed line: p-value, full line: odds ratio. The
number of overlapping hits is statistically significant at any threshold except for cut-offs set at
z-scores of ≤ -2.25, -2 and -1.5. The number of hits is only higher than expected (odds ratio bigger
than 1) for the cut-offs set at z-scores of ≤ -2.5 and -1.75.
gene in one screen but not the other. Plate effects are screening artifacts that result from
the influence of the well position on luciferase expression, for example caused by increased
evaporation in wells at the edges of the plate. Since siRNAs targeting a distinct gene most
probably have different plate positions in different libraries, the corresponding luciferase
reads might be differently affected by these plate position effects. In addition, unstable
performance of the assay could contribute to technical variation between the screens. To
estimate the variability of the assay, I compared the three plates of screen A with the kinase
pilot screen which are identical. When plotting the z-scores of each gene of the pilot kinase
screen and the kinase plates of the genome-wide screen against each other, a diagonal is
visible, indicating the presence of numerous genes with similar z-scores in both screens
(Figure 3.2). Comparing Figure 3.2 to Figure 2.12 illustrates that the overlap between
the two genome-wide screens is lower than the overlap between the kinase plates, even
though in the latter case two different assays (small scale vs. large scale experiments)
are compared. Hence, the use of two different libraries probably contributed more to the
technical variation of the two screens than the assay itself.
Other reasons for the low overlap could be high false negative rates in both screens,
with different false negatives in both screens, or a high false positive rate in at least one
screen, minimizing the overlap [28]. False positives result from screening artifacts or off-
target effects, whereas false negatives can be caused by screening artifacts as well as by
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Figure 3.2: Comparison of the pilot kinase screens with the kinase plates of screen A. The z-scores
of all genes in the pilot kinase screen and all genes of the first three plates of screen A, which are
identical, are plotted against each other. The diagonal indicates perfect reproducibility of z-scores
between the two screens. Even though two different assays - a small scale vs. a large scale experiment
- are compared, plotted values are distributed along the diagonal, indicating that similar results
were obtained by the two screens (pearson correlation coefficient of 0.6).
inefficient gene silencing. I estimated the false positive rate by evaluating the percentage
of positively retested candidates in both screens. About 50% of the retested candidates
identified in screen A could be confirmed in subsequent retests; for candidates of screen
B the rate was about 60%. Comparable false positive rates have been observed for other
similar screens (unpublished observations).
In order to assess the false negative rate of the screens in a systematic manner, I de-
termined the fraction of known regulators of inflammation identified by the screens. Two
online databases storing information on which proteins that are involved in different sig-
naling pathways were employed to retrieve two gene sets, the "TNF signaling gene set" and
the "inflammation gene set". The TNF signaling gene set contained 52 genes of which 49
were covered, the inflammation gene set contained 157 genes of which 155 were targeted by
the libraries. 8 genes (16.3 %) of the TNF signaling gene set passed the cut-off of ≤ -1.25
that was applied to the combined analysis of both screens in screen A, 6 (12.2 %) in screen
B and 2 genes (4.1 %) in the overlap (supplementary table A.4). Of the inflammation gene
set 18 genes (11.6 %) passed the z-score cut-off of ≤ -1.25 in screen A, 19 (12.3 %) in screen
B and 4 genes (2.6 %) in the overlap (supplementary table A.5). The enrichment of known
components of inflammatory signaling pathways did not reach statistical significance (as
assessed by Exact Fisher Test, data not shown). However, the false negative rate might be
overestimated since the gene sets were not filtered for positive regulators.
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3.1.4 Comparison to other RNAi screens for TNF-α signaling
TNF-α and NF-κB signaling were also dissected by other groups using RNAi screening in
the mammalian system. Table 3.1 lists these published mammalian screens. None of the
screens made use of immune cells for studying TNF-α signaling. One study used HEK293T
cells like I did [271]. All published screens and the screens presented in this thesis share
similar stimulation conditions (varying from 10-50 ng/ml TNF-α for 6-24 hours) and the
use of a luciferase reporter to monitor NF-κB transcriptional activity. However, none of
the published screens were genome-wide as the two screens presented here.
The first TNF-α screen was published by Brummelkamp et al. [32]. The screen that
focused on de-ubiquinating enzymes only identified one negative regulator, CYLD. An-
other published screening paper described one negative regulator, WIP1 [46]. The authors
claimed to have identified 15 phosphatases implicated in TNF-α signaling, but did not
provide a list of candidates. I did not identify CYLD nor WIP1 in my screens since the
employed assay set-up was not suited to find negative regulators. None of the candidates of
other published screens passed the z-score cut-off of ≤ -2.5 that I applied in the individual
analysis of the screens that I performed.
The difference in the candidate lists between my screens and the published screens can
probably be explained by the difference in the screening assays and the reagents used. Dif-
ferent cells, reporters and slightly different stimulation conditions were used in each study.
Nevertheless both screens that I performed and most of the published screens identified
not only known pathway components but also novel TNF-α pathway regulators according
to stringent criteria whose phenotypes could be reconfirmed.
Interestingly, even though published TNF-α screens exhibit only little overlap, another
report studying RIP1-dependent necroptosis unexpectedly identified other TNF-α pathway
components and one of the candidates presented in this thesis, SPP1, as hits in a genome-
wide screen [101]. This supports my hypothesis that SPP1 might be a novel regulator of
TNF-α-induced NF-κB activity.
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3.1.5 Various assays are required to place candidates into the pathway
The consequences of TNF-α signaling are strongly dependent on kinetics. Firstly, TNF-α
signaling is regulated by feedback loops. For instance, TNF-α induces its own expression
thereby amplifying TNF-α signaling activity [211, 51]. Secondly, the expression of some
TNF-α target genes - the early response genes - is induced quickly after TNF-α stimulation,
whereas expression of other TNF-α target genes - the late response genes - is induced with
a delay [104]. Several different factors determine the gene expression program activated by
NF-κB. Duration of the stimulating signal and the timing of NF-κB nuclear translocation
oscillations are well established to influence target gene expression [104]. Also, the site
of NF-κB phosphorylation and thereby its nuclear interaction partners are known to be
important (e.g. [82]). Besides, it has been speculated that promoters of some target genes
are stably engaged by core factors of the transcription machinery and are therefore more
sensitive to activation by NF-κB and hence less sensitive to a partial disruption of the
NF-κB activating signaling cascade [183, 21]. These aspects of TNF-α signaling had to
be taken into consideration when monitoring NF-κB transcriptional activity after TNF-α
stimulation.
In both luciferase assay and ELISA, cells were treated for 16 hours with TNF-α. These
assays therefore monitored NF-κB transcriptional activity induced by extended TNF-α
signaling. As a consequence, neither assay allowed me to distinguish between phenotypes
caused by direct effects on TNF-α signaling or phenotypes caused by disruption of feedback
loops. For this reason I employed assays suitable for differentiating between direct and
indirect effects. I decided to measure the presence of a signaling intermediate and the
induction of TNF-α target genes. Other assays suitable to distinguish between direct effects
and feedback loops are for example microscopic nuclear translocation assays or EMSA
(electrophoretic mobility shift assay).
I established a western blot to monitor the fast induction of phospho-IκB-α. Using this
assay I could show that the knockdown of SPP1, GAB3 and CASP4 abolished phosphory-
lation of IκB-α after 5 minutes of stimulation (Figure 2.25) und thus that their silencing
affected direct signaling to NF-κB.
Another way to assess the effects of short stimulation with TNF-α is measuring induc-
tion of target gene expression by qRT-PCR. Expression of TNF-α early and late response
genes peaks after approximately 1.5 and 6-8 hours, respectively [104]. Therefore, TNF-α
target gene expression was assessed after 2 and 8 hours of induction. The time-dependent
effects of TNF-α signaling and hence of its disruption is exemplified by the phenotype of
CASP4 knockdown in ELISA and qRT-PCR assay. Whereas CASP4 depletion strongly
decreased IL-8 secretion after 16 hours of stimulation (Figure 2.19), IL-8 mRNA levels
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were unaffected after 2 and 8 hours of stimulation (Figure 2.22). Since CASP4 silencing
showed no direct effect on IL-8 induction, the reduced IL-8 secretion upon CASP4 silencing
was probably caused by disruption of TNF-α-induced feedback loops that further induce
production of IL-8.
Additionally, I used a global approach to assess target gene expression in candidate
knockdown cells after TNF-α stimulation. Data acquired through gene expression profiling
support the requirement of the candidates for TNF-α-induced target gene expression. Tar-
get gene expression signatures after silencing of GAB3 and CASP4 were strikingly similar
(Figure 2.23); in both cases repressed TNF-α target gene expression was observed. A simi-
lar phenomenon has been described for IKK-dependent target gene expression in IKK-α/β
knockout cells [174]. However, whereas knockdown of GAB3 and CASP4 affected target
gene expression at both time points (2 and 8 hours after treatment), SPP1 silencing only
showed an effect after 8 hours of TNF-α stimulation (Figure 2.24). Since SPP1 most likely
acts in the direct signaling cascade from TNFR1 to NF-κB (Figure 2.25A), it would be
interesting to address the question why SPP1 knockdown did not show an immediate effect
on target gene expression. A possible explanation might be that SPP1 knockdown affects
NF-κB nuclear oscillations as has been observed for other regulators of NF-κB activity
[54, 255]. Consequently, a clear phenotype might only be observed at a later time point
after stimulation with TNF-α [177]. Interestingly, TNF-α target genes in HEK293T cells
could not be grouped according to their expression profiles into early and late response
genes as has been reported for other cell lines [104, 236]. This observation indicates that
HEK293T cells show different signaling properties, at least with regards to mechanisms
regulating NF-κB-induced target gene expression. A disadvantage of microarray experi-
ments is their inferior sensitivity compared to qRT-PCR experiments. For instance, the
changes in expression of the target genes observed in the qRT-PCR assays were not high
enough to be detected in the microarray experiment.
Taken together, both qRT-PCR as well as microarray-based gene expression profiling
revealed different effects of candidate knockdown depending on the target gene and on
duration of stimulation. These effects can probably be explained by the different gene
regulatory mechanisms for each of the target genes that are influenced in different ways by
the knockdown of the three candidates.
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3.2 Potential Novel Regulators of TNF-α Signaling Identified
by Genome-wide RNAi Screening
I validated the phenotypes of seven hits in depth (Figure 2.14 presents the process of hit
selection) whose phenotypes were assessed to be specific as siRNAs targeting these seven
hits neither affected HEK293T cell viability (Figure 2.17) nor were identified in unrelated
genome-wide RNAi screens that were performed in the laboratory (data not shown): SPP1,
GAB3, CASP4, MEN1, USP2, LILRA2 and ITGA5. The latter are two plasma transmem-
brane proteins. LILRA2 is an integrin expressed by cells of the immune system. ITGA5
serves as a transmembrane receptor for extracellular SPP1, another candidate identified
in the screen. Both proteins could thus be involved in the same TNF-α-induced feedback
loop to NF-κB.
Another candidate is the de-ubiquitinating enzyme USP2. As ubiquitination plays an
important role at different levels of the TNF-α pathway, USP2 is an interesting candidate.
Its function in TNF-α signaling has been studied by Marie Metzig (MD thesis). Its ex-
pression is most probably needed for the activation of the IKK and can be correlated to
different stages of cancer.
MEN1 is a nuclear protein. Inside the nucleus, activated NF-κB relies on the interac-
tion with other proteins to efficiently induce the expression of target genes. MEN1 has
already been described to interact with NF-κB [98]. Whereas I identified MEN1 as a pos-
itive regulator of TNF-α signaling, Heppner et al. reported MEN1 to negatively regulate
NF-κB function [98]. However, studies exploring MEN1’s function in NF-κB activation
have been based on overexpression [98]. It is thus possible that artificially high amounts
of MEN1 inhibit NF-κB action, whereas lower endogenous protein levels are needed for
proper interaction of NF-κB with DNA.
The candidates GAB3, SPP1 and CASP4 are described in more detail below, as they
were selected for further characterization (Figure 2.19).
Overexpression of none of the candidates resulted in the induction of TNF-α signaling
(data not shown). Likewise, none of the phenotypes resulting from candidates knockdown
could be rescued (reversed) by the overexpression of corresponding mouse orthologues
(data not shown). There could be different reasons as to why the mouse orthologues did
not reconstitute TNF-α signaling activity after candidate knockdown. On the one hand,
the ability of a mouse protein to substitute its human orthologue is dependent not only
on the overall degree of homology between the two proteins but also on the presence of
the human structural motif that is important for its role in the pathway. Similarities be-
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tween the mouse and human orthologues of the screening candidates might have not been
sufficient. On the other hand, overexpression of a protein can lead to artifacts such as
protein mislocation or protein misfolding due to protein overproduction which will hinder
the overexpressed protein from fulfilling its functions.
3.2.1 GAB3 in TNF-α signaling
GAB3 was identified in both screens (z-scores of -1.86 and -2.41; supplementary table A.3).
GAB3 knockdown decreased the expression of IL-8 and BIRC3 in a statistically significant
manner (Figure 2.21). GAB3 function in the signaling cascade was determined to be at
the level or upstream of the IKK, as assessed by TNF-α-induced IκB-α phosphorylation
(Figure 2.25B).
GAB3 was first described in 2002 on the basis of its sequence homology to GAB1 [259].
Together with GAB2, these proteins form the family of "GRB2-associated binding" (GAB)
proteins. This family of scaffolding proteins is involved in signaling mediated by growth
factor, cytokine and antigen receptors [180, 201]. GAB proteins share a well-conserved
N-terminal pleckstrin homology (PH) domain and are related to the Drosophila scaffold
protein DOS. They contain multiple tyrosine residues that become phosphorylated upon
receptor ligation and serve as binding sites for Src homology (SH) 2 domains. An additional
binding site for SH3 domains is provided by proline-rich regions. Upon receptor stimulation,
GAB family members recruit signaling molecules to the plasma membrane via these SH2
and SH3 binding domains [201].
GAB1 is the best-studied GAB family member. It plays a role in epidermal growth factor
receptor (EGFR)-mediated activation of NF-κB in glioblastoma cell lines [123]. Ligation of
EGFR has been shown to induce an interaction of GAB1 with the protein tyrosine phos-
phatase SHP2 that mediates the activation of PI(3)K/AKT. Activated PI(3)K/AKT in
turn might activate NF-κB [123]. GAB2 has been shown to be involved in NF-κB signaling
as well: Wada et al. have demonstrated that GAB2 interacts with the TNFR superfam-
ily member RANK upon receptor ligation. In osteoclasts, this interaction is necessary for
RANK-induced activation of NF-κB [245].
GAB3 expression is lower than GAB1 and GAB2 expression. GAB3 is mostly expressed
by cells of the hematopoietic system, lymphocytes and bone marrow-derived macrophages
[208]. Based on its expression profile, a function for GAB3 in immunity and hematopoiesis
was proposed [259]. However, GAB3 knockout mice do not show obvious defects in hemato-
poiesis or immune cell function [208].
GAB3 was the only member of this family identified in both screens [siGAB1 was un-
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Figure 3.3: Models of GAB3’s mode of action in TNF-α signaling. Analogously to GAB1’s role in
EGFR signaling (left grey panel), GAB3 could interact SHP2 and PI(3)K upon TNF-α stimulation.
This interaction could then activate NF-κB via PI(3)K. GAB3 could also mediate NF-κB activation
by interacting with SHP2 in a PI(3)K-independent manner. Alternatively, GAB3 could activate
PI(3)K by its interaction with GRB2. Besides, GAB3 was shown to interact with the adaptor
molecule GRAP2 which could link it to MAPK-mediated activation of NF-κB. Finally, analogously
to GAB2’s role in RANK signaling (right grey panel), GAB3 could directly interact with TNFR1
to activate NF-κB.
remarkable (z-scores of 0.04 and 1.5), whereas siGAB2 showed a low z-score in only one of
the screens (z-scores of 0.16 and -2.29)]. GAB3 interacts constitutively with GRB2 [259],
a known interactant of TNFR1, bridging TNFR1 signaling and the Ras signaling cas-
cade [100]. Ras is known to influence NF-κB through the activation of PI(3)K [41]. Upon
treatment with macrophage colony-stimulating factor (M-CSF) and IL-3, GAB3 is phos-
phorylated which enables its interaction with SHP2 and PI(3)K [259]. Whereas PI(3)K
can activate NF-κB via protein kinase C [193], SHP2 mediates activation of NF-κB both
PI(3)K-dependently [123] and PI(3)K-independently [268]. Further, GAB3 has been de-
scribed to associate with GRB2-related adaptor protein (GRAP) 2 [26], a scaffold pro-
tein involved in MAPK (mitogen-activated protein kinase) signaling [25]. Hence, numer-
ous GAB3 interaction partners may mediate GAB3’s interaction with TNFR1 to activate
NF-κB. This mode of action would be similar to GAB1-mediated NF-κB activation upon
EGFR ligation. Analogous to GAB2’s function in RANK signaling, GAB3 could also bind
to TNFR1 directly, supporting the recruitment of signaling pathway components. These
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two possible modes of action are represented in Figure 3.3.
In order to further analyze the role of GAB3 in TNF-α signaling, it could be tested
whether GAB3 becomes phosphorylated after TNF-α treatment, as was described for
M-CSF and IL-3. The GAB3 antibodies I have tested so far were not specific enough
to reliably detect the protein in cell lysates. Immunoprecipitation experiments could be
performed to test the hypothesis that GAB3 associates with TNFR1 either directly or
possibly via TNFR1-bound GRB2. These experiments could also assess whether TNF-α
treatment induces an interaction between GAB3 and PI(3)K, SHP2 or GRAP2. Further,
since the other GAB family members have been shown to be able to interact with GRB2,
PI(3)K and SHP2, it would be interesting to test if these two factors influence TNF-α
signaling as well, even though they were not identified in my screens.
3.2.2 SPP1 in TNF-α signaling
SPP1 was identified as potential regulator of TNF-α signaling in screen A (z-score -2.84).
Its silencing significantly decreased the induction of the TNF-α target genes IL-8, BIRC3
and TNF-α upon stimulation (Figure 2.20).
The cytokine-like SPP1 has first been described to be a secreted protein acting ex-
tracellularly but is now known to also fulfill functions intracellularly [33]. The protein is
upregulated in several inflammatory diseases, e.g. multiple sclerosis and rheumatoid arthri-
tis [225, 261, 52]. SPP1 is broadly expressed and can be extensively post-translationally
modified by phosphorylation, N- and O-glycosylation as well as cleavage [221, 49, 210].
Most reports have focused on extracellular SPP1. In essence, secreted SPP1 binds to in-
tegrins and CD44 on cell surfaces, thereby promoting migration and inducing expression
of cytokines through NF-κB and MAPK signaling [8, 254, 273, 272]. Secreted SPP1 thus
plays roles in inflammation, angiogenesis and tumor metastasis [53]. Its serum levels are el-
evated in cancer patients and patients suffering from inflammatory diseases [53, 127]. SPP1
knockout mice exhibit a partly immunocompromised phenotype with attenuated responses
to e.g. bacterial infection, arthritis and multiple sclerosis [175, 269, 38].
Since extracellular SPP1 is an activator of NF-κB [55, 133] and one of its cell surface
receptors, ITGA5 [110], was also identified as required for TNF-α signaling in this study, I
suspected a feedback loop via SPP1/ITGA5. However, my results show that SPP1 knock-
down diminished TNF-α-induced IκB-α phosphorylation already after 5 minutes of TNF-α
stimulation (Figure 2.25). SPP1 seems therefore not to be part of a TNF-α-induced feed-
back loop. To test whether extracellular SPP1 can rescue the siSPP1 phenotype in TNF-α
signaling, I treated SPP1 knockdown cells with recombinant SPP1. The treatment did not
reconstitute NF-κB activity (data not shown). However, the used recombinant SPP1 was
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not post-translationallly modified, and these modifications could be required for its func-
tion. It would be interesting to assess the potential of neutralizing SPP1 antibodies to block
TNF-α-induced activation of NF-κB in order to gain further insights into which variant of
SPP1, the extra- or the intracelluar one, mediates its function in TNF-α signaling.
Alternative translation yields a SPP1 variant that lacks the secretion signal and thus
localizes inside the cell [215, 277]. Little is known about the function of intracellular SPP1.
It is expressed in osteoclasts, fibroblasts, macrophages as well as dendritic and T cells where
it modulates the cytoskeleton, cell shape and cell migration [277, 231, 215]. SPP1 is also
involved in osteogenic differentiation and cell proliferation [273, 276, 274]. The intracellular
protein has been shown to localize to distinct spots at the plasma membrane as well as in
cell processes, co-localizing with CD44 and ezrin [277, 273]. Interestingly, SPP1 has also
been shown to co-localize with the death domain (DD) containing protein MyD88. By
immunoprecipitation and microscopy, Shinohara et al. have demonstrated a co-localization
with MyD88 upon induction of Toll-like receptor (TLR) 9 in plasmacytoid dendritic cells
[216]. However, SPP1 was only required for interferon regulatory factor (IRF) 7-induced
production of interferon α but not for NF-κB-induced expression of IL-6 and TNF-α [216].
Recently, CASP8 has been demonstrated to cleave the secreted variant of SPP1 [131].
Cleavage was induced in HeLa cells upon oxidative stress, preluding cell death [131]. In
contrast, uncleaved SPP1 inhibited apoptosis induced by oxidative stress, probably by
regulating AKT activity [131]. Interestingly, TNF-α treatment did not induce SPP1 cleav-
age [131]. An intriguing hypothesis is that uncleaved intracellular SPP1 influences NF-κB
activation after TNF-α stimulation by controlling activity of AKT [41].
My results indicate that SPP1 acts at the level or upstream of the activation of the IKK
since silencing abolished TNF-α-induced phosphorylation of IκB-α (Figure 2.25). There-
fore, I assessed whether the intracellular localization of SPP1 would support a function at
the TNFR1 complex. While the secreted variant of SPP1 localizes to Golgi and vesicles,
the intracellular version has been described to be cytoplasmic [275, 277]. However, stain-
ing of endogenous SPP1 detected only to-be-secreted protein that co-localized with Golgi
and early endosome markers (data not shown). I was not able to detect any cytoplasmic
staining, probably because of the high intensity of the staining in the Golgi and in vesicles.
Overexpression of a CFP-tagged SPP1 construct indicated that SPP1 is cytoplasmic, but
this observation may be confounded overexpression of the protein (data not shown). The
staining pattern of endogenous SPP1 did not change upon TNF-α stimulation (data not
shown); neither exocytosis of vesicles nor accumulation at distinct foci was induced.
A conceivable hypothesis on SPP1’s action in TNF-α signaling is that SPP1 might
interact with DD proteins in the TNFR1 complex, analogously to its TLR-induced inter-
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Figure 3.4: Model of SPP1’s mode of action in TNF-α signaling. Analogously to its function in
Toll-like receptor (TLR) 9 signaling (left grey panel), SPP1 could interact with DD proteins in the
TNFR1 complex - TNFR1, TRADD, RIP1 - to facilitate activation of NF-κB.
action with the DD protein MyD88 [216]. This model is represented in Figure 3.4. Even
though SPP1 is not involved in NF-κB activation by TLR9 [216], it could be involved
in TNFR1-mediated activation of NF-κB, e.g. by interaction with different adaptor and
effector proteins. It would be interesting to assess whether SPP1 is able to interact with
one of the DD proteins in the TNFR1 complex, namely TNFR1, TRADD and RIP1.
3.2.3 CASP4 as a novel regulator of TNF-α signaling
Caspase 4 (CASP4) was identified in screen B (z-score: -2.53). Its silencing significantly
reduced expression of the TNF-α target genes BIRC3, TNF-α, CCL20 and NFKBIA
(Figure 2.22). My results indicate that CASP4 acts at the level or upstream of the ac-
tivation of the IKK since its knockdown interfered with TNF-α-induced phosphorylation
of IκB-α (Figure 2.25C).
Caspases are mainly involved in apoptosis induction, however other functions have be-
gun to emerge as well [1]. Upon activation, usually by cleavage of the pro-caspase into two
subunits, caspases act as cysteine proteases. CASP4 belongs to the family of inflamma-
tory caspases which are, as the name implies, involved in immune function. In addition to
CASP4, two other caspases are members of the family of inflammatory caspases: CASP1
and CASP5 [163]. Both of them did not significantly alter NF-κB reporter activity in ei-
ther of the screens I have performed. All inflammatory caspases share caspase recruitment
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domains (CARD) which are related to the DD. Besides mediating homotypic protein in-
teractions [253], CARD domains further promote interaction with RING, kinase and DD
domains [194]. These domains are also found in components of the TNF-α signaling cas-
cade. Accordingly, CARD domain containing proteins are involved in the regulation of
NF-κB signaling [24].
CASP1 is the best-studied human inflammatory caspase. It represents the catalytically
active component of the inflammasome, an intracellular protein complex activated through
pathogen-associated molecular patterns (PAMPs) [164]. Upon activation, CASP1 cleaves
pro-IL-1β and pro-IL18 into mature cytokines [164]. Once secreted, these two cytokines
are potent mediators of inflammation and activate NF-κB [71, 85]. CASP5, a component
of the inflammasome as well, is also involved in pro-IL-1β processing [162].
Interestingly, CASP4 and CASP5 probably arouse by gene duplication of the mouse in-
flammatory caspase Caspase-11 [164]. Caspase-11 has been implicated in signaling through
TLR4 [251] and to be an upstream regulator of mouse Caspase-1, the orthologue of hu-
man CASP1 [251]. Besides, mouse inflammatory caspase 12 has been reported to bind to
TRAF2 [267], rendering it a potential regulator of TNF-α signaling.
Few functional data are available on CASP4. It has been identified based on its se-
quence homology to CASP1 [122]. Both caspases share conserved residues in the catalytic
site. While CASP4 barely cleaves the CASP1 substrate pro-IL-1β [122], it cleaves and
activates CASP1 [72]. CASP4 is expressed in most tissues [122] and its expression has
been demonstrated to be induced by interferons [4]. It can be cleaved in an autocatalytical
manner or by CASP8 into two subunits of 21 and 10 kDa, respectively [121].
The Induced Proximity Model [200] suggests that caspases are enzymatically activated
upon induced aggregation leading to the cleavage of the zymogen. My results indicate that
CASP4 is not cleaved upon treatment with TNF-α (Figure 2.30). However, no control for
CASP4 cleavage was used since a specific activator of CASP4 is not known. Yet it would
be interesting to see whether the pan-caspase-activator citrate would induce cleavage of
CASP4 that could be detected by immunoblot [128].
The absent cleavage of CASP4 might be explained by another recent model, which pro-
poses that interaction with other factors induces caspase activation, rather than caspase
cleavage [213]. Thus, CASP4 could be catalytically active without being cleaved. I tested
whether treatment of HEK293T cells with a CASP4 inhibitor affected NF-κB activation
by TNF-α. First experiments indicate that CASP4’s catalytical activity is dispensable for
its role in TNF-α signaling (data not shown). However, these results have to be interpreted
with caution since no positive control for actual CASP4 inhibition was available. An alter-
80
native to measure CASP4 enzymatic activity after TNF-α treatment could be colorimetric
assays where the cleavage of a caspase substrate can be detected via spectrometry. The
disadvantage of these assays is yet that there is no really caspase-specific substrate.
Similar to my observations regarding CASP4, CASP8 has been reported to be involved
in TNF-α-induced NF-κB activation independent from its caspase activity [42]. How ex-
actly CASP8 mediates NF-κB activation is still elusive. Shikama et al. reported that the
death effector domain of CASP8 is required for its role in NF-κB activation [214]. They
showed that CASP8 can interact with RIP1 and TRAF2 [214]. Jun at al. in contrast pro-
posed that CASP8 does not bind TRAF2 directly but via its interaction with CASP8AP2
[120]. The authors stated that siRNA-mediated silencing of CASP8 decreased NF-κB re-
porter activity upon TNF-α treatment in HEK293 cells. I could not confirm these results
using the dual luciferase assay in HEK293T cells (data not shown). Likewise, Su et al.
reported CASP8 not to be involved in TNF-α-mediated activation of NF-κB in mouse fi-
broblasts [228]. However, CASP8 was shown to be involved in TLR4- and antigen receptor-
induced activation of NF-κB, two signaling pathways that are similar to TNFR1 signaling
[228]. Both CASP4 and CASP8 could thus act alike as scaffold proteins. Figure 3.5 presents
this conceivable analogous mode of action of CASP4 in TNF-α signaling. Putative inter-
action partners among TNF-α pathway components for CASP4 could be CARD domain
proteins such as IKK-γ as well as RING and DD domain proteins such as TRAF2 and
RIP1, respectively [24].
CASP4 has been reported to be an ER (endoplasmatic reticulum)-resident protein [102,
186]. Yet by immunostaining of endogenous CASP4 in HeLa cells I could show that CASP4
mainly localizes to the cytoplasm (Figure 2.29). Cytoplasmic localization of CASP4 would
allow interaction with the likewise cytoplasmic TNFR1 complex.
Two reports have demonstrated that CASP4 can interact with TRAF proteins. Laksh-
manan et al. have shown that CASP4 played a role in TLR4-mediated activation of NF-κB
by interaction with TRAF6 and IRAK1 [140]. Pastorino et al. have reported that CASP4
is involved in TNF-α- and ethanol-induced liver damage [185]. They have shown that
TRAF2 is recruited to ER-localized CASP4 in HepG2 cells. However, this interaction was
only observed when cells were treated with both TNF-α and ethanol, but not with TNF-α
alone [185]. Similarly, I could not detect any interaction of CASP4 and TRAF2 by im-
munoprecipitation of the two endogenous proteins nor by immunofluorescence microscopy
in HeLa cells (data not shown). This was true for untreated as well as TNF-α treated
cells. One explanation for these results might be that TNF-α alone may not induce inter-
action between TRAF2 and CASP4, in agreement with Pastorino and coworkers. Another
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Figure 3.5: Model of CASP4’s mode of action in TNF-α signaling. As described for other caspases
such as CASP8 (left grey panel), CASP4 could serve as a scaffold protein at the TNFR1 complex.
As a CARD domain protein, CASP4 could interact either with DD proteins like TNFR1 and RIP1,
TRAF proteins like TRAF5 or other CARD proteins like IKK-γ.
explanation might be that the interaction between CASP4 and TRAF2 is too transient
or weak to be detected working with endogenous protein levels. It would be interesting
to repeat the immunoprecipitation assays while overexpressing one of the two proteins,
although these kind of experiments would have to be interpreted carefully due to possible
overexpression artifacts. Similarly, I could not detect an interaction of CASP4 with RIP1
(data not shown). IKK-γ and the other TRAF protein present at the TNFR1 complex,
TRAF5, represent plausible targets for future investigations.
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3.3 Outlook
Making use of carefully designed assays, RNAi screens represent a powerful technique to
identify novel components of signaling pathways. Application of stringent filters to select
primary hits and multiple secondary assays are required to determine the most promising
candidates for further characterization, as presented here. However, also the caveats of
RNAi screens have to considered. As reported here and by others (e.g. [157, 66, 226]), the
high false positive and negative rates in high-throughput experiments can be problematic
aggravating interpretation of screening results. Better statistical methods to analyze RNAi
screening data might help to decrease false positive and negative rates. This is especially
important for facilitating the use of RNAi screening data for gaining systems biology per-
spectives on biological processes. In addition, improved and more standardized screening
designs could yield more robust results, enabling a better comparability of screens. Unspe-
cific effects of siRNA transfection procedures or of siRNAs themselves is another challenge
that has to be faced. In the near future a worthwhile method to exclude these unspecific
effects and to confirm RNAi phenotypes could be knockout cells created by zinc finger
nucleases, a technique that has recently been developed [191, 37].
After selection of screening hits and their confirmation, the biggest challenge consists in
assessing the biological function of identified novel regulators. By using assays monitoring
fast signaling events after TNF-α stimulation I could show that SPP1, GAB3 and CASP4
play a role in the direct signaling cascade from TNFR1 to IKK. Further research has to
focus on the functional characterization of these candidates. Rescue experiments using hu-
man expression constructs that will not be targeted by siRNAs will be established. These
rescues will allow functional studies, e.g. deletion of protein domains to assess their require-
ment for signaling activity. Additionally, in order to map SPP1, GAB3 and CASP4 into
the TNFR1 pathway, interaction partners have to be identified. In parallel to optimizing
immunoprecipitation conditions, constructs for Yeast-2-Hybrid screening are currently de-
signed for employing a method other than a candidate approach for identifying interaction
partners of SPP1, GAB3 and CASP4. By these means, the exact role of the three novel
regulators of TNF-α signaling - SPP1, GAB3 and CASP4 - will be determined.
Chapter 4
Material and Methods
4.1 Material
4.1.1 Cell lines
Cell line Cell type supplied with by
HEK293T human embryonic kidney cells C. Niehrs, DKFZ, Heidelberg
HeLa human cervix carcinoma cells DKFZ, Heidelberg
HepG2 hepatoma cells T. Dick, DKFZ, Heidelberg
4.1.2 Chemicals, media, buffers and solutions
Chemicals All chemicals were purchased from Sigma if not stated otherwise (see below).
adenosine triphosphate (ATP) Roche
bicine Gerbu
bovine serum albumin (BSA) Gerbu
ethylenediaminetetraacetic acid (EDTA) Applichem
H2SO4 V. Stadler, DKFZ, Heidelberg
3-(N-Morpholino)propanesulfonic acid (MOPS) Applichem
NaCl VWR
sodium dodecyl sulphate (SDS) Gerbu
TritonX-100 Applichem
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Media, buffers and solutions
Human complete medium Dulbecco’s Modified Eagle Medium
(DMEM), Invitrogen, #41965062
supplemented with 10% fetal calf serum
Fetal calf serum Biochrom, #S0115
RPMI 1640 medium Invitrogen, #31870074
Trypsin-EDTA (1x) Invitrogen, #25200056
PBS (1x) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4; Invitrogen, #P3813
Cryoprotective medium Fetal calf serum containing
10% dimethylsulfoxide (DMSO)
Trypan Blue Sigma, #T8154
Cell lysis buffer 1x PBS, 10% Triton, protease inhibitor,
phosphatase inhibitors
5x siRNA buffer Dharmacon/Thermo Fisher Scientific,
#B-002000-UB-100
Laemmli buffer 62.5 mM Tris-Cl (pH 6.8), 10% glycerol, 2% SDS,
5% β-Mercaptoethanol, 0.02% Bromophenol Blue,
0.1 M DTT
SDS PAGE running buffer 50 mM Tris Base, 50 mM MOPS, 1.025 mM EDTA,
69.3 mM SDS
Western Blot transfer buffer 0.5 M BisTris, 0.5 M bicine, 0.02 M EDTA
TBS-Tween (TBS-T) 0.137 M NaCl, 0.02 M Tris-HCl (pH 7.8),
0.1 % Tween20
Western Blot blocking buffer 5% milk in TBS-T
Antibody dilution buffer 0.5% milk in TBS-T
Western Blot stripping solution 0.2 M NaOH
ELISA blocking buffer 1% BSA in 1x PBS
ELISA washing buffer 0.05% Tween20 in 1x PBS
ELISA sample buffer 0.1% BSA in 1x PBS
ELISA stopping buffer 2 N H2SO4
Immunofluorescence blocking buffer 1% BSA in 1x PBS
SOC 2% tryptone, 0.5% yeast extract,
10 mM MgCl2, 20 mM glucose
buffer G Promega, #R007A
50x Tris-acetate-EDTA 1 M Tris base, 50 mM EDTA,
(TAE) buffer 9 mM NaCl, 25 mM KCl,
17.5% glacial acetic acid
FACS buffer 4% FCS in PBS
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4.1.3 siRNAs, plasmids and transfection reagents
Genome-wide knockdown experiments were performed with a synthetic siRNA library,
library A, vended by Dharmacon (Human Genome Set (#G-005000), Druggable Set (#G-
004650), Human Protein Kinases (#G-003500) and G Protein-Coupled Receptors (#G-
003600); Dharmacon/Thermo Fisher Scientific) - covering all unique genes annotated in
the human Reference Sequence (RefSeq) collection (National Center for Biotechnology
Information) version 5.0 - and a synthetic siRNA library, library B, vended by Qiagen
(#1027490, Human Druggable Genome Set Version 3.0 and Human Whole Genome Sup-
plement Set Version 1.0). Libraries sequences were annotated using RefSeq release 27.
Screening results were validated making use of deconvoluted siRNA-pools (siGENOME
set of four upgrade, Dharmacon/Thermo Fisher Scientific) and siRNA pools picked from
the genome-scale siRNA library from Qiagen. Sequences of the siRNAs that were used in
further experiments are listed in table4.1. All these siRNAs were purchased from Dharma-
con (Thermo Fisher Scientific). Lyophilized siRNAs were reconstituted in 1x siRNA buffer
and further diluted with nuclease-free water to a concentration of 500 nM (Dharmacon
siRNAs) or 200 nM (Qiagen siRNAs).
Dharmafect 1 transfection reagent Dharmacon/Thermo Fisher Scientific,
#T-2001-04
TransIT-LT1 Transfection reagent VWR/Mirrus,
#731-0029MIRUMIR2306
4-4-FL NF-κB dependent firefly luciferase
expression plasmid,
based on "pGL3 promoter" (Promega)
act-RL Renilla luciferase expression plasmid,
bearing β-actin promoter,
based on "pRL null" (Promega)
CMV-RL T. Dick, DKFZ, Heidelberg
TK-RL Promega
pcDNA5 empty vector, Invitrogen
RIP1 Tobias Haas
TRADD Tobias Haas
IKK-β Tobias Haas
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Table 4.1: siRNA sequences of controls and candidates. NA: not available. (For IDs of all siRNAs
used in this work see supplementary table A.10.)
RefSeq Symbol siRNA sequence
NM_001065 TNFRSF1A 1 D-005197-01 CAAAGGAACCUACUUGUACUU
2 D-005197-02 GAGCUUGAAGGAACUACUAUU
3 D-005197-03 CACAGAGCCUAGACACUGAUU
4 D-005197-04 UCCAAGCUCUACUCCAUUGUU
NM_001066 TNFRSF1B 1 D-003934-01 GCACAUGCCGGCUCAGAGAUU
2 D-003934-02 CAUCAGACGUGGUGUGCAAUU
3 D-003934-03 UCACUUGCCUGCCGAUAAGUU
4 D-003934-04 UAAUAGGAGUGGUGAACUGUU
NM_033306 CASP4 1 D-004404-01 GGACUAUAGUGUAGAUGUA
2 D-004404-02 GAGACUAUGUAAAGAAAGA
3 D-004404-04 GAGGGAAUCUGCGGAACUG
4 D-004404-17 UAGAGGAAGUAUUUCGGAA
NM_001081573 GAB3 1 D-015239-01 GAAGAAAGCUACAUCGAAA
2 D-015239-02 GAGAUGACCCAAACACUAA
3 D-015239-03 UGUGAUAGCUGGUCAAACU
4 D-015239-04 CCACCAUUCAGGUAGAUAA
NM_001040058 SPP1 1 D-012558-05 CAUCUUCUGAGGUCAAUUAUU
2 D-012558-06 UGAACGCGCCUUCUGAUUGUU
3 D-012558-07 CCGAUGUGAUUGAUAGUCAUU
4 D-012558-08 GGACUGAGGUCAAAAUCUAUU
NM_002205 ITGA5 D-008003-05 ACACGUUGCUGACUCCAUU
D-008003-06 GAACGAGUCAGAAUUUCGA
D-008003-07 CAAACGCUCCCUCCCAUAU
D-008003-20 UGAAGAUGCCCUACCGAAU
NM_130799 MEN1 D-011082-02 GAUCAUACAUGCGCUGUGA
D-011082-03 GGAGCUGGCUGUACCUGAA
D-011082-04 GAUCAUGCCUGGGUAGUGU
D-011082-17 CGGCAGAAGGUGCGCAUAG
NM_006866 LILRA2 D-019855-01 GCUGAGGAGUACCAUCUAU
D-019855-02 AAAUCAGCAUCCUGGGUUA
D-019855-03 CCAGAGAAGCCUACAAGAU
D-019855-04 CUACAGCCACAAUCACUCA
NM_004205, USP2 D-006069-01 CCAGCAAGCUCACAACAUUUU
NM_171997 D-006069-02 UCGCUGACGUGUACAGAUUUU
D-006069-03 GAACCUCGAUCAUCUUCCUUU
D-006069-04 GCCGACAGAUGUGGAGAAAUU
NM_021975 RelA D-003533-03 GGAUUGAGGAGAAACGUAAUU
D-003533-04 CUCAAGAUCUGCCGAGUGAUU
D-003533-05 GGCUAUAACUCGCCUAGUGUU
D-003533-18 GAUUGAGGAGAAACGUAA
NM_003804 RIP1 D-004445-03 GAAAGAGUAUUCAAACGAAUU
D-004445-04 CCACUAGUCUGACGGAUAAUU
D-004445-05 GAAGCCAACUACCAUCUUUUU
D-004445-06 GCACAAAUACGAACUUCAAUU
NA siCon #1 D-001210-01-20
NM_002335 LRP5 D-003844-01 CCAACGACCUCACCAUUGAUU
D-003844-02 GCAUGACGCUGGUGGACAAUU
D-003844-03 CCGACGAGCUCAUGUGUGAUU
D-003844-04 CGUCAAAGCCAUCGACUAUUU
NA siRL NA P-002070-01-05 AAACATGCAGAAAATGCTG
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Cloning of 4-4-FL As a pathway specific reporter, a NF-κB-dependent firefly luciferase
(FL) expression plasmid was cloned (4-4-FL). The first step of the cloning consisted in
annealing and ligating six oligos (table 4.2) containing all together eight times the following
NF-κB binding site: GGGGACTTTCC [NF-κB binds the consensus sequence 5’-GGGRN
W YYCC-3’ (where G stands for purine base, N denotes any base, W is an adenine or
thymine, Y denotes a pyrimidine base] [209, 143, 43]). The ends bore XmaI (5’ end) and
BglII (3’ end) restriction sites that were used to ligate it into "pGL3 promoter". Correct
cloning was controlled by sequencing the insert from both ends (see Figure 4.1).
Figure 4.1: Plasmid map of the 4-4-FL NF-κB reporter. fluc: firefly luciferase, amp: ampicillin,
prom: promoter, SV: Simian Virus.
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Cloning of act-RL The β-actin promoter, an approx. 1100 bp sequence in the 5’ un-
translated region of the β-actin coding sequence, was amplified using PCR primers bearing
restriction sites for HindIII (5’ end) and SpeI (3’ end, table 4.2). These restriction sites
were used to insert the promoter sequence into cut "pRL null" being cut with the same
restriction enzymes. Correct cloning was controlled by sequencing the inserted promoter
sequence from both ends (see Figure 4.2).
Figure 4.2: Plasmid map of the act-RL co-reporter. amp: ampicillin, bact: β-actin, RLuc: Renilla
luciferase.
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4.1.4 Antibodies
antigen company application dilution
phospho-IκB-α Cell Signaling, #9246S immunoblotting 1:2000
(5A5, mouse)
α-tubulin Sigma, #T9026 immunoblotting 1:10 000
(DM1A, mouse)
CASP4 MBL, #M029-3 immunoblotting 1:1000
(4B9, mouse) immunofluorescence 1:500
TRAF-2 Cell Signaling, #4724 immunofluorescence 1:100
(C192, rabbit)
calnexin M. Weiss (DKFZ) immunofluorescence 1:100
(mouse)
anti-mouse IgG1 HRP Southern Biotech, #1070-05 immunoblotting 1:20 000
(goat)
anti-mouse HRP GE Healthcare, #NA931 immunoblotting 1:10 000
(sheep)
anti-rabbit Alexa594 Invitrogen, #A11012 immunofluorescence 1:1000
(goat)
anti-mouse Alexa488 Invitrogen, #A11001 immunofluorescence 1:1000
(goat)
Enbrel P. Krammer (DKFZ) cell culture 12.5 µg/ml
IgG control P. Krammer (DKFZ) cell culture 12.5 µg/ml
TNFRSF1A BD Pharmingen, #550514 FACS 1:50
(MABTNFR1-B1, mouse)
TNFRSF1B BD , #551311 FACS 1:50
(M1) (rat)
mouse and rat H. Walzcak, London FACS 1:200
isotype controls
F(ab’)2 Anti-Mouse Southern Biotech, #1032-08 FACS 1:100
IgG (H+L) Biotin (goat)
Anti-Rat IgG Southern Biotech, #3030-08 FACS 1:200
Biotin (goat)
Streptavidin-PE BD FACS 1:200
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4.1.5 Enzymes and kits
human CXCL8/IL-8 ELISA R&D, #DY208
CellTiterGlo Promega, #G7571
BCA assay Pierce (Perbio), #23227
QIAprep Spin Miniprep Kit Qiagen, #27106
Endofree Plasmid Maxi Kit Qiagen, #12362
ECL Plus Amersham, #RPN 2131
phosphatase inhibitor Sigma, Phosphatase Inhibitor Cocktails 1 and 2
Complete Mini Protease Inhibitor Roche, #11836153001
XmaI NEB, #R0180S
BglII NEB, #R0144S
SpeI NEB, #R0133S
HindIII NEB, #R0104S
Phusion NEB, #F-530 S
T4 DNA ligase NEB, #M0202S
T4 polynucleotide kinase (PNK) NEB, #M0201S
Lambda Protein Phosphatase NEB, #P0753S
Taq DNA Ploymerase Qiagen, #201207
probes master Roche, #4887301001
superscript III with RT-buffer Invitrogen, #18080044
RNAse inhibitor Fermentas, #EO0381
4.1.6 Oligos
Oligos for cloning
Table 4.2 lists the oligos that were used for cloning of the luciferase contructs for the dual
luciferase assay. For 4-4-FL cloning, oligos 1a and 1b, 2a and 2b and 3a and 3b were first
annealed to each other, before 1 was ligated with 2 and 3. The ligated insert was cut with
XmaI (5’, oligo 1) and BglII (3’, oligo 3). The oligos for act-RL cloning were used as PCR
primers.
qPCR primers
Table 4.3 lists all qRT-PCR primers and respective universal probe library (UPL) probes
that were used in qRT-PCR assays.
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Table 4.2: Oligos for cloning of luciferase contructs.
4-4-FL cloning
oligo sequence
1a CCGGGTCAGAGGGGACTTTCCGAGAGGCGTCAG
AGGGGACTTTCCGAGAGGCGTCAGAGGGGACTTTCCGAGA
1b TGACGCCTCTCGGAAAGTCCCCTCTGACGCCTCTC
GGAAAGTCCCCTCTGACGCCTCTCGGAAAGTCCCCTCTGAC
2a GGCGTCAGAGGGGACTTTCCGAGAGGCGTCAGAG
GGGACTTTCCGAGAGGCGTCAGAGGGGACT
2b TCTCGGAAAGTCCCCTCTGACGCCTCTCGGAAAGTC
CCCTCTGACGCCTCTCGGAAAGTCCCCTC
3a TTCCGAGAGGCGTCAGAGGGGACTTTCCGA
GAGGCGTCAGAGGGGACTTTCCGAGAGGCGA
3b AGATCTCGCCTCTCGGAAAGTCCCCTCTG
ACGCCTCTCGGAAAGTCCCCTCTGACGCC
act-RL cloning
oligo sequence
left primer agtcaagcttgcgagggcagtgcagactttctctatc
right primer agtcactagtatctcaaggcgaggctcgtgctc
Table 4.3: qRT-PCR primers for references, controls, candidates and target genes.
RefSeq Gene Symbol Forward Primer Reverse Primer UPL #
NM_002046 GAPDH agccacatcgctcagacac gcccaatacgaccaaatcc 60
NM_000194 HPRT1 tgaccttgatttattttgcatacc cgagcaagacgttcagtcct 73
NM_021975 RelA cgggatggcttctatgagg ctccaggtcccgcttctt 47
NM_001065 TNFRSF1A gagaggccatagctgtctgg gaggggtatattcccaccaac 59
NM_000594 TNF cagcctcttctccttcctgat gccagagggctgattagaga 29
NM_000584 IL8 agacagcagagcacacaagc atggttccttccggtggt 72
NM_004591 CCL20 gctgctttgatgtcagtgct tcaaagttgcttgctgcttc 39
NM_020529 NFkBIA gtcaaggagctgcaggagat gatggccaagtgcaggaa 38
NM_001165 BIRC3 cttgtccttgctggtgcat aagaagtcgttttcctcctttgt 44
NM_001081573 GAB3 tccagagaagacgaagaaagcta cgtaagggcaccactgct 25
NM_006866 LILRA2 caacccctacctgctgtctc gtgttggcctagggatgct 1
NM_002205 ITGA5 caacatctgtgtgcctgacc ccaggtacacatggttctgc 11
NM_001040058 SPP1 tttcgcagacctgacatcc ggctgtcccaatcagaagg 61
NM_130799 MEN1 gacccactcaccctctacca tgtgttcatcccgatagtaggtc 30
NM_033306 CASP4 gamma gaccaaatatcccccaataaaaa caaagcttgagggcatctgt 2
NM_004205 USP2 ttcgactcgtccatactcca tggcactcagtggggact 34
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4.1.7 Miscellanous
nuclease-free water Acros Organics, #327390050
TNF-α Biosource/Invitrogen, #PHC3015
vecta shield Biozol, #VEC-H-1000
NuPage precast 10% Bis-Tris non-gradient gels Invitrogen, #NP0301BOX
PageRuler Prestained Protein ladder plus Fermentas, #SM1811
ECL detection membrane GE Healthcare, #RPN2132
Fuji Super RX 100NIF medical X-ray film Kisker, #RX1318
DH5α competent Escherichia coli,
Invitrogen, #18263012
dNTPs Fermentas, #R0182
oligo dT primer home-made (see pimer list)
Hoechst Invitrogen, #H1399
RNase-Free Spray Steinbrenner, #SL-5454
non-fat dry milk Biorad, #170-6404
Parafilm VWR, #291-1219
Stericup-GP, Filtertop + Bottle Millipore, #SCGPU05RE
Sybr Safe Invitrogen, #S33102
TrackIt 100 bp DNA ladder Invitrogen, #10488058
Lysis buffer and substrates for home-made, confidential recipe
luciferase assays
4.2 Methods
4.2.1 Cell culture and cell maintenance
Human embryonic kidney (HEK) 293T cells, human cervix carcinoma cells (HeLa) and
hepatoma cells (HepG2) were maintained in complete medium at 37◦C in a humidified
atmosphere with 5% CO2. Every 2-3 days, the adherent cell layer was washed with PBS,
incubated for approximately 30 seconds (HEK293T) or 4 minutes with 1x trypsin and
separated cells were resuspended in complete medium. Cells were diluted 1:5 and 1:10
being seeded in 75 cm2 cell culture flasks with vented cap (BD Falcon). All cell types were
always kept below a maximum confluence of 80-95% and a passage number lower than
passage 20.
To preserve cells, cells out of one 75 cm2 cell culture flask were resuspended in 2 ml
ice-cold cryoprotective medium and aliquoted into screw cap cryogenic vials (Corning)
(i.e. approximately 4-5 million cells per vial). Vials were placed in isopropanol filled "Mr.
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Frosty" (Neolab) and gently cooled down by being placed at -80◦C over night prior to being
stored in liquid nitrogen. Cells were thawed at 37◦C (waterbath Julabo TW12) before being
spun down (Centrifuge 5804, Eppendorf) in 9 ml culture medium and seeded in 12 ml in
a 75 cm2 cell culture flask.
For determing cell number when cells were seeded for assays, cells were stained with
trypan blue and counted using a standard Neubauer hemocytometer (VWR).
4.2.2 Transfection protocols
siRNA transfections
Generally, siRNAs were transfected into cells using a reverse transfection method, i.e. cells
were seeded onto siRNAs mixed with the transfection reagent DharmaFect1. siRNA final
concentration was 50 nM for Dharmacon siRNAs and 20 nM for Qiagen siRNAs. Genome-
wide screens were done in duplicates. All other experiments in 384-well format were carried
out at least in quadruplicates and were repeated at least three times. For experiments with
more than two plates, the Biomek FX pipetting robot (Beckman Coulter) was used to
distribute siRNAs in the 384-well plates. Transfection reagent, cells, plasmid mix and
TNF-α were pipetted using an automated 8-channel liquid dispenser (Multidrop, Thermo
Labsystems).
384-well plate format 0.05 µl DharmaFECT1 were gently mixed with 4.95 µl RPMI
per well and incubated for 10 min at room temperature before another 10 µl RPMI were
added. This mix was then pipetted to 5 µl 500 nM (Dharmacon) or 200 nM (Qiagen)
siRNA (in siRNA buffer) followed by another incubation for 30 min at room temperature.
4*103 (HEK293T) or 4.5*103 (HepG2) cells in 30 µl (antibiotics free) culture medium were
seeded on top of the siRNAs, plates were shortly spun (Centrifuge 5804, Eppendorf) to
collect all liquid at the bottom of the wells and then kept in the incubator (Binder) for
three days to allow for protein depletion.
96-well plate format - HEK293T cells Per well (Microtest Tissue Culture Plate 96
well Flat Bottom, Falcon), 0.2 µl DharmaFECT1 were gently mixed with 9.8 µl RPMI
and incubated for 10 min at room temperature. This mix was then added to 10 µl 500 nM
siRNA (in RPMI) followed by another incubation for 30 min at room temperature. 1.7*104
cells in 80 µl (antibiotics free) culture medium were seeded on top of the siRNAs and kept
in the incubator for three days to allow for protein depletion.
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24-well plate format - HeLa cells 0.35 µl DharmaFECT1 were gently mixed with
49.65 µl RPMI per well (24-well tissue culture plate, Greiner) and incubated for 10 min at
room temperature. This mix was then added to 50 µl 500 nM siRNA (in RPMI) followed
by another incubation for 30 min at room temperature. 2*104 cells in 400 µl (antibiotics
free) culture medium were seeded on top of the siRNAs, gently mixed to distribute cells
equally in the well and kept in the incubator for two days to allow for protein depletion.
6well plate format - HeLa cells Per well, 1.5 µl DharmaFECT1 were gently mixed
with 196 µl RPMI in a 1.5 ml tube (Eppendorf) and incubated for 10 min at room temper-
ature. Then 2.5 µl siRNA [20 µM] were added, followed by another incubation for 30 min.
The mix was pipetted into the well, 1.3*105 cells in 800 µl were added and gently mixed.
Transfected cells were kept in the incubator for two days to allow for protein depletion.
Dual luciferase assay and plasmid transfections
Dual luciferase assay Luciferase assays were performed in 384-well format (white
plates, Greiner). TransIT served as transfection reagent. Cells were contained in 50 µl
(antibiotics free) culture medium per well, seeded on the day before.
Per well, 0.2 µl TransIT were gently mixed with 4.8 µl RPMI and incubated for 10
min at room temperature before being added to 15 µl RPMI containing the plasmids.
For HEK293T cells, in total 50 ng plasmid were transfected: 2 ng of the Firely luciferase
expression plasmid, 20 ng of the Renilla luciferase expression plasmid and 28 ng empty
plasmid. For HepG2 cells, 2 ng of the Firely luciferase expression plasmid and 55 ng of the
Renilla luciferase expression plasmid were used. After addition of the transfection reagent,
the mix was incubated for another 30 min. Then, the transfection mix was added to the
cells, plates were shortly spun (Centrifuge 5804, Eppendorf) to collect all liquid at the
bottom of the wells and then kept in the incubator (Binder) for two days to allow for
plasmid expression.
16 (HEK293T) or 24 (HepG2) hours prior to the readout, cells were stimulated with
10 µl TNF-α in (antibiotics free) culture medium to yield a final concentration of 20
(HEK293T) or 50 (HepG2) ng/ml.
For the luciferase readout, medium was sucked off wells using a 24-channel wand (V&P
scientific) and 20 µl lysis buffer was added. Cells were lysed for 20 min prior to addition of 30
µl of the substrates, first for the firefly luciferase and then - after measuring luminescence
with a Mithras LB940 plate reader (Berthold Technologies) - for the Renilla luciferase.
firefly luciferase luminescence was measured without filter, Renilla luciferase luminescence
using a filter at 485 nm. Data was analyzed by dividing the measured firefly luciferase
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luminescence counts by the Renilla luciferase luminescence counts and then avaraging
values corresponding to one treatment.
4.2.3 Measuring cell viability using the CellTiterGlo assay
Cell viability was measured in 384-well format (white plates, Greiner) using the CellTiter-
Glo assay which assesses ATP content in wells of lysed cells for infering cell number. The
CellTiterGlo reagent contains a luciferase and its substrate which is converted in a lumi-
nescent product ATP-dependently.
Medium was sucked off using a 24-channel wand (V&P scientific) and per well 20 µl of
a mix of CellTiterGlo reagent with (serum and antibiotics free) DMEM (1:4) was added.
After an incubation for 20 min in the dark, luminescence was measured without filter with
a Mithras LB940 plate reader (Berthold Technologies).
4.2.4 ELISA
For ELISA, cells were reverse transfected with siRNAs using the standard protocol (see
4.2.2). ELISAs were carried out in parallel to luciferase assays, but instead of transfect-
ing plasmids, 20 µl (antibiotics free) medium was added per well. After 16 (HEK293T)
or 24 (HepG2) hours of incubation with a final concentration of 20 (HEK293T) or 25
(HepG2) ng/ml TNF-α, supernatents were harvested pooling 8 equally treated wells. In-
terleukin (IL)-8 concentration of supernatents, undiluted or 1:2 diluted in reagent diluent,
was assessed using the human CXCL8/IL-8 ELISA kit by following exactly manufacturer’s
instructions. Measurements were carried out in technical duplicates in 96-well format (Max-
iSorp F, Nunc), the standard supplied by the vendor was applied in a range from 0 - 1000
pg/ml. Absorbance was measured with the Mithras LB940 plate reader (Berthold Tech-
nologies) having the filter set at 450 nm.
4.2.5 Handling bacteria
Transformation DH5α E. coli (50 µl aliquot) were thawed on ice before adding the
plasmid to be transformed with: for re-transformations 0.5 µl vector, for first transforma-
tions after cloning 5 µl vector were used. After an incubation of approximately 15 min on
ice, bacteria were heat-shocked at 42◦C for 30 seconds and then placed on ice for 2 min.
Then, bacteria were mixed with 500 µl SOC medium and incubated at 37◦C for 45-60
min while shaking (Thermomixer!). After spinning down in a benchtop centrifuge (5415D,
Eppendorf) for 10 min at 5000 rpm, half of the medium was discarded and bacteria were
resupended in the other half. Bacteria (50 - 200 µl) were plated on agar plates containing
the appropriate antibiotic for selection which where then placed at 37◦C over night.
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Colony PCR For verifying that bacteria contained the plasmid with the intended insert,
colony PCRs were performed. For this purpose, 10 µl sterile water were pipetted into a
PCR tube (Biozym), one bacterial colony was picked with a yellow tip and then mixed
with the water. 3 µl of this mix were taken for a PCR.
The general PCR mix contained - besides these 3 µl - 5 µl PCR buffer (coral load,
supplied with Qiagen Taq polymerase), 1 µl dNTPs (10 mM), 2 µl each 5’ and 3’ primers
(10 pmol/µl), 2 µl Taq in a total volume of 50 µl (filled up with H2O).
The general PCR protocol was the following:
one cycle: 5 min at 95◦C
then 35 cycles: 1 min at 95◦C,
1 min at ((melting temperature oligos)-2)◦C,
1 min/kb at 72◦C
then 1 cycle 72◦C for 10 min
and finally cooling down to 4◦C.
PCRs were evaluated on 1% agarose gels in 1x TAE buffer.
4.2.6 Cloning
PCR using Phusion When the proof-reading DNA polymerase "Phusion" was used,
the following PCR protocol was used:
one cycle: 30 sec at 98◦C
then 35 cycles: 10 sec at 98◦C,
30 sec at ((melting temperature oligos)+3)◦C,
30 sec/kb at 72◦C
then 1 cycle 72◦C for 10 min
and finally cooling down to 4◦C.
PCRs were evaluated on 1% agarose gels in 1x TAE buffer.
Digest of DNA Restriction digests were done in a final volume of 20 µl (filled up with
water). 10 µl of a mini prep (prepared according to manufacturer’s instructions) were mixed
with 2 µl of the appropriate buffer, 1 µl total enzyme (so 0.5 µl per enzyme if it was a
double digest) and - when needed - 2 µl BSA. Digest were done for 1-2 h at 37◦C. If needed,
enzymes were heat-inactivated at 65◦C for 20 min.
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Annealing of oligos 10 µl of 2 to-be-annealed oligos (100 µM) were mixed with each
other and added to 2.5 µl buffer G, 15 µl MgCl2 (25 nM) and 12.5 µl H2O in a 1.5 ml tube
(Eppendorf). After mixing, the tube was placed in a water bath (Yulebo) heated up to
95◦C. After 5 min, the waterbath was switched off, leaving the tube inside to slowly cool
down over night.
For ligations, annealed oligos had to be phosphorylated. For this purpose, 15 µl annealed
oligos (100 µM) were mixed with 2 µl polynucleotide kinase (PNK) buffer, 2 µl ATP (10
mM) and 1 µl PNK. The mix was incubated for an hour at 37◦C before the enzyme was
heat-inactivated at 65◦C for 20 min.
Ligation of inserts into vectors Inserts were ligated into cut vectors usually at the ra-
tio 1:3 or 1:1, calculated using "Promega Biomath" (http://www.promega.com/biomath).
Reaction batches were pipetted in a final volume of 20 µl (filled up with water):
x µl oligo
200 ng vector (cut)
1 µl T4 DNA ligase
2 µl T4 DNA ligase buffer
Ligations were performed over night at 16◦C.
4.2.7 RNA extraction, cDNA synthesis and quantitative real time PCR
RNA extraction was done with the help of the RNeasy kit. Usually, RNA was extracted
from cells being reverse transfected in 96-well plates according to the standard protocol
(see 4.2.2). After two days of transfection, medium was sucked of and 50 µl RLT buffer
per well were added. After waiting for 2-3 min at room temperature, the RLT-cell mix was
pipetted up and down with small tips (for shearing genomic DNA), transferred into PCR
tubes (Biozym) and then frozen over night at -80◦C. Thawed on the next day, the content
of the PCR tubes corresponding to one row of a 96-well plate were pooled and RNA was
extracted according to manufacturer’s instructions, performing DNase digest on column.
RNA was eluted from the column in 30 µl.
RNA concentration was measured using a nanodrop ND-1000 (Peqlab) and 1 µg of RNA
was taken for cDNA synthesis. For this purpose, RNA was mixed with 1 µl of dNTPs (10
mM) as well as of oligo dT primer (0.5 µg/ml) in a volume of 12.25 µl in nuclease free
water in a PCR tube and incubated for 5 min at 65◦C. After cooling the mix down on ice
for approximately 1-2 min, 4 µl of RT buffer, 1 µl DTT, 0.25 µl RNase inhibitor and 0.5 µl
superscriptIII were added. Then the tube was incubated at 50◦C for 90 min, followed by an
98
incubation at 70◦C for 10 min. Assuming that all RNA was reverse transcribed into cDNA,
cDNA concentration usually used for qRT-PCR was 50 ng/µl. (As control, a "minus RT"
reaction batch was also pipetted, proceeding in exactly the same way as decribed above,
but adding nuclease free water instead of superscriptIII.)
qRT-PCRs were performed in 384-well format (LightCycler 480 Multiwell Plate 384,
Roche) using the UPL library from Roche. Two mastermixes were prepared: (A) one con-
taining the probes master and the cDNA, and (B) one containing the 5’ and 3’ primers
and the corresponding probe. For A, 5.5 µl probes master was mixed with 1.1 µl cDNA
(50 ng/µl) per 384-well plate well. Since the measurements were made in technical dupli-
cates, the 2.5-fold of the given amounts were used. For B, 0.114 µl probe, 0.436 µl primer
mix (20 µM each 5’ and 3’ primer) and 3.85 µl nuclease free water were mixed. To have
sufficient volume for technicel dublicates, the 2.2-fold of the given amounts were used. Mix
B was distributed into a 96-well plate (VWR), 9.68 µl per well. Then, 15 µl per well mix
A was added and mixed, before 11 µl each were aliquoted into two wells of the qRT-PCR
plate and the plate was sealed (LightCycler 480 qPCR seal, Roche). For increasing accu-
racy, pipetting steps were done using electronic pipettes (Eppendorf Research Pro) and
multichannel pipettes (Finnpipette, Thermo Labsystems).
The qRT-PCR program consisted in one cycle first denaturation at 95◦C for 10 min,
followed by 45 cycles of a three steps program - 10 sec denaturation at 95◦C, 20 sec
annealing at 55◦C, 1 sec elongation at 72◦C - and finished with one cycle cooling at 40◦C
for 20 sec.
Analysis of qPCR data was performed according to [189].
4.2.8 Expression profiling
RNA was extracted using the RNeasy kit as decribed above (4.2.7). RNA quality was as-
sessed by measuring mRNA depletion mediated by respective siRNAs and TNF-α-mediated
induction of target genes by qRT-PCT before RNA was handed over to the core facility.
RNA was hybridized onto Illumina human Sentrix-8 chips.
4.2.9 Cell lysis, measurement of protein concentration, SDS page and
Western Blotting
For immunoblotting experiments HeLa cells were reverse transfected with siRNAs in 24-
well format using the standard transfection protocol (see 4.2.2). After two days of siRNA
treatment, cells were starved for 3-4 hours by exchanging the culture medium with serum
free DMEM. Then, medium was sucked off again and exchanged with culture medium or
50 ng/ml TNF-α containing medium to stimulate cells for either 0, 5, 10 or 20 min (4 wells
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per condition). After the stimulation, medium was sucked off, cells were washed with PBS
and then trypsinized. Cell pellets were spun down at 5000 rpm for 5 min in a benchtop
centrifuge (5415D, Eppendorf) and washed twice with ice cold PBS prior to cell lysis for
30 min in 70 µl lysis buffer containing protease and phosphatase inhibitors. After spinning
for 20 min at 13 000 rpm at 4◦C, the supernatent was harvested and protein concentration
determined using the BCA assay, following manufacturer’s instructions. 10 - 20 ng protein
were mixed with 5x Laemmli buffer in a total of 20 µl and boiled at 96◦C for 5 min. Then,
proteins were separated on 10% NuPage Bis-Tris non-gradient gels (Novex, Invitrogen) in
1x MOPS buffer. Gels were run at 100 V until samples had migrated into the gel and
then at 200 V (PowerPac Universal, Biorad). After the protein transfer onto nitrocellulose
membranes by wet transfer (XCellII Blot Module, Invitrogen) in 2x NuPage transfer buffer,
membranes were blocked with 5% non-fat dry milk in TBS-Tween (TBS-T) over night at
4◦C. Before adding the phospho-specific antibody in 5% BSA-TBS-T, membranes were
washed three times for 10 min with TBS-T; if the first antibody was not a phospho-specific
one, membranes were only washed once shortly with TBS-T. Incubation with the first
antibody was done over night at 4◦C. Before and after the following 1 h incubation with the
corresponding secondary antibody (in 0.5% milk-TBS-T), membranes were washed three
times for 10 min in TBS-T. Blots were developed by enhanced chemiluminescence following
the manufacturer’s protocol (Amersham Pharmacia Biotech). To reuse the membrane for
incubation with further antibodies, blots were stripped with 0.2 M NaOH for 5 min, then
first washed with water and then with TBS-T for 5 min each. Afterwards, membranes were
blocked again.
4.2.10 Confocal immunofluorescence microscopy
HeLa cells were reverse transfected with siRNAs in 24-well format using the standard
transfection protocol (see 4.2.2 with the exception that cells were seeded onto cover slips
(Neolab)). After two days of siRNA treatment, cells were starved for 3-4 hours by ex-
changing the culture medium with serum free DMEM, followed by another exchange with
medium containing 50 ng/ml TNF-α. After stimulation for different periods of time medium
was sucked off again, cells were washed and fixed for 20 min at room temperature using
4% Pfa in PBS. After two times washing with PBS, cells were permeabilized with 0.2%
Triton-X100 in PBS for 5 min at room temperature, followed by another PBS wash. Cells
were blocked for at least an hour prior to incubation with the first antibody over night in
a wet chamber at 4◦C. For that, cover slips were placed upside down on 20 µl drops of
antibody diluted in blocking buffer on parafilm. On the next day, cover slips were washed
three times with PBS for 5 min followed by the incubation with the secondary antibody for
100
an hour at room temperature in a wet chamber at 4◦C. After another three PBS washes,
cells were stained with Hoechst (1 µg/ml) for 5 min at room temperature and then washed
again three times for 5 min in PBS. Cover slips were mounted in vecta shield on objectives
(Roth) and sealed with nail polish after drying. Samples were stored at 4◦C. Samples were
analyzed using a Leica SP5 microscope.
4.2.11 FACS staining
HeLa cells were transfected with siRNAs in 6-well format (see 4.2.2). After two days of
incubation to allow for protein depletion, cells were washed once in PBS and then scraped
off the wells. Cells were spun down at 1000 rpm for 5 min (Centrifuge 5804, Eppendorf),
resuspended in ice cold FACS buffer and transferred into 1.5 ml tubes (Eppendorf). Then
cells were spun down in a benchtop centrifuge (5415D, Eppendorf) at 5 000 rpm for 2 min
before being resupended in 50 µl FACS buffer containing the primary antibody. Prior to
three washes in ice cold FACS buffer, cells were incubated for 30 min on ice. Subsequently,
cells were incubated in 50 µl FACS buffer containing the secondary antibody, followed by
three washes in FACS buffer. Cells were then stained for 20 min with Streptavidin-PE in
FACS buffer before being washed four times in FACS buffer. Cells were resuspended in
80 µl FACS buffer, transferred into a V-bottom 96-well plate (microplate, Greiner) and
analyzed using a FACSArray (BD). Settings for detecting HeLa cells were the following:
FSC: 40
SSC: 350
Yellow (PE): 310
4.2.12 Computational analyses
Analysis of RNAi screening data
After RNAi screening, large data sets arise that have to be analyzed systematically. Stan-
dardization of values is achieved by excluding intrinsic experimental variations (e.g. due to
signal variations of the reporter gene when reading multiple plates). To this end, normal-
ization is performed separately for each plate, replicate and channel. This step comprises
a log2 transformation of the measured values in order to obtain a (more) symmetrical
data distribution around 0. The screens were then normalized using the method "shorth
normalization" (so that the shorth values of all plates are relatively constant). The shorth
of x is the shortest interval that covers half of the values in x. The shorth is a more robust
estimator of location than the median. After shorth normalization, the ratio of the exper-
imental reporter (firefly luciferase) to the invariant coreporter (Renilla luciferase) value
is determined; this is done to exclude possible artifacts such as cell death affecting both
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experimental and invariant reporter genes. To determine the most significant candidate
phenotypes of the screen, averaged results from multiple independent assays have to be
used. All these steps are implemented into the R/Bioconductor software package "cellHTS"
[29]. This software also offers different means for quality assessment of the screening data
(e.g. plate views displaying the measured values for each well in a color code so that plate
position effects become apparent). cellHTS also computes the Z’-factor which is a statis-
tical way to express how well the distribution of values for positive and negative controls
seperate:
Z ′ = 1− 3 σpos + σneg|µpos − µneg|
where µ are the mean values [of positive (pos) and negative (neg) controls] and σ depicts
their standard deviation. The Z’-factor is a commonly used statistical means to assess the
quality of an assay, with a Z’-factor of 1-0.5 depicting a very good assay, a Z’-factor of 0.5-0
an acceptable assay and a Z’-factor of <0 depicting a non-acceptable assay [19]. However,
the Z’-factor is not really suited to report the quality of a screen as it can only assess
whether good positive and negative controls were used.
Analysis by cellHTS yields a list (top table) in which siRNAs are scored and ranked
according to the strength of their phenotype, expressed as z-scores. The z-score is a sta-
tistical means to expresses how many standard deviation an observation is above or below
the mean of all measurements
z =
x− µ
σ
where x depicts the measured value that has to be standardized, µ is the mean of all
measurements of the same plate and σ is the standard deviation of this mean. In the
analysis of the screens presented here a negative z-score means a reduction in signaling
pathway activity, whereas a positive z-score means an increase.
Using online databases for determining screening false negative rates
In order to assess the false negative rate of screens in a systematic manner, the fraction
of known regulators of inflammation identified by the screens was determined. Two online
databases storing information on which proteins are involved in which signaling pathways
were employed. GeneIDs and symbols of genes involved in TNF-α and NF-κB signaling
were retrieved from the BioCarta pathways database [17]. This "TNF signaling gene set"
contained 82 genes. Additionally, GeneIDs and symbols of genes mediating inflammatory
responses were retrieved from the PANTHER database [169, 170]. This "inflammation
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gene set" contained 315 genes. The expression of the genes of both lists in HEK293T
cells was assessed using sequencing data of total mRNA extracted from HEK293T cells
(Dierk Ingelfinger, unpublished data). Genes that were not expressed were excluded from
the TNF signaling and inflammation gene sets. After this filtering, the TNF signaling gene
set contained 52 genes of which 51 genes were targeted by the overlap of the two libraries
(matched by GeneID). Of the remaining 157 genes of the inflammation gene set, 155 genes
were targeted by the overlap of the two libraries (matched by GeneID). These genes were
tested for their z-scores in screening hit lists.
Analysis of microarray data
Microarray data was read into R using the package "beadarray" [64] . After quality control
of the different chips using the package "arrayQualityMetrics" [129], data was normalized
using the "vsn" method [113, 114]. Then, two different TNF-α-induced target gene expres-
sion signatures were defined: (i) genes altered after 2 hours of TNF-α treatments and (ii)
genes altered after 8 hours of TNF-α treatment as compared to unstimulated cells. In order
to define a TNF-α-induced gene expression signature, first differentially expressed genes in
TNF-α stimulated cells were determined that were treated with the negative contol siRNA.
Moderated t-statistics of these differentially expressed genes was calculated using the em-
pirical Bayes [220]. Only those genes were considered in the gene expression signature that
passed a false discovery rate (FDR; calculated by the Benjamini and Hochberg method)
of maximal 0.1. Subsequently, only those genes out of these significantly differentially
expressed genes were selected that were previously published to be TNF-α target genes
(downloaded from "bioinfo.lifl.fr :: Bioinformatics Software Server" [18]). The expression
signature of these genes was then assessed in all samples. Differential gene expression was
assessed using the package "limma" [220]. Expression levels of differentially expressed genes
were visualized using a Trellis dot plot. Similarity of gene expression signatures between
different samples was assessed using the heatmap.2 function of the "gplots" package.
Appendix A
Supplement
Table A.1: Hit list of screen A. The list was filtered against a list of cytotoxic siRNAs generated
in a viability screen. Genes listed here passed a z-score cut-off of ≤ -2.5, decreased firefly luciferase
expression by at least half of the plate median and did not decrease Renilla luciferase expression
by more than 30%.
Symbol GeneID RefSeq z-score
WDR12 55759 NM_018256 -4.98
SPG7 6687 NM_003119 -4.81
SLC5A1 6523 NM_000343 -4.1
WFS1 7466 NM_006005 -4.1
CHFR 55743 NM_018223 -4.07
WAS 7454 NM_000377 -3.99
SLC4A4 8671 NM_003759 -3.91
SSFA2 6744 NM_006751 -3.88
GEMIN7 79760 NM_024331 -3.71
VAMP3 9341 NM_004781 -3.7
PDE3A 5139 NM_005471 -3.62
SLC8A3 6547 NM_002804 -3.53
TARDBP 23435 NM_007375 -3.5
GJB5 2709 NM_004822 -3.44
WHSC2 7469 NM_005663 -3.42
SLC6A12 6539 NM_002797 -3.39
SLC6A7 6534 NM_002793 -3.37
KNTC1 9735 NM_014708 -3.35
DSCR3 10311 NM_014814 -3.35
EMR2 30817 NM_003590 -3.33
SLC5A2 6524 NM_003041 -3.33
SPP1 6696 NM_000582 -3.29
PIGO 84720 NM_032634 -3.17
PGS1 9489 NM_024419 -3.14
FLJ14466 84876 NM_032482 -3.13
FARSLB 10056 NM_005687 -3.09
RARRES3 5920 NM_004585 -3.05
SSB 6741 NM_003142 -3.05
RIOK2 55781 NM_018343 -3.01
WIT-1 51352 NM_015855 -3
WDR8 49856 NM_017818 -2.96
SPOCK 6695 NM_004598 -2.95
OR1L3 26735 XM_377073 -2.93
KIF4A 24137 NM_012310 -2.92
S100A5 6276 NM_002962 -2.92
PLUNC 51297 NM_016046 -2.91
TBPL2 387332 NM_178431 -2.88
SOX12 6666 NM_006943 -2.87
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PABPC1 26986 NM_002568 -2.84
SPAG4 6676 NM_003116 -2.83
ZDHHC3 51304 NM_016053 -2.8
SLC9A1 6548 NM_006503 -2.77
STIM1 6786 NM_003156 -2.77
ZNF462 58499 NM_020801 -2.74
LAPTM4A 9741 NM_014713 -2.72
PDE1B 5153 NM_000924 -2.71
CUL3 8452 NM_003590 -2.7
TNIP3 79931 NM_024873 -2.68
USP2 9099 NM_004205 -2.67
TOMM7 54543 NM_016077 -2.67
ABTB2 25841 NM_002492 -2.66
SLC39A10 57181 NM_019895 -2.66
ERN1 2081 NM_001433 -2.64
TMC1 117531 NM_138691 -2.64
CCT4 10575 NM_006430 -2.64
H1FX 8971 NM_006026 -2.64
XPO7 23039 NM_015024 -2.63
GOLPH2 51280 NM_015948 -2.63
MGC14126 84984 NM_032898 -2.62
SLC6A11 6538 NM_002795 -2.6
PTPDC1 138639 NM_152422 -2.59
LRDD 55367 NM_018494 -2.59
SPTLC2 9517 NM_003908 -2.58
LOC389429 0 XM_371847 -2.58
PIGA 5277 NM_002108 -2.57
CAMK1D 57118 NM_020397 -2.55
KLK4 9622 NM_004674 -2.55
GTF2A1 2957 NM_015859 -2.55
FREB 84824 NM_022342 -2.53
AKR1C2 1646 NM_001354 -2.51
AKR1C2 1646 NM_001354 -2.51
CEBPD 1052 NM_001088 -2.51
LOC387882 387882 NM_021649 -2.5
FLJ35696 388341 XM_036729 -2.5
Table A.2: Hit list of screen B. Genes listed here passed a z-score cut-off of ≤ -2.5, decreased firefly
luciferase expression by at least half of the plate median and did not decrease Renilla luciferase
expression by more than 30 %.
Symbol GeneID RefSeq z-score
PSMD14 10213 NM_005805 -6.59
PSMC1 NA NM_002802 -5.95
PSMA6 5687 NM_002791 -5.48
PSMD7 5713 NM_002811 -5
HNRPC NA NM_004500 -4.96
PSMC4 5704 NM_006503, NM_153001 -4.93
PSMD3 NA NM_002809 -4.89
SUPT5H NA NM_003169 -4.88
DDX48 9775 NM_014740 -4.78
PSMD1 NA NM_002807 -4.78
PSMA5 5686 NM_002790 -4.47
SP1 6667 NM_138473 -4.39
RELA 5970 NM_021975 -4.32
p44S10 NA NM_014814 -4.2
CKB 1152 NM_001823 -4.19
PSMA7 5688 NM_002792 -4.16
POLR2E NA NM_002695 -4.1
CDCA1 83540 NM_031423, NM_145697 -4.09
PSMC6 NA NM_002806 -4.03
CCL25 6370 NM_005624 -3.76
CKAP5 9793 NM_001008938, NM_014756 -3.55
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KIAA0999 23387 NM_025164 -3.4
SMARCD3 6604 NM_001003801, NM_001003802, -3.26
NM_003078
NOP17 55011 NM_017916 -3.25
C14orf68 283600 NM_207117 -3.14
PLXNA4B 91584 NM_181775 -3.12
INS 3630 NM_000207 -3.08
PSMD11 NA NM_002815 -3.06
RPS14 NA NM_005617 -3.04
C10orf64 NA NM_173524 -3.01
PRO1855 NA NM_018509 -3.01
SEZ6L2 26470 NM_012410, NM_201575 -2.92
POLR2D NA NM_004805 -2.92
RAD51L3 5892 NM_002878, NM_133629 -2.91
POLR2F NA NM_021974 -2.84
C13orf23 80209 NM_025138, NM_170719 -2.79
WEE1 7465 NM_003390 -2.78
APC 324 NM_000038 -2.75
GPR119 139760 NM_178471 -2.75
KIF2B 84643 NM_032559 -2.73
MS4A4A 51338 NM_024021, NM_148975 -2.72
CLTC NA NM_004859 -2.71
MKRN2 23609 NM_014160 -2.67
ITGB4BP 3692 NM_002212, NM_181466, -2.64
NM_181467, NM_181468,
NM_181469
FLJ10980 NA NM_019600 -2.61
NHP2L1 NA NM_001003796 -2.59
GH2 2689 NM_002059, NM_022556, -2.54
NM_022557, NM_022558
MEN1 4221 NM_000244, NM_130799, -2.53
NM_130800, NM_130801,
NM_130802, NM_130803,
NM_130804
CASP4 837 NM_001225, NM_033306, -2.53
NM_033307 -2.53
Table A.3: Hit list resulting from the overlap of screens A and B. Genes are listed that passed a
z-score cut-off of ≤ -1.25 in both screens.
Symbol GeneID RefSeq z-score A z-score B
TRIB3 57761 NM_021158 -1.69 -2.95
CHKB 1120 NM_005198 -1.47 -2.55
CHUK 1147 NM_001278 -1.57 -1.77
PLK3 1263 NM_014911 -1.39 -1.65
COL4A3BP 10087 NM_022766 -1.92 -1.35
RHOD 29984 NM_014578 -2.41 -1.6
RHOF 54509 NM_019034 -1.79 -1.39
RANBP2 5903 NM_002194 -2.11 -1.9
GKAP1 80318 NM_025211 -3.3 -1.84
SHFM1 7979 NM_005914 -2.2 -2.83
NPEPPS 9520 NM_006310 -2.69 -1.82
ACTG1 71 NM_001614 -1.77 -1.31
PTGS1 5742 NM_000962 -1.97 -1.3
EIF5 1983 NM_001969 -1.65 -1.75
PSCD2 9266 NM_000124 -1.57 -1.87
SRCAP 10847 NM_006662 -2.17 -1.66
RAB6A 5870 NM_002869 -1.29 -1.63
ACTA2 59 NM_001613 -1.39 -2.91
KIF11 3832 NM_004523 -2.68 -2.13
ACP5 54 NM_001611 -1.35 -1.39
PDCD1 5133 NM_005018 -1.26 -1.25
PPM1F 9647 NM_014634 -2.64 -1.81
MPL 4352 NM_005373 -1.29 -1.39
ITGA10 8515 NM_003637 -1.7 -1.28
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ITGA5 3678 NM_002205 -2 -1.92
HNF4G 3174 NM_004133 -1.36 -1.48
IL6R 3570 NM_000565 -2.91 -1.3
NTF5 4909 NM_006179 -2.68 -1.78
CHRNA1 1134 NM_002195 -2.15 -2.28
MDM2 4193 NM_002392 -1.63 -1.71
USP21 27005 NM_012475 -1.26 -2.26
HDAC6 10013 NM_006044 -3.37 -1.35
LOC220594 220594 NM_145809 -3.13 -1.3
CHFR 55743 NM_018223 -2.65 -1.33
RAD51 5888 NM_006037 -2.77 -1.87
GFAP 2670 NM_002055 -3.43 -2.02
KRT20 54474 NM_019010 -1.38 -2.1
TNPO1 3842 NM_002270 -1.6 -1.57
NUP153 9972 NM_005124 -1.51 -2.94
APOA2 336 NM_001643 -3.18 -1.77
CNGB1 1258 NM_001297 -1.7 -1.41
CDH3 1001 NM_001793 -3.52 -1.45
CDR1 1038 NM_004065 -3.26 -1.48
IKBKB 3551 XM_032491 -1.27 -2.18
NLK 51701 NM_000875 -2.04 -1.51
MAP4K5 11183 NM_006575 -1.53 -1.27
FLJ13265 79935 NM_024877 -1.52 -1.29
GLTSCR2 29997 NM_015710 -4.25 -1.76
HBZ 3050 NM_005332 -1.85 -1.33
GAB3 139716 NM_080612 -1.86 -2.41
HERPUD1 9709 NM_014685 -1.29 -2.03
HPS6 79803 NM_018173 -1.69 -2.09
MGC7036 196383 NM_145058 -3.28 -1.31
OLIG3 167826 NM_022737 -1.55 -1.59
OTOF 9381 NM_032832 -2.14 -2.55
MED8 112950 NM_052877 -2.3 -1.28
PSMD4 5710 NM_002810 -2.68 -1.51
NKTR 4820 NM_005385 -2.22 -1.54
PIB5PA 27124 NM_014422 -2.26 -2.12
OCLN 4950 NM_173470 -1.28 -1.52
RAB31 11031 NM_006868 -1.85 -1.65
SOST 50964 NM_002879 -1.67 -1.89
PTTG2 10744 NM_006607 -2.18 -3.36
WDR1 9948 NM_005112 -3 -3.35
RIOK2 55781 NM_018343 -1.89 -1.51
PTGES 9536 NM_004878 -2.34 -1.72
WHSC2 7469 NM_005663 -3.99 -1.53
SMARCB1 6598 NM_018663 -2.31 -2.04
BFSP1 631 NM_001195 -1.35 -2.08
ATP5G3 518 NM_001689 -3.16 -1.53
CYP2A13 1553 NM_000766 -1.45 -1.39
ADCY2 108 NM_020546 -1.8 -1.56
EML1 2009 NM_004434 -2.76 -2.66
ITGB4BP 3692 NM_004475 -1.37 -2.64
GRID1 2894 XM_043613 -2.96 -2.43
KLK1 3816 NM_001490 -1.25 -1.96
LAMP1 3916 NM_004486 -1.46 -2.82
LRP4 4038 XM_035037 -1.43 -3.07
NUP88 4927 NM_002532 -2.55 -1.86
PCYT1A 5130 NM_005017 -1.37 -1.37
SLC8A2 6543 NM_002802 -3.08 -1.38
PSMD13 5719 NM_002817 -1.58 -1.74
VCP 7415 NM_007126 -1.7 -1.73
SEMA5A 9037 NM_003966 -1.87 -2.05
LRRFIP2 9209 NM_006309 -3.74 -1.82
G10 8896 NM_003910 -3.11 -1.99
DLGAP2 9228 NM_004745 -3.73 -1.59
KLK4 9622 NM_004674 -1.42 -2.54
DHX34 9704 NM_194428 -1.81 -2.2
NAALADL1 10004 NM_005468 -3.58 -1.37
KIAA0555 9832 NM_014790 -2.58 -1.78
SV2A 9900 NM_014849 -1.56 -1.93
RBM19 9904 NM_016196 -1.49 -1.69
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AP1M2 10053 NM_005498 -1.44 -1.44
ZAP128 10965 NM_006821 -1.56 -1.81
CKAP4 10970 NM_006825 -2.92 -1.99
POP1 10940 NM_015029 -2.5 -1.28
PRSS21 10942 NM_006799 -2.69 -1.63
LILRA2 11027 NM_006866 -2.88 -2.5
CYP4F8 11283 NM_021004 -1.7 -1.86
LSM6 11157 NM_147200 -1.48 -2.62
SRISNF2L 23132 NM_015106 -2.98 -2.3
POLA2 23649 NM_002689 -1.56 -1.51
ZDHHC8 29801 NM_013373 -2.52 -1.65
VILL 50853 NM_015873 -1.78 -1.98
EXOSC3 51010 NM_016042 -1.25 -1.92
PACAP 51237 NM_018413 -2.34 -1.72
TOMM7 54543 NM_016077 -1.54 -1.57
ARS2 51593 NM_015908 -1.5 -1.7
HSMPP8 54737 NM_017520 -2.76 -3.32
FLJ20584 54991 NM_017891 -1.79 -1.74
LRRC8 56262 NM_019594 -1.43 -1.45
CPXM 56265 NM_019609 -1.26 -1.98
RNF150 57484 XM_291090 -1.81 -1.76
SHD 56961 NM_020209 -1.55 -2.03
CFL1 1072 NM_005507 -1.78 -2.44
ATF7IP 55729 NM_018179 -3.32 -2.85
DSC1 1823 NM_001087 -1.48 -2.71
ANKRD1 27063 NM_014391 -1.57 -1.32
FLJ22318 64777 NM_022762 -1.65 -1.26
SLC2A11 66035 NM_022488 -2.38 -1.28
MGC2744 80755 NM_024955 -1.26 -2.02
MGC13186 84284 NM_032324 -1.44 -1.51
MGC12458 84288 NM_032328 -1.34 -1.55
IMMP2L 83943 NM_032549 -1.76 -2.09
RAB34 83871 NM_031934 -1.4 -1.38
FMNL2 114793 NM_052905 -1.92 -1.31
KIAA1904 114794 XM_056282 -1.26 -2
TSLP 85480 NM_033035 -1.52 -1.48
EGLN2 112398 NM_033106 -1.38 -1.44
MGC35194 93190 NM_152290 -2.62 -1.63
MGC15396 91369 NM_052855 -1.81 -1.48
LOC92162 92162 NM_138455 -1.41 -2.5
ZNF526 116115 NM_133444 -1.39 -2
CACNA2D4 93589 NM_172364 -1.55 -1.56
NY-REN-41 91057 NM_080654 -2.27 -1.68
PEX11G 92960 NM_080662 -2.43 -1.97
MRGPRE 116534 XM_171536 -1.31 -2.45
NOR1 127700 NM_145047 -1.64 -1.71
CST11 140880 NM_080830 -1.62 -1.66
SFRS11 9295 NM_004768 -1.51 -2.22
SMAD2 4087 NM_005901 -1.94 -1.4
ZFPM1 161882 NM_153813 -2.57 -2.52
FAM9B 171483 NM_145653 -1.25 -1.34
DNAJB8 165721 NM_153330 -1.66 -2.08
GGN 199720 NM_152657 -1.44 -1.65
SLC37A2 219855 XM_166184 -2.08 -1.75
FLJ25530 220296 NM_152722 -2.04 -1.6
FLJ36674 284040 NM_173622 -1.92 -2.16
PHGDHL1 337867 NM_177967 -1.36 -1.43
ABCC11 85320 NM_032583 -1.52 -1.58
MGC39606 399668 NM_203306 -1.28 -1.54
RP13-15M17.2 199953 XM_114067 -1.49 -1.4
GTF2A1 2957 NM_015859 -1.68 -1.56
GTF2A2 2958 NM_004492 -1.38 -2.29
FOXA3 3171 NM_004497 -1.42 -1.36
FOXD1 2297 NM_004472 -1.97 -1.52
OR2W5 441932 XM_372254 -2.97 -1.45
OR1L3 26735 XM_377073 -3.08 -2.02
MGC88374 440184 XM_373358 -1.36 -1.62
OR6C75 390323 NM_001005497 -1.8 -1.42
OR11G2 390439 NM_001005503 -2.67 -1.7
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BAI2 576 NM_001703 -1.79 -1.48
F2RL2 2151 NM_004101 -1.99 -2.29
DEFB4 1673 NM_004942 -3.4 -1.76
ADRA1D 146 NM_000678 -2.48 -1.28
ADRA2A 150 NM_000681 -2.69 -1.28
MC1R 4157 NM_002386 -3.6 -2.38
TAS2R48 259294 NM_032119 -1.27 -1.81
MYT1 4661 NM_004535 -1.45 -1.46
SUPT4H1 6827 NM_003168 -1.49 -1.72
CYB5R2 51700 NM_003757 -1.84 -1.48
CD38 952 NM_003403 -2.08 -1.6
ITPA 3704 NM_033453 -1.56 -2.72
AOF2 23028 NM_015013 -3.36 -2.02
HIF1AN 55662 NM_017902 -1.44 -1.65
MAN2B2 23324 XM_052620 -2.71 -1.47
Table A.4: Genes of the TNF test set that passed the z-score filter or ≤ -1.25 in at least one of
screens (column "cut-off -1.25"). For comparison, column "cut-off -2.5" highlights whether these
genes also passed the cut-off of ≤ -2.5 applied in individual screening analysis. no: this gene did
not reach the cut-off in any of the screens, yes(A): reached the cut-off in screen A, yes(B): reached
the cut-off in screen B, yes (A/B): reached the cut-off in both screens.
Symbol GeneID RefSeq z-score A z-score B cut-off -2.5 cut-off -1.25
CHUK 1147 NM_001278 -1.57 -1.77 no yes (A/B)
IKBKB 3551 XM_032491 -1.27 -2.18 no yes (A/B)
LMNB1 4001 NM_005573 -4.29 -0.55 yes (A) yes (A)
PAK1 5058 NM_025194 -2.13 0.09 no yes (A)
MAP2K3 5606 NM_002756 -1.9 0.49 no yes (A)
RELA 5970 NM_021975 -0.53 -4.32 yes (B) yes (B)
TNFRSF1A 7132 NM_001065 0.31 -4.8 yes (B) yes (B)
TRAF3 7187 NM_004652 -0.53 -1.45 no yes (B)
IKBKAP 8518 NM_003640 -1.28 0.01 no yes (A)
TRADD 8717 NM_003789 -1.18 -2.33 no yes (B)
RIPK1 8737 NM_003804 -3.39 0.53 yes (A) yes (A)
LMNB2 84823 NM_032737 -1.6 -0.31 no yes (A)
Table A.5: Genes of the inflammation test set that passed the z-score filter or ≤ -1.25 in at least
one of screens (column "cut-off -1.25"). For comparison, column "cut-off -2.5" highlights whether
these genes also passed the cut-off of ≤ -2.5 applied in individual screening analysis. no: this gene
did not reach the cut-off in any of the screens, yes(A): reached the cut-off in screen A, yes(B):
reached the cut-off in screen B, yes (A/B): reached the cut-off in both screens.
Symbol GeneID RefSeq z-score A z-score B cut-off -2.5 cut-off -1.25
ADCY6 112 NM_015270 -1.47 0.48 no yes (A)
ADRBK2 157 NM_005160 -1.69 0.5 no yes (A)
AKT1 207 NM_005163 -1.29 -0.51 no yes (A)
CAMK2D 817 NM_001221 0.75 -1.7 no yes (B)
COL6A1 1291 NM_001848 1.03 -1.11 no yes (B)
GNG7 2788 NM_000675 -2.03 -0.3 no yes (A)
GRK5 2869 NM_005308 0.15 -2.65 yes (B) yes (B)
0.25
HRAS 3265 NM_005343 -2.79 -0.57 yes (A) yes (A)
IKBKB 3551 XM_032491 -1.27 -2.18 no yes (A/B)
INPP5D 3635 NM_005541 -1.79 0.26 no yes (A)
ITGA6 3655 NM_000210 -1.87 -0.53 no yes (A)
ITPR3 3710 NM_022076 -0.68 -2.92 yes (B) yes (B)
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Symbol GeneID RefSeq z-score A z-score B cut-off -2.5 cut-off -1.25
NFATC2 4773 NM_012340 -1.52 1.41 no yes (A)
NFKBIE 4794 NM_004556 -0.16 -2.13 no yes (B)
NRAS 4893 NM_002524 -2.59 0.22 yes (A) yes (A)
PAK1 5058 NM_025194 -2.13 0.09 no yes (A)
PDPK1 5170 NM_004690 0.94 -1.42 no yes (B)
PRKACB 5567 NM_002731 0.07 -1.45 no yes (B)
PRKCA 5578 NM_002737 -1.4 -0.09 no yes (A)
PRKCI 5584 NM_002740 -0.99 -1.34 no yes (B)
MAPK1 5594 NM_002745 -0.88 -1.28 no yes (B)
MAPK3 5595 NM_002746 -1.75 0.47 no yes (B)
PRKY 5616 NM_002760 -0.54 -1.53 no yes (B)
PTGS1 5742 NM_000962 -1.97 -1.3 no yes (A/B)
RELA 5970 NM_021975 -0.53 -4.32 yes (B) yes (B)
RELB 5971 NM_002200 0.18 -2.29 no yes (B)
SHC1 6464 NM_003029 0.88 -1.59 no yes (B)
IKBKE 9641 NM_014002 -2.03 0.01 no yes (A)
ARPC1B 10095 NM_005720 -1.85 0.32 no yes (A)
ACTR1A 10121 NM_005736 -0.38 -1.89 no yes (B)
RHOD 29984 NM_014578 -2.41 -1.6 no yes (A/B)
RHOF 54509 NM_019034 -1.79 -1.39 no yes (A/B)
LTB4R2 56413 NM_019839 -3.74 -0.68 yes (A) yes (A)
Table A.6: Phenotypes of knockdown of all selected hits using dual luciferase assay in HEK293T
cells to assess NF-κB transcriptional activity. Mean: Average of at least two biological replicates
expressed as relative Iluciferase expression as compared to negative control (mock transfected
cells) is given (in %). stdev: standard deviation of these two measurements. p-value: p-values were
calculated using Student’s T-test. Q-: siRNA pool vended by Qiagen. Other siRNAs are either
individual siRNAs or siRNA pools vended by Dharmacon.
GeneID siRNA mean stdev p-value
6696 Q-SPP1 70.868 24.792 0.119
SPP1-5 58.297 29.785 0.093
SPP1-6 44.289 8.787 0.006
SPP1-7 57.873 14.896 0.029
SPP1-8 25.837 3.078 0.000
SPP1-pool 35.214 2.820 0.000
51352 Q-WIT1 38.715 15.413 0.015
WIT1-1 69.140 14.186 0.046
WIT1-2 50.575 15.179 0.022
WIT1-3 51.453 23.181 0.049
WIT1-4 107.254 71.954 0.450
WIT1-pool 66.693 29.994 0.128
5606 Q-MAP2K3 75.447 31.209 0.191
MAP2K3-2 121.069 35.950 0.245
MAP2K3-4 56.442 12.923 0.010
MAP2K3-5 60.650 28.935 0.083
MAP2K3-6 86.900 6.754 0.040
MAP2K3-pool 61.265 23.207 0.056
29941 Q-PKN3 79.689 34.280 0.245
PKN3-5 85.419 12.019 0.101
PKN3-6 76.654 8.994 0.020
PKN3-7 56.477 16.250 0.018
PKN3-8 127.733 25.307 0.119
PKN3-pool 92.270 13.894 0.255
6676 Q-SPAG4 63.576 29.312 0.110
SPAG4-1 139.887 28.475 0.078
SPAG4-2 67.960 15.054 0.032
SPAG4-3 176.226 45.966 0.056
SPAG4-4 75.112 25.408 0.140
SPAG4-pool 101.530 29.592 0.475
6694 Q-SPP2 70.604 39.158 0.200
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SPP2-1 78.709 11.650 0.046
SPP2-2 44.882 4.236 0.000
SPP2-3 135.838 45.738 0.185
SPP2-4 103.550 21.147 0.418
SPP2-pool 76.901 6.348 0.008
6744 Q-SSFA2 70.511 12.245 0.038
SSFA2-1 107.079 34.960 0.402
SSFA2-2 64.556 9.537 0.008
SSFA2-3 80.696 20.616 0.149
SSFA2-4 141.059 63.303 0.224
SSFA2-pool 77.800 28.223 0.184
1152 Q-CKB 61.704 14.904 0.034
6370 Q-CCL25 33.652 9.794 0.005
9793 Q-CKAP5 69.666 44.241 0.217
23387 Q-KIAA0999 52.282 33.338 0.090
5685 Q-PSMA4 54.628 1.078 0.000
55209 Q-SETD5-1 72.468 25.272 0.132
Q-SETD5-2 51.611 28.148 0.068
Q-SETD5-3 47.936 19.624 0.032
Q-SETD5-4 46.065 15.687 0.020
55011 Q-NOP17 44.373 20.025 0.030
4089 Q-SMAD4 51.972 15.669 0.025
57761 Q-TRIB3 46.193 24.677 0.046
26470 Q-SEZ6L2 52.455 32.610 0.088
5756 Q-PTK9 74.794 14.632 0.068
PTK9-5 83.306 21.408 0.193
PTK9-9 86.698 18.340 0.206
PTK9-10 82.637 9.656 0.063
PTK9-12 80.422 12.701 0.081
PTK9-pool 100.946 26.192 0.482
10298 Q-PAK4 49.315 14.514 0.019
139760 Q-GPR119 81.491 34.626 0.264
84643 Q-KIF2B 55.781 0.236 0.000
51338 Q-MS4A4A 60.904 4.439 0.003
1213 Q-CLTC 66.473 19.073 0.065
2300 Q-FOXL1 70.906 31.171 0.159
3692 Q-ITGB4BP 61.540 29.272 0.102
9381 Q-OTOF 64.605 31.573 0.127
54538 Q-ROBO4 77.640 30.413 0.204
ROBO4-1 36.306 2.303 0.000
ROBO4-2 23.168 4.467 0.001
ROBO4-3 53.546 15.599 0.026
ROBO4-4 93.475 18.528 0.334
ROBO4-pool 49.286 7.358 0.005
837 Q-CASP4 87.539 10.838 0.123
CASP4-1 20.152 7.878 0.002
CASP4-2 117.491 29.018 0.242
CASP4-4 39.476 3.287 0.001
CASP4-17 98.367 6.642 0.381
CASP4-pool 36.523 8.992 0.005
2689 Q-GH2 64.653 21.971 0.075
6367 Q-CCL22 63.699 18.851 0.056
4221 Q-MEN1 37.498 7.562 0.004
MEN1-2 88.177 2.422 0.010
MEN1-3 115.465 6.810 0.042
MEN1-4 54.650 5.080 0.003
MEN1-17 25.473 6.957 0.002
MEN1-pool 96.113 66.421 0.471
4055 Q-LTBR 59.867 5.702 0.005
10970 Q-CKAP4 81.001 46.849 0.312
1263 Q-PLK3 60.737 27.643 0.091
50964 Q-SOST 64.161 25.501 0.093
57484 Q-RNF150 67.113 23.355 0.092
9622 Q-KLK4 89.213 32.854 0.344
3678 Q-ITGA5 72.485 1.144 0.000
ITGA5-5 74.109 0.748 0.000
ITGA5-6 106.421 15.769 0.311
ITGA5-7 75.007 2.041 0.002
ITGA5-20 45.388 2.876 0.001
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ITGA5-pool 66.664 4.900 0.005
9972 Q-NUP153 51.017 12.686 0.016
11031 Q-RAB31 43.544 4.303 0.001
5903 Q-RANBP2 48.997 7.268 0.005
55662 Q-HIF1AN 37.669 15.517 0.015
4193 Q-MDM2 50.725 15.821 0.024
1072 Q-CFL1 39.900 16.161 0.017
27124 Q-PIB5PA 77.431 40.688 0.257
7415 Q-VCP 51.067 33.491 0.087
Q-SHFMA 22.655 4.382 0.001
9037 Q-SEMA5A 55.756 17.467 0.035
SEMA5A-1 105.965 0.005 0.000
SEMA5A-3 132.431 9.441 0.020
SEMA5A-4 39.029 3.890 0.001
SEMA5A-17 92.053 21.015 0.323
SEMA5A-pool 99.870 0.697 0.409
9904 Q-RBM19 52.408 18.940 0.035
10311 Q-DSCR3 104.366 32.037 0.432
DSCR3-1 90.055 14.596 0.214
DSCR3-2 83.911 26.572 0.238
DSCR3-3 63.212 7.022 0.003
DSCR3-4 103.975 24.037 0.419
DSCR3-pool 77.864 16.399 0.084
Q-RAPGEF3 129.023 84.804 0.338
RAPGEF3-1 99.504 47.995 0.495
RAPGEF3-2 126.518 52.829 0.274
RAPGEF3-3 65.030 20.593 0.054
RAPGEF3-4 74.959 10.251 0.023
RAPGEF3-pool 46.386 14.807 0.008
49856 Q-WDR8 121.988 69.330 0.349
WDR8-1 40.479 13.251 0.012
WDR8-2 46.640 10.115 0.009
WDR8-3 59.407 3.008 0.001
WDR8-4 61.305 5.883 0.006
WDR8-pool 47.061 3.257 0.001
9099 Q-USP2 85.467 26.404 0.259
USP2-1 37.534 6.682 0.003
USP2-2 84.303 8.207 0.057
USP2-3 58.446 7.068 0.007
USP2-4 44.179 12.915 0.013
USP2-pool 62.988 18.439 0.052
55795 Q-FLJ11305 72.893 31.128 0.172
57705 Q-C10orf64 121.445 111.415 0.405
55379 Q-PRO1855 107.056 50.816 0.431
PRO1855-1 69.813 2.213 0.001
PRO1855-2 75.242 21.858 0.125
PRO1855-3 57.864 0.582 0.000
PRO1855-4 42.069 3.348 0.001
PRO1855-pool 63.464 0.992 0.000
148753 Q-MGC16664 138.250 114.953 0.342
11326 Q-VSIG4 76.934 31.190 0.203
1823 Q-DSC1 90.540 0.376 0.000
27342 Q-RABGEF1 95.102 33.830 0.428
RABGEF1-1 42.111 9.714 0.007
RABGEF1-2 51.937 1.289 0.000
RABGEF1-3 87.114 3.607 0.019
RABGEF1-4 74.275 8.506 0.025
RABGEF1-pool 61.357 1.775 0.001
56204 Q-FLJ10980 126.497 81.382 0.345
56961 Q-SHD 90.429 58.831 0.420
93190 Q-MGC35194 77.701 41.045 0.261
MGC35194-1 66.358 5.972 0.008
MGC35194-2 123.609 1.777 0.001
MGC35194-3 28.887 0.090 0.000
MGC35194-4 17.210 3.284 0.000
MGC35194-pool 23.163 1.109 0.000
139716 Q-GAB3 76.352 35.583 0.223
GAB3-1 101.937 24.732 0.461
GAB3-2 26.406 8.852 0.004
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GAB3-3 46.055 21.822 0.036
GAB3-4 82.265 37.303 0.285
GAB3-pool 41.785 26.155 0.044
9900 Q-SV2A 94.587 59.487 0.455
11027 Q-LILRA2 88.236 22.577 0.269
LILRA2-1 24.617 8.011 0.003
LILRA2-2 89.088 31.590 0.337
LILRA2-3 30.308 8.665 0.004
LILRA2-4 38.895 8.240 0.004
LILRA2-pool 46.531 8.739 0.007
116 Q-PACAP 88.872 39.208 0.363
54737 Q-HSMPP8 55.148 12.800 0.019
167826 Q-OLiG3 129.448 70.077 0.306
6598 Q-SMARCB1 74.442 0.835 0.000
9704 Q-DHX34 71.378 14.415 0.053
DHX34-1 151.152 3.502 0.001
DHX34-2 79.714 25.708 0.190
DHX34-3 84.157 32.186 0.279
DHX34-4 102.954 76.520 0.481
DHX34-pool 85.093 45.609 0.345
9948 Q-WDR1 50.047 14.773 0.021
9647 PPM1F-1 128.086 18.191 0.028
PPM1F-2 239.628 74.954 0.044
PPM1F-3 88.587 15.604 0.199
PPM1F-4 166.511 35.311 0.043
PPM1F-pool 133.775 20.777 0.059
SPTCL2-1 88.849 26.871 0.308
SPTCL2-2 96.881 43.616 0.465
SPTCL2-3 149.792 43.352 0.110
SPTCL2-4 95.335 11.904 0.318
SPTCL2-pool 117.692 20.306 0.163
CYB7B1-1 142.499 33.206 0.092
CYB7B1-2 129.478 37.945 0.187
CYB7B1-3 113.623 24.727 0.257
CYB7B1-4 146.678 52.804 0.160
CYB7B1-pool 127.943 40.888 0.213
6500 SKP1A-5 146.364 55.360 0.171
SKP1A-8 91.556 17.920 0.286
SKP1A-9 57.293 15.377 0.017
SKP1A-10 45.202 13.642 0.006
SKP1A-pool 42.452 6.878 0.001
30817 EMR2-1 79.731 40.836 0.277
EMR2-2 142.371 34.725 0.100
EMR2-3 123.122 43.017 0.261
EMR2-4 176.632 52.757 0.073
EMR2-pool 125.607 67.285 0.322
Table A.7: Phenotypes of knockdown of all selected hits using IL-8 ELISA in HEK293T cells to
assess NF-κB transcriptional activity. Mean: Average of at least two biological replicates expressed
as relative IL-8 secretion as compared to negative control (siLRP5 transfected cells) is given (in
%). stdev: standard deviation of these two measurements. p-value: p-values were calculated using
Student’s T-test. siRNAs are either individual siRNAs or siRNA pools vended by Dharmacon.
GeneID siRNA mean stdev p-value
6696 SPP1-5 66.929 9.366 0.019
SPP1-6 124.381 18.723 0.103
SPP1-7 75.284 2.126 0.002
SPP1-8 37.846 11.411 0.008
SPP1-pool 66.747 1.886 0.001
51352 WIT1-1 87.096 3.417 0.017
WIT1-2 39.630 2.650 0.000
WIT1-3 44.277 8.190 0.005
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WIT1-4 65.781 9.055 0.017
WIT1-pool 35.313 7.002 0.003
5756 PTK9-5 97.065 4.151 0.211
PTK9-9 100.849 16.421 0.474
PTK9-10 107.094 13.031 0.261
PTK9-12 107.657 5.293 0.089
PTK9-pool 111.346 5.173 0.045
54538 ROBO4-1 89.727 20.527 0.276
ROBO4-2 119.797 4.752 0.014
ROBO4-3 160.602 26.842 0.043
ROBO4-4 119.065 11.280 0.070
ROBO4-pool 189.911 29.674 0.025
837 CASP4-1 29.281 5.155 0.001
CASP4-2 82.406 10.635 0.072
CASP4-4 49.671 6.315 0.004
CASP4-17 90.592 10.680 0.170
CASP4-pool 42.524 4.049 0.001
4221 MEN1-2 129.168 7.116 0.014
MEN1-3 79.613 16.833 0.114
MEN1-4 39.672 23.079 0.033
MEN1-17 51.088 6.935 0.005
MEN1-pool 80.070 1.433 0.001
3678 ITGA5-5 77.646 10.890 0.050
ITGA5-6 80.452 3.302 0.007
ITGA5-7 53.779 0.707 0.000
ITGA5-20 112.746 12.499 0.143
ITGA5-pool 71.023 4.229 0.005
9037 SEMA5A-1 133.543 12.068 0.030
SEMA5A-3 129.467 0.328 0.000
SEMA5A-4 95.061 4.221 0.120
SEMA5A-17 102.601 9.861 0.372
SEMA5A-pool 100.350 2.982 0.442
49856 WDR8-1 37.309 0.633 0.000
WDR8-2 47.898 0.478 0.000
WDR8-3 94.046 13.902 0.303
WDR8-4 65.350 4.506 0.004
WDR8-pool 49.030 2.436 0.001
9099 USP2-1 36.173 1.630 0.000
USP2-2 88.321 9.745 0.116
USP2-3 92.137 6.606 0.117
USP2-4 41.375 5.763 0.002
USP2-pool 56.154 3.647 0.002
55379 PRO1855-1 188.102 5.129 0.001
PRO1855-2 71.589 10.560 0.031
PRO1855-3 64.942 9.462 0.017
PRO1855-4 88.564 12.424 0.161
PRO1855-pool 126.144 36.512 0.209
27342 RABGEF1-1 115.467 14.494 0.135
RABGEF1-2 83.041 29.983 0.254
RABGEF1-3 79.675 21.995 0.161
RABGEF1-4 62.551 12.341 0.025
RABGEF1-pool 81.004 9.457 0.052
93190 MGC35194-1 124.075 6.138 0.016
MGC35194-2 74.675 5.143 0.010
MGC35194-3 80.524 17.497 0.128
MGC35194-4 94.587 9.201 0.246
MGC35194-pool 102.185 5.024 0.301
139716 GAB3-1 73.465 5.750 0.011
GAB3-2 31.074 14.579 0.011
GAB3-3 67.764 9.666 0.021
GAB3-4 69.814 8.702 0.020
GAB3-pool 60.617 10.379 0.017
11027 LILRA2-1 19.824 9.489 0.003
LILRA2-2 102.693 5.466 0.279
LILRA2-3 78.345 2.992 0.005
LILRA2-4 45.618 4.235 0.002
LILRA2-pool 50.406 12.938 0.016
9704 DHX34-1 53.258 15.813 0.026
DHX34-2 67.080 6.766 0.010
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DHX34-3 56.655 14.048 0.024
DHX34-4 73.473 27.014 0.150
DHX34-pool 65.556 6.157 0.008
9647 PPM1F-1 85.606 19.124 0.199
PPM1F-2 90.188 29.275 0.341
PPM1F-3 64.122 22.405 0.076
PPM1F-4 96.591 28.843 0.441
PPM1F-pool 83.793 33.391 0.282
SPTCL2-1 86.563 0.830 0.001
SPTCL2-2 104.157 19.868 0.398
SPTCL2-3 70.394 10.949 0.031
SPTCL2-4 83.124 29.286 0.250
SPTCL2-pool 96.976 28.792 0.448
6694 SPP2-1 55.353 8.321 0.008
SPP2-2 60.741 14.868 0.032
SPP2-3 54.049 7.701 0.007
SPP2-4 57.641 11.861 0.019
SPP2-pool 49.444 11.134 0.012
6744 SSFA2-1 68.411 23.115 0.096
SSFA2-2 48.624 8.598 0.007
SSFA2-3 32.968 3.138 0.001
SSFA2-4 90.060 20.832 0.285
SSFA2-pool 49.763 8.219 0.007
6676 SPAG4-1 74.207 10.484 0.037
SPAG4-2 42.272 8.835 0.006
SPAG4-3 79.181 20.697 0.145
SPAG4-4 106.136 37.395 0.419
SPAG4-pool 57.558 17.399 0.037
29941 PKN3-5 87.924 28.041 0.302
PKN3-6 72.692 15.705 0.067
PKN3-7 56.812 6.134 0.005
PKN3-8 44.203 4.872 0.002
PKN3-pool 47.900 6.419 0.004
10311 DSCR3-1 79.838 11.883 0.069
DSCR3-2 54.328 11.002 0.014
DSCR3-3 58.708 3.577 0.002
DSCR3-4 75.261 28.211 0.170
DSCR3-pool 65.195 16.577 0.049
5606 MAP2K3-2 59.276 1.418 0.000
MAP2K3-4 92.985 29.508 0.384
MAP2K3-5 38.612 6.003 0.002
MAP2K3-6 44.142 3.111 0.001
MAP2K3-pool 51.041 5.672 0.003
CYB7B1-1 112.739 42.347 0.356
CYB7B1-2 71.645 12.998 0.045
CYB7B1-3 86.935 42.375 0.353
CYB7B1-4 66.489 16.472 0.051
CYB7B1-pool 82.187 22.605 0.191
6500 SKP1A-5 88.114 21.614 0.259
SKP1A-8 94.825 46.001 0.444
SKP1A-9 100.879 36.822 0.488
SKP1A-10 101.277 54.122 0.488
SKP1A-pool 142.344 42.240 0.146
30817 EMR2-1 58.258 9.017 0.011
EMR2-2 62.055 11.039 0.020
EMR2-3 96.843 17.892 0.413
EMR2-4 81.957 13.075 0.095
EMR2-pool 71.026 10.671 0.031
RAPGEF3-1 189.849 85.238 0.137
RAGGEF3-2 152.268 20.971 0.036
RAPGEF3-3 81.494 20.950 0.169
RAPGEF3-4 74.571 12.202 0.049
RAPGEF3-pool 95.531 39.412 0.444
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Table A.8: Phenotypes of knockdown of all selected hits using dual luciferase assay in HepG2
cells to assess NF-κB transcriptional activity. Mean: Average of two biological replicates expressed
as relative luciferase expression as compared to negative control (mock transfected cells) is given
(in %). stdev: standard deviation of these two measurements. p-value: p-values were calculated
using Student’s T-test. Q-: siRNA pool vended by Qiagen. For Qiagen siRNAs only one biological
replicate was available (given is then the average of four technical replicates.) Other siRNAs are
either individual siRNAs or siRNA pools vended by Dharmacon. NA: not available.
GeneID siRNA mean stdev p-value
5756 Q-PTK9 49.158 NA NA
PTK9-5 143.647 2.402 0.001
PTK9-9 92.498 14.790 0.274
PTK9-10 151.584 6.849 0.004
PTK9-12 118.726 20.606 0.164
PTK9-pool 133.474 33.624 0.147
54538 Q-ROBO4 68.177 NA NA
ROBO4-1 56.306 12.869 0.020
ROBO4-2 34.979 1.496 0.000
ROBO4-3 116.275 14.621 0.128
ROBO4-4 131.934 31.192 0.142
ROBO4-pool 97.572 11.484 0.397
837 Q-CASP4 63.147 NA NA
CASP4-1 25.178 2.347 0.000
CASP4-2 180.619 51.802 0.079
CASP4-4 43.419 11.492 0.010
CASP4-17 109.446 0.948 0.002
CASP4-pool 47.811 11.884 0.012
4221 Q-MEN1 44.307 NA NA
MEN1-2 137.628 34.110 0.130
MEN1-3 119.196 43.534 0.298
MEN1-4 71.432 5.023 0.008
MEN1-17 48.470 10.257 0.010
MEN1-pool 121.732 5.901 0.017
55379 Q-PRO1855 135.969 NA NA
PRO1855-1 150.609 41.071 0.112
PRO1855-2 159.993 35.623 0.070
PRO1855-3 256.281 93.242 0.071
PRO1855-4 90.411 13.218 0.206
PRO1855-pool 200.319 104.195 0.153
27342 Q-RABGEF1 57.859 NA NA
RABGEF1-1 51.483 7.856 0.006
RABGEF1-2 38.426 9.632 0.006
RABGEF1-3 58.385 4.314 0.003
RABGEF1-4 77.304 23.468 0.152
RABGEF1-pool 52.379 10.277 0.011
3678 Q-ITGA5 99.962 NA NA
ITGA5-5 90.908 17.882 0.273
ITGA5-6 119.878 3.759 0.009
ITGA5-7 46.771 20.390 0.033
ITGA5-20 111.039 22.792 0.282
ITGA5-pool 63.035 10.416 0.019
9037 Q-SEMA5A 57.809 NA NA
SEMA5A-1 141.663 26.443 0.078
SEMA5A-3 171.527 22.408 0.023
SEMA5A-4 197.778 5.622 0.001
SEMA5A-17 68.240 5.269 0.007
SEMA5A-pool 181.487 28.167 0.027
93190 Q-MGC35194 49.766 NA NA
MGC35194-1 65.499 13.946 0.036
MGC35194-2 58.979 15.406 0.032
MGC35194-3 25.678 0.001 0.000
MGC35194-4 58.107 1.114 0.000
MGC35194-pool 32.063 5.707 0.002
139716 Q-GAB3 42.772 NA NA
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GeneID siRNA mean stdev p-value
GAB3-1 96.073 26.983 0.428
GAB3-2 31.327 12.311 0.008
GAB3-3 62.068 32.581 0.121
GAB3-4 81.974 9.644 0.059
GAB3-pool 62.958 20.992 0.065
11027 Q-LILRA2 73.566 NA NA
LILRA2-1 46.411 3.756 0.001
LILRA2-2 99.549 25.099 0.491
LILRA2-3 16.661 1.987 0.000
LILRA2-4 24.924 4.302 0.001
LILRA2-pool 28.772 1.663 0.000
9704 Q-DHX34 87.683 NA NA
DHX34-1 109.765 36.123 0.370
DHX34-2 61.148 1.007 0.000
DHX34-3 61.135 20.383 0.057
DHX34-4 104.147 34.854 0.441
DHX34-pool 56.103 18.811 0.040
51352 Q-WIT1 74.959 NA NA
WIT1-1 91.110 28.679 0.352
WIT1-2 59.772 27.111 0.085
WIT1-3 156.997 18.893 0.025
WIT1-4 110.247 23.942 0.303
WIT1-pool 126.265 47.850 0.259
9099 Q-USP2 102.437 NA NA
USP2-1 50.697 17.059 0.027
USP2-2 192.069 138.189 0.223
USP2-3 48.460 20.977 0.037
USP2-4 91.023 36.146 0.379
USP2-pool 70.659 19.688 0.085
49856 Q-WDR8 115.668 NA NA
WDR8-1 72.779 50.619 0.263
WDR8-2 39.626 15.602 0.016
WDR8-3 58.828 29.055 0.091
WDR8-4 37.330 6.821 0.003
WDR8-pool 44.714 4.439 0.002
6696 Q-SPP1 65.752 NA NA
SPP1-5 94.741 22.244 0.385
SPP1-6 34.684 8.669 0.004
SPP1-7 122.162 18.800 0.119
SPP1-8 78.461 6.611 0.022
SPP1-pool 66.182 22.330 0.083
Table A.9: Phenotypes of all selected hits using IL-8 ELISA in HepG2 cells to assess NF-κB tran-
scriptional activity. Mean: Average of two biological replicates expressed as relative IL-8 secretion
as compared to negative control (mock transfected cells) is given (in %). stdev: standard deviation
of these two measurements. p-value: p-values were calculated using Student’s T-test. Q-...: siRNA
pool vended by Qiagen. For Qiagen siRNAs only one biological replicate was available (given is
then the average of four technical replicates.) Other siRNAs are either individual siRNAs or siRNA
pools vended by Dharmacon. NA: not available.
GeneID siRNA mean stdev p-value
5756 Q-PTK9 36.907 NA NA
PTK9-5 274.649 37.173 0.011
PTK9-9 70.996 6.563 0.012
PTK9-10 0.182 0.257 0.000
PTK9-12 47.548 10.410 0.010
PTK9-pool 28.615 4.470 0.001
54538 Q-ROBO4 87.414 NA NA
ROBO4-1 0.000 0.000 NA
ROBO4-2 143.096 52.719 0.184
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GeneID siRNA mean stdev p-value
ROBO4-3 162.938 36.553 0.068
ROBO4-4 217.074 68.372 0.068
ROBO4-pool 104.773 26.292 0.411
837 Q-CASP4 26.283 NA NA
CASP4-1 0.000 0.000 NA
CASP4-2 247.429 71.703 0.050
CASP4-4 4.180 3.340 0.000
CASP4-17 86.343 11.085 0.112
CASP4-pool 1.869 2.643 0.000
4221 Q-MEN1 53.743 NA NA
MEN1-2 0.935 1.322 0.000
MEN1-3 616.600 246.150 0.049
MEN1-4 90.571 15.978 0.246
MEN1-17 98.751 13.662 0.454
MEN1-pool 114.894 62.204 0.384
55379 Q-PRO1855 145.603 NA NA
PRO1855-1 85.327 7.534 0.055
PRO1855-2 262.726 61.966 0.033
PRO1855-3 11.682 16.521 0.009
PRO1855-4 498.486 184.535 0.046
PRO1855-pool 34.353 6.928 0.003
27342 Q-RABGEF1 100.163 NA NA
RABGEF1-1 259.614 35.967 0.012
RABGEF1-2 142.393 65.609 0.229
RABGEF1-3 117.733 23.824 0.201
RABGEF1-4 48.435 24.868 0.050
RABGEF1-pool 242.487 165.776 0.174
3678 Q-ITGA5 196.927 NA NA
ITGA5-5 147.857 83.352 0.251
ITGA5-6 156.378 114.209 0.279
ITGA5-7 34.447 25.772 0.035
ITGA5-20 138.585 108.479 0.332
ITGA5-pool 61.548 18.337 0.049
9037 Q-SEMA5A 162.275 NA NA
SEMA5A-1 243.064 115.188 0.111
SEMA5A-3 260.767 143.358 0.127
SEMA5A-4 805.056 599.039 0.119
SEMA5A-17 106.868 62.370 0.445
SEMA5A-pool 228.015 122.741 0.139
93190 Q-MGC35194 187.283 NA NA
MGC35194-1 177.220 149.952 0.271
MGC35194-2 142.745 64.838 0.225
MGC35194-3 450.007 249.880 0.093
MGC35194-4 603.355 400.298 0.109
MGC35194-pool 675.482 413.285 0.094
139716 Q-GAB3 72.213 NA NA
GAB3-1 73.120 7.121 0.017
GAB3-2 8.776 2.005 0.000
GAB3-3 0.000 0.000 NA
GAB3-4 103.994 26.961 0.427
GAB3-pool 0.177 0.251 0.000
11027 Q-LILRA2 33.475 NA NA
LILRA2-1 21.351 14.062 0.008
LILRA2-2 172.179 50.673 0.091
LILRA2-3 147.089 8.922 0.009
LILRA2-4 57.834 10.736 0.015
LILRA2-pool 83.162 15.663 0.134
9704 Q-DHX34 38.542 NA NA
DHX34-1 32.622 9.406 0.005
DHX34-2 55.418 21.049 0.048
DHX34-3 411.867 68.688 0.012
DHX34-4 260.127 13.636 0.002
DHX34-pool 246.797 58.420 0.035
51352 Q-WIT1 150.834 NA NA
WIT1-1 54.781 7.467 0.007
WIT1-2 30.223 23.339 0.026
WIT1-3 144.236 45.744 0.152
WIT1-4 184.048 19.263 0.013
WIT1-pool 91.724 39.173 0.397
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9099 Q-USP2 88.885 NA NA
USP2-1 45.727 28.881 0.059
USP2-2 498.566 197.601 0.052
USP2-3 292.184 82.941 0.041
USP2-4 10.599 14.990 0.007
USP2-pool 37.105 34.796 0.062
49856 Q-WDR8 221.608 NA NA
WDR8-1 362.622 188.160 0.094
WDR8-2 1.720 2.433 0.000
WDR8-3 139.814 12.758 0.024
WDR8-4 591.299 265.796 0.060
WDR8-pool 168.323 50.920 0.099
6696 Q-SPP1 34.129 NA NA
SPP1-5 1.443 2.040 0.000
SPP1-6 6.992 9.889 0.003
SPP1-7 154.742 35.594 0.081
SPP1-8 8.380 11.851 0.004
SPP1-pool 6.992 9.889 0.003
Table A.10: Table listing IDs of all siRNAs vended by Dharmacon that were used in this work.
Symbol Dharmacon-ID
CASP4 M-004404-00
CCL22 M-007834-00
CCL25 M-007837-01
CFL1 M-012707-00
CKAP4 M-012755-00
CKAP5 M-006847-00
CKB M-006706-01
CLTC M-004001-00
DHX34 M-032233-00
DSC1 M-011995-00
DSCR3 M-012163-00
EMR2 M-005488-00
FLJ10587 M-016480-00
FLJ10980 M-022243-00
FLJ11305 M-020730-00
FOXL1 M-008986-00
GAB3 M-015239-00
GH2 M-011668-00
GPR119 M-005521-00
HIF1AN M-004073-01
HSMPP8 M-021680-00
ITGA5 M-008003-01
ITGB4BP M-010096-01
KIAA0999 M-004779-02
KIF2B M-008345-01
KLK4 M-005915-01
LILRA2 M-019855-00
LTBR M-008023-01
MAP2K3 M-003509-01
MDM2 M-003279-02
MEN1 M-011082-00
MGC16664 M-018554-00
MGC35194 M-016852-00
MS4A4A M-017214-00
NOP17 M-020963-00
NUP153 M-005283-00
ORMDL3 M-017002-00
OTOF M-011942-00
PACAP M-004433-00
PAK4 M-003615-02
PIB5PA M-009108-00
PKN3 M-004647-00
PLK3 M-003257-02
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Symbol Dharmacon-ID
PPM1F M-009544-00
PRO1855 M-010669-00
PSCD2 M-011925-01
PSMA4 M-017211-00
PTK9 M-003168-03
RAB31 M-010065-01
RABGEF1 M-008541-00
RANBP2 M-004746-01
RAPGEF3 M-007676-00
RBM19 M-021123-00
RNF150 M-010713-00
ROBO4 M-015216-00
SEMA5A M-019490-00
SETD5 M-028069-00
SEZ6L2 M-008062-00
SHD M-023905-00
SKP1A M-003323-02
SMAD4 M-003902-01
SMARCB1 M-010536-00
SOST M-014616-00
SPAG4 M-011397-00
SPP1 M-012558-00
SPP2 M-019720-00
SSFA2 M-015325-00
SV2A M-007631-00
TRIB3 M-003754-01
TRIM68 M-007007-00
USP2 M-006069-00
VCP M-008727-01
VSIG4 M-012788-00
WDR1 M-011984-00
WDR8 M-013318-00
WIT1 M-013209-00
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Nomenclature
4-4-FL NF-κB-dependent firefly luciferase expression construct
act-RL Renilla luciferase expression construct where the luciferase gene is
under the control of the β-actin promoter
AKT v-akt murine thymoma viral oncogene homolog
AP activator protein
ARE AU-rich element
ATP adenosine triphosphate
BAG4 Bcl-2-associated athanogen
BAX BCL2-associated X protein
BCA bicinchoninic acid
BIRC baculoviral IAP repeat-containing
BMP bone morphogenic protein
bp basepair
BSA bovine serum albumine
CARD caspase recruitment domain
CASP caspase
CASP8AP caspase 8 associated protein
CCL CC-motif chemokine ligand
CCND1 cyclin D1
CD cluster of differentiation
cDNA complementary DNA
CMV cytomegalovirus
CPB cAMP responsive element binding protein (CREB) binding protein
CTSL1 cathepsin L1
CXCL C-X-C motif chemokine ligand
CYLD cylindromatosis
DD death domain
DMEM Dulbecco’s Modified Eagle Medium
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DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
DOS daughter of sevenless
dsRNA double-stranded RNA
DUB de-ubiquitinating
e.g. exempli gratia
EDTA ethylenediaminetetraacetic acid
EGFR epidermal growth factor receptor
ELISA enzyme-linked immunosorbent assay
EMSA electrophoretic mobility shift assay
endo-siRNA endogenous siRNA
ERK extracellular signal-regulated kinase
esiRNA endoribonuclease-prepared short interfering RNA
et al. et alia
FACS fluorescence activated cell sorting
FADD Fas-associated death domain
FCS fetal calf serum
FL Firefly luciferase
GAB GRB2-associated binding protein 3
GADD growth arrest- and DNA damage-inducible gene
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GO gene ontology
GRAP GRB2-related adaptor protein
GRB growth factor receptor-bound protein
GTP guanosine triphosphate
h hour(s)
HAT histone acetyl transferase
HIV human immunodeficiency virus
HRP horseradish peroxidase
HRPT Hypoxanthine-guanine phosphoribosyltransferase
IκB inhibitor of κB
i.e. id est
IAP inhibitor of apoptosis
IKK IκB kinase
IL interleukin
IRAK interleukin-1 receptor-associated kinase
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IRF interferon regulatory factor
ITGA5 integrin, α 5
JNK Jun N-terminal kinase
JunB jun B proto-oncogene
kb kilobase
LILRA leukocyte immunoglobulin-like receptor, subfamily A
LPS lipopolysaccharide
LRP low-density lipoprotein receptor-related protein
LT lymphotoxin
M-CSF macrophage colony-stimulating factor
MAPK mitogen-activated protein kinase
MEKK MAPK kinase kinase
MEN menin
min minute(s)
miRNA microRNA
ml milliliter
MOPS 3-(N-Morpholino)propanesulfonic acid
mRNA messenger RNA
MYB v-myb myeloblastosis viral oncogene homolog
MYC v-myc myelocytomatosis viral oncogene homolog
MyD88 myeloid differentiation primary response gene (88)
NES nuclear export signal
NF-κB nuclear factor κB
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha; encodes IκB-α
NLR NOD protein-like receptor
NLS nuclear localization signal
nM nanomolar
NO nitric oxide
NOD nucleotide oligomerization domain
PAMP pathogen-associated molecular pattern
PBS phosphate-buffered saline
PCR polymerase chain reaction
PE phycoerythrin
Pfa paraformaldehyde
PH pleckstrin homology
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PI propidium iodide
PI(3)K phosphoinositide-3-kinase
PIM1 pim-1 oncogene
piRNA Piwi-interacting RNA
PKB/C protein kinase B/C
PRR pattern recognition receptor
QQ quantile-quantile
qRT-PCR quantitative realtime PCR
RANKL receptor activator of NF-κB ligand
Ras rat sarcoma
rasiRNA repeat-associated siRNAs
RHD Rel homology domain
RIG retinoic acid inducible gene
RING really interesting new gene
RIP receptor interacting protein
RISC RNA-induced silencing complex
RL Renilla luciferase
RLU relative light units, representing the strength of luciferase lumines-
cence
RNA ribonucleic acid
RNAi RNA interference
ROS reactive oxygen species
rpm revolutions per minute
SCF Skp-1/Cul/F box
scnRNA small-scan siRNAs
SDS sodium dodecyl sulphate
sec seconds
SH Src homology
SHP protein tyrosine phosphatase
shRNA short-hairpin RNAs
siCon siControl #1
siRNA small interfering RNA
SMase sphingomyelinase
SPP (OPN) secreted phosphoprotein (Osteopontin)
TAB TAK1-binding protein
TACE TNF-αconverting enzyme
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TAD transcription activation domain
TAE Tris-acetate-EDTA
TAK transforming growth factor-β-activated kinase
TAP1 transporter 1, ATP-binding cassette, sub-family B
tasiRNA trans-acting siRNAs
TK thymidin kinase
TLR Toll-like receptor
TNF-α tumor necrosis factor-α
TNFAIP TNF-α-induced protein
TNFR-C tumor necrosis factor-α receptor 1 complex I
TNFRSF1A (TNFR1) TNF receptor superfamily member 1A
TNFRSF1B (TNFR2) TNF receptor superfamily member 1B
TRADD TNFR1-associated death domain protein
TRAF TNFR-associated factor
TRAIL TNF-related apoptosis-inducing ligand
TRAPS TNFR-associated periodic syndrome
TTP tristetraprolin
Ubc ubiquitin conjugating enzyme
UBD ubiquitin binding domain
Uev Ubc-like factor ubiquitin conjugationg enzyme variant
UPL universal probe library
USP ubiquitin specific peptidase
UTR untranslated region
V volt
vs. versus
w/ with
w/o without
WIT Wilms tumor upstream neighbor
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